{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/harishb/Documents/pixacore/venv/lib/python3.13/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import glob\n",
    "import base64\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "os.environ[\"PATH\"] = \"/opt/homebrew/bin:\" + os.environ.get(\"PATH\", \"\")\n",
    "\n",
    "from unstructured.partition.pdf import partition_pdf\n",
    "from unstructured.partition.pptx import partition_pptx\n",
    "from unstructured.partition.xlsx import partition_xlsx\n",
    "from unstructured.chunking.title import chunk_by_title\n",
    "\n",
    "from langchain_core.documents import Document\n",
    "from langchain_core.messages import HumanMessage\n",
    "from langchain_openai import OpenAIEmbeddings, ChatOpenAI\n",
    "from langchain_chroma import Chroma\n",
    "\n",
    "embedding_model = OpenAIEmbeddings(model=\"text-embedding-3-large\")\n",
    "\n",
    "llm = ChatOpenAI(temperature=0, model=\"gpt-4o\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "def process_image_with_vision(base64_image):\n",
    "    \"\"\"Process image using vision model to extract content\"\"\"\n",
    "    try:\n",
    "        enhanced_prompt = \"\"\"\n",
    "        Analyze this image and extract all information in a way that answers potential questions users might ask.\n",
    "\n",
    "        For charts/graphs:\n",
    "        - Identify the highest, lowest, and notable values with specific numbers\n",
    "        - Explain trends, patterns, and relationships in the data\n",
    "        - Answer questions like \"what has the highest/lowest value\", \"which items are above/below a threshold\"\n",
    "        - Provide rankings and comparisons\n",
    "\n",
    "        For tables in images:\n",
    "        - Extract all data points with specific numbers and percentages  \n",
    "        - Identify the most/least common items\n",
    "        - Explain relationships between columns and rows\n",
    "\n",
    "        For text content:\n",
    "        - Extract all readable text verbatim\n",
    "        - Preserve important numbers, dates, and key facts\n",
    "        - Maintain structure and hierarchy\n",
    "\n",
    "        For diagrams/flowcharts:\n",
    "        - Describe the process, flow, or relationships shown\n",
    "        - Explain connections between elements\n",
    "        - Identify key decision points or outcomes\n",
    "\n",
    "        Write your response in natural language that would match how someone would ask questions about this content. Include specific numbers, rankings, and be explicit about comparisons and superlatives (highest, lowest, most common, etc.).\n",
    "        \"\"\"\n",
    "        \n",
    "        message = HumanMessage(content=[\n",
    "            {\n",
    "                \"type\": \"text\", \n",
    "                \"text\": enhanced_prompt\n",
    "            },\n",
    "            {\n",
    "                \"type\": \"image_url\", \n",
    "                \"image_url\": {\"url\": f\"data:image/png;base64,{base64_image}\"}\n",
    "            }\n",
    "        ])\n",
    "        \n",
    "        response = llm.invoke([message])\n",
    "        return response.content\n",
    "        \n",
    "    except Exception as e:\n",
    "        print(f\"    ‚ùå Error processing image with vision model: {str(e)}\")\n",
    "        return None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# =============================================================================\n",
    "# STEP 1: FIND ALL FILES IN DATA FOLDER\n",
    "# =============================================================================\n",
    "data_folder = \"./AMTAGVI\"\n",
    "print(f\"\\nüìÅ Looking for files in: {data_folder}\")\n",
    "\n",
    "# Find all PDF and PowerPoint files\n",
    "pdf_files = glob.glob(os.path.join(data_folder, \"**/*.pdf\"), recursive=True)\n",
    "pptx_files = glob.glob(os.path.join(data_folder, \"**/*.pptx\"), recursive=True)\n",
    "xlsx_files = glob.glob(os.path.join(data_folder, \"**/*.xlsx\"), recursive=True)\n",
    "png_files = glob.glob(os.path.join(data_folder, \"**/*.png\"), recursive=True)\n",
    "jpg_files = glob.glob(os.path.join(data_folder, \"**/*.jpg\"), recursive=True)\n",
    "jpeg_files = glob.glob(os.path.join(data_folder, \"**/*.jpeg\"), recursive=True)\n",
    "\n",
    "# all_files = pdf_files + pptx_files + xlsx_files\n",
    "all_files = pdf_files + pptx_files + xlsx_files + png_files + jpg_files + jpeg_files\n",
    "\n",
    "print(f\"Found {len(pdf_files)} PDF files and {len(pptx_files)} PowerPoint files and {len(xlsx_files)} xlsx files and {len(png_files)} PNG files and {len(jpg_files)} JPG files and {len(jpeg_files)} JPEG files \")\n",
    "\n",
    "print(f\"Total files to process: {len(all_files)}\")\n",
    "\n",
    "if len(all_files) == 0:\n",
    "    print(\"‚ùå No files found! Make sure your data folder contains PDF or PPTX files.\")\n",
    "    exit()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# =============================================================================\n",
    "# STEP 2: PROCESS EACH FILE (PARTITION INTO ELEMENTS)\n",
    "# =============================================================================\n",
    "print(f\"\\nüîÑ Processing files...\")\n",
    "\n",
    "all_elements = []\n",
    "\n",
    "for file_path in all_files:\n",
    "    print(f\"Processing: {os.path.basename(file_path)}\")\n",
    "    \n",
    "    try:\n",
    "        if file_path.endswith('.pdf'):\n",
    "            # Process PDF files\n",
    "            elements = partition_pdf(\n",
    "                filename=file_path,\n",
    "                strategy=\"hi_res\",\n",
    "                hi_res_model_name=\"yolox\",\n",
    "                infer_table_structure=True,\n",
    "                languages=[\"eng\"], \n",
    "                extract_image_block_types=[\"Image\"], \n",
    "                extract_image_block_to_payload=True \n",
    "            )\n",
    "        \n",
    "        elif file_path.endswith(('.pptx', '.ppt')):\n",
    "            # Process PowerPoint files\n",
    "            elements = partition_pptx(\n",
    "                filename=file_path,\n",
    "                infer_table_structure=True,\n",
    "                include_slide_notes=True,\n",
    "                strategy=\"hi_res\"\n",
    "            )\n",
    "\n",
    "        elif file_path.endswith('.xlsx'): \n",
    "           elements = partition_xlsx(\n",
    "               filename=file_path, \n",
    "               infer_table_structure=True\n",
    "            )\n",
    "           \n",
    "        elif file_path.endswith(('.png', '.jpg', '.jpeg', '.gif', '.bmp')):\n",
    "            # Process standalone images - convert to base64 first\n",
    "            with open(file_path, \"rb\") as image_file:\n",
    "                image_data = image_file.read()\n",
    "            base64_image = base64.b64encode(image_data).decode()\n",
    "            \n",
    "            vision_content = process_image_with_vision(base64_image)\n",
    "            \n",
    "            if vision_content:\n",
    "                # Create a mock element for standalone images\n",
    "                class MockElement:\n",
    "                    def __init__(self, text, file_path):\n",
    "                        self.text = text\n",
    "                        self.category = \"Image\"\n",
    "                        self.metadata = MockMetadata(file_path)\n",
    "                \n",
    "                class MockMetadata:\n",
    "                    def __init__(self, file_path):\n",
    "                        self.filename = os.path.basename(file_path)\n",
    "                        self.file_path = file_path\n",
    "                        \n",
    "                    def to_dict(self):\n",
    "                        return {\n",
    "                            'filename': self.filename,\n",
    "                            'filetype': 'standalone_image',\n",
    "                            'content_type': 'image_vision_extracted',\n",
    "                            'image_source': 'standalone'\n",
    "                        }\n",
    "                \n",
    "                vision_element = MockElement(vision_content, file_path)\n",
    "                elements = [vision_element]\n",
    "        else:\n",
    "            print(f\"  ‚ö†Ô∏è Unsupported file type: {file_path}\")\n",
    "            continue\n",
    "\n",
    "        all_elements.extend(elements)\n",
    "        print(f\"  ‚úÖ Extracted {len(elements)} elements\")\n",
    "                \n",
    "    except Exception as e:\n",
    "        print(f\"  ‚ùå Error processing {file_path}: {str(e)}\")\n",
    "        continue\n",
    "\n",
    "print(f\"\\nüìä Total elements extracted from all files: {len(all_elements)}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# =============================================================================\n",
    "# SAVE PROCESSED ELEMENTS FOR FUTURE RUNS\n",
    "# =============================================================================\n",
    "import pickle\n",
    "\n",
    "# Only save if all_elements exists and has data\n",
    "if all_elements:\n",
    "    print(f\"üíæ Saving {len(all_elements)} elements...\")\n",
    "    with open(\"./partitioned_elements.pkl\", \"wb\") as f:\n",
    "        pickle.dump(all_elements, f)\n",
    "    print(\"‚úÖ Saved!\")\n",
    "else:\n",
    "    print(\"‚ö†Ô∏è No all_elements to save\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "36759 elements have been loaded\n"
     ]
    }
   ],
   "source": [
    "import pickle\n",
    "\n",
    "with open(\"./partitioned_elements.pkl\", \"rb\") as f:\n",
    "    all_elements = pickle.load(f)\n",
    "\n",
    "print(f\"{len(all_elements)} elements have been loaded\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "üîç Filtering out unwanted sections...\n",
      "üìä Filtered 1194 elements from 36759 total\n",
      "\n",
      "üóëÔ∏è REMOVED ELEMENTS:\n",
      "\n",
      "üìÑ prc-us-00483-ref2-Tawbi 2022.pdf (28 removed)\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] 1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [NarrativeText] 3. Durham NM, Nirschl CJ, Jackson CM, et al. Lymphocyte Activation Gene 3 (LAG-3) modulates the abil...\n",
      "  ‚Ä¢ [NarrativeText] 4. Workman CJ, Cauley LS, Kim I-J, Blackman MA, Woodland DL, Vignali DAA. Lymphocyte activation gene...\n",
      "  ‚Ä¢ [NarrativeText] 5. Hemon P, Jean-Louis F, Ramgolam K, et al. MHC class II engagement by its li- gand LAG-3 (CD223) c...\n",
      "  ‚Ä¢ [NarrativeText] 6. Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergisticall...\n",
      "  ‚Ä¢ [NarrativeText] 9. Ascierto PA, Melero I, Bhatia S, et al. Initial efficacy of anti-lymphocyte activa- tion gene-3 (...\n",
      "  ‚Ä¢ [NarrativeText] 10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:...\n",
      "  ‚Ä¢ [NarrativeText] 11. American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. Chi- cago: American Coll...\n",
      "  ‚Ä¢ [NarrativeText] 13. Rabin R, de Charro F. EQ-5D: a mea- sure of health status from the EuroQol Group. Ann Med 2001; ...\n",
      "  ‚Ä¢ [NarrativeText] 14. Phillips T, Millett MM, Zhang X, et al. Development of a diagnostic programmed cell death 1‚Äìliga...\n",
      "  ‚Ä¢ [NarrativeText] EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007; 5: 70. 18. Wolchok JD, Chiar...\n",
      "  ‚Ä¢ [NarrativeText] 19. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone vers...\n",
      "  ‚Ä¢ [NarrativeText] 20. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, ESMO Guide- lines Committee. Cut...\n",
      "  ‚Ä¢ [NarrativeText] 21. Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Onco...\n",
      "  ‚Ä¢ [NarrativeText] noma without BRAF mutation. N Engl J\n",
      "  ‚Ä¢ [NarrativeText] 7. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with speciali...\n",
      "  ‚Ä¢ [NarrativeText] 8. Lipson E, Gopal A, Neelapu SS, et al. Initial experience administering BMS- 986016, a monoclonal ...\n",
      "  ‚Ä¢ [NarrativeText] 15. Dillon LM, Wojcik J, Desai K, et al. Distribution and prevalence of LAG-3 ex- pression in sample...\n",
      "  ‚Ä¢ [NarrativeText] 16. Askew RL, Xing Y, Palmer JL, Cella D, Moye LA, Cormier JN. Evaluating mini- mal important differ...\n",
      "  ‚Ä¢ [NarrativeText] 17. Pickard AS, Neary MP, Cella D. Estima- tion of minimally important differences in\n",
      "  ‚Ä¢ [UncategorizedText] Med 2015; 372: 320-30.\n",
      "  ‚Ä¢ [NarrativeText] 24. Long GV, Dummer R, Hamid O, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizu...\n",
      "  ‚Ä¢ [NarrativeText] 25. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in ad- vanced melanoma. N...\n",
      "  ‚Ä¢ [NarrativeText] Copyright ¬© 2022 Massachusetts Medical Society.\n",
      "  ‚Ä¢ [NarrativeText] n engl j med 386;1 nejm.org January 6, 2022\n",
      "  ‚Ä¢ [NarrativeText] The New England Journal of Medicine\n",
      "  ‚Ä¢ [NarrativeText] Downloaded from nejm.org at Copyright Clearance Center on January 6, 2022. For personal use only. No...\n",
      "\n",
      "üìÑ Medical Lifileucel Scientific Communication Platform_Revision_11-15-24-dm (1).pptx (388 removed)\n",
      "  ‚Ä¢ [Title] References (1 of 4)\n",
      "  ‚Ä¢ [NarrativeText] National Comprehensive Cancer Network. NCCN Guidelines: Melanoma, cutaneous. Version 3.2024. 2024.\n",
      "  ‚Ä¢ [NarrativeText] Andtbacka RHI, Collichio F, Harrington KJ, et al. Final Analyses of OPTiM: A Randomized Phase III Tr...\n",
      "  ‚Ä¢ [NarrativeText] Davar D, Ding F, Saul M, et al. High-Dose Interleukin-2 (HD IL-2) for Advanced Melanoma: A Single Ce...\n",
      "  ‚Ä¢ [NarrativeText] Siegel RL, Giaquinto AN, Jemal A. Cancer Statistics, 2024. CA Cancer J Clin. 2024;74:12-49.\n",
      "  ‚Ä¢ [NarrativeText] SEER Cancer Stat Facts. Melanoma of the Skin. National Cancer Institute. Bethesda, MD. https://seer....\n",
      "  ‚Ä¢ [NarrativeText] Davis LE, Shalin SC, Tackett AJ. Current State of Melanoma Diagnosis and Treatment. Cancer Biol Ther...\n",
      "  ‚Ä¢ [NarrativeText] Arnold M, Singh D, Laversanne M, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections ...\n",
      "  ‚Ä¢ [Title] References (2 of 4)\n",
      "  ‚Ä¢ [NarrativeText] Regan¬†MM,¬†Mantia¬†CM,¬†Werner¬†L, et al. Treatment-free Survival Over Extended Follow-up of Patients Wi...\n",
      "  ‚Ä¢ [NarrativeText] Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab Versus Placebo in Resected Stage I...\n",
      "  ‚Ä¢ [NarrativeText] Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE...\n",
      "  ‚Ä¢ [NarrativeText] Long GV, Hodi S, Lipson EJ, et al. Relatlimab and Nivolumab Versus Nivolumab in Previously Untreated...\n",
      "  ‚Ä¢ [NarrativeText] Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab Versus Nivolumab in Untreated Ad...\n",
      "  ‚Ä¢ [NarrativeText] Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab ...\n",
      "  ‚Ä¢ [NarrativeText] Ascierto P,A, McArthur GA, Dreno B, et al. Cobimetinib Combined with Vemurafenib in Advanced BRAF(V6...\n",
      "  ‚Ä¢ [PageBreak] \n",
      "  ‚Ä¢ [Title] References (3 of 4)\n",
      "  ‚Ä¢ [NarrativeText] Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year Outcomes with Dabrafenib Plus Trametinibd in Me...\n",
      "  ‚Ä¢ [NarrativeText] Drummer R, Ascierto PA, Gogas HJ, et al. Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafe...\n",
      "  ‚Ä¢ [NarrativeText] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in ...\n",
      "  ‚Ä¢ [NarrativeText] Warner AB, Palmer JS, Shoushtari AN, et al. Long-term Outcomes and Responses to Retreatment in Patie...\n",
      "  ‚Ä¢ [NarrativeText] Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafen...\n",
      "  ‚Ä¢ [NarrativeText] Long GV, Menzies AM, Nagrial AM, et al. Prognostic and Clinicopathologic Associations of Oncogenic B...\n",
      "  ‚Ä¢ [NarrativeText] Krauthammer M, Kong Y, Bacchiocchi A, et al. Exome Sequencing Identifies Recurrent Mutations in NF1 ...\n",
      "  ‚Ä¢ [NarrativeText] Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year Outcomes With Dabrafenib Plus Trametinib in Met...\n",
      "  ‚Ä¢ [NarrativeText] Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant Advanced Melanoma Treated With V...\n",
      "  ‚Ä¢ [PageBreak] \n",
      "  ‚Ä¢ [Title] References (4 of 4)\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Patel S, Othus M, Prieto V, et al. Neoadjuvant versus adjuvant pembrolizumab for resected stage III-...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Khattak A,¬†Carlino, C, Meniawy T,¬†et al. Abstract CT001: A Personalized Cancer Vaccine, mRNA-4157, C...\n",
      "  ‚Ä¢ [NarrativeText] Khattak A,¬†Carlino, C, Meniawy T,¬†et al.  A Personalized Cancer Vaccine, mRNA-4157, Combined With Pe...\n",
      "  ‚Ä¢ [NarrativeText] Khattak A,¬†Weber JS,¬†Meniawy T,¬†et al. Distant Metastasis-Free Survival Results From the Randomized,...\n",
      "  ‚Ä¢ [NarrativeText] Sullivan RJ, Carlino M, Weber JS, et al. mRNA-4157 (V940), a Personalized Cancer Vaccine, in Combina...\n",
      "  ‚Ä¢ [NarrativeText] Carlino MS, Khattak A, Weber JS, et al. Minimal residual disease by circulating tumor DNA as a bioma...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Tawbi HA, Hodi FS, Lipson EJ, et al. Nivolumab (NIVO) Plus Relatlimab (RELA) vs NIVO in Previously U...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in ...\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, Lewis KD, Kluger H, et al. Efficacy and Safety of Lifileucel, a One-Time Autologous Tumor...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Ascierto PA, Lipson EJ, Dummer R, Larkin J, et al. Nivolumab and Relatlimab in Patients with Advance...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Robert C, Milhem MM, Sacco JJ, et al. Primary efficacy, safety, and survival data from the registrat...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Menzies AM, Pires da Silva I, Trojaniello C,  et al. CTLA-4 Blockade Resistance after Relatlimab and...\n",
      "  ‚Ä¢ [Title] References (1 of 3)\n",
      "  ‚Ä¢ [NarrativeText] SEER Cancer Stat Facts. Cervical Cancer. National Cancer Institute. Bethesda, MD. https://seer.cance...\n",
      "  ‚Ä¢ [NarrativeText] Siegel RL, Miller KD, Fuchs HE. Cancer Statistics, 2021. CA Cancer J Clin. 2021;7:7-33.\n",
      "  ‚Ä¢ [NarrativeText] Zhou H, Li Q, Xu C, et al. Prognosis of Stage III Cervical Cancer: A Two-way Outcome Study. Transl C...\n",
      "  ‚Ä¢ [NarrativeText] Bandyopadhyay A, Mukherjee U, Ghosh S, Ghosh S, Sarkar SK. Pattern of Failure With Locally Advanced ...\n",
      "  ‚Ä¢ [NarrativeText] Katanyoo K. Comparing Treatment Outcomes of Stage IIIB Cervical Cancer Patients Between Those With a...\n",
      "  ‚Ä¢ [NarrativeText] Espenel S, Garcia MA, Trone JC,¬†et al.¬†From IB2 to IIIB Locally Advanced Cervical Cancers: Report of...\n",
      "  ‚Ä¢ [NarrativeText] Poolkerd S, Leelahakorn S, Manusirivithaya S, et al. Survival Rate of Recurrent Cervical Cancer Pati...\n",
      "  ‚Ä¢ [NarrativeText] Liu SP, Yang JX, Cao DY, Shen K. Analysis of 30 Patients With Persistent or Recurrent Squamous Cell ...\n",
      "  ‚Ä¢ [NarrativeText] Zhou S, Peng F. Patterns of Metastases in Cervical Cancer:  A Population-based Study. Int J Clin Exp...\n",
      "  ‚Ä¢ [NarrativeText] American Cancer Society. Survival Rates for Cervical Cancer. https://www.cancer.org/cancer/cervical-...\n",
      "  ‚Ä¢ [Title] References (2 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Tewari KS, Sill MW, Penson RT, et al. Final Overall Survival of the Phase III Randomised Trial of Ch...\n",
      "  ‚Ä¢ [NarrativeText] Tewari KS, Sill MW, Long HJ, 3rd, et al. Improved Survival With Bevacizumab in Advanced Cervical Can...\n",
      "  ‚Ä¢ [NarrativeText] Skelton WP 4th, Castagno J, Cardenas-Goicoechea J, Daily K, Yeung A, Markham MJ. Bevacizumab Eligibi...\n",
      "  ‚Ä¢ [NarrativeText] Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervica...\n",
      "  ‚Ä¢ [NarrativeText] Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in Squamous Cell Carcinoma of the Cervix: A Pha...\n",
      "  ‚Ä¢ [NarrativeText] Garcia AA, Blessing JA, Vaccarello L, et al. Phase II Clinical Trial of Docetaxel in Refractory Squa...\n",
      "  ‚Ä¢ [NarrativeText] Miller DS, Blessing JA, Bodurka DC, et al. Evaluation of Pemetrexed (Alimta, LY231514) as Second Lin...\n",
      "  ‚Ä¢ [NarrativeText] Schilder RJ, Blessing J, Cohn DE. Evaluation of Gemcitabine in Previously Treated Patients With Non-...\n",
      "  ‚Ä¢ [Title] References (3 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Chung HC, Ros W, Delord J-P, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advan...\n",
      "  ‚Ä¢ [NarrativeText] Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and Safety of Tisotumab Vedotin in Previously Tr...\n",
      "  ‚Ä¢ [NarrativeText] TIVDAK (tisotumab vedotin-tftv) for injection. Prescribing instructions. Seagen Inc. and Genmab; 202...\n",
      "  ‚Ä¢ [NarrativeText] O'Malley  D, Neffa M, Monk BJ, et al. 724MO - Balstilimab (anti-PD-1) in Combination With Zalifrelim...\n",
      "  ‚Ä¢ [NarrativeText] Tewari KS, Monk BJ, Vergote I, et al. VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim Analy...\n",
      "  ‚Ä¢ [NarrativeText] O'Malley DM, Oaknin A, Monk BJ, et al. Phase II Study of the Safety and Efficacy of the Anti-PD-1 An...\n",
      "  ‚Ä¢ [NarrativeText] Naumann RW, Oaknin A, Meyer T, et al. Efficacy and Safety of Nivolumab (Nivo) 1 Ipilimumab (Ipi) in ...\n",
      "  ‚Ä¢ [NarrativeText] Randall LM, Walker AJ, Jia AY, et al. Expanding Our Impact in Cervical Cancer Treatment: Novel Immun...\n",
      "  ‚Ä¢ [PageBreak] \n",
      "  ‚Ä¢ [Title] References (1 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incid...\n",
      "  ‚Ä¢ [NarrativeText] Jemal A, Fedewa SA. Lung Cancer Screening With Low-dose Computed Tomography in the United States‚Äî201...\n",
      "  ‚Ä¢ [NarrativeText] Lewis JA, Petty WJ, Tooze JA, et al. Low-dose CT Lung Cancer Screening Practices and Attitudes Among...\n",
      "  ‚Ä¢ [NarrativeText] Planchard D, Popat S, Kerr K, et al. Metastatic Non-small Cell Lung Cancer: ESMO Clinical Practice G...\n",
      "  ‚Ä¢ [NarrativeText] Molina JR, Yang P, Cassivi SD, et al. Non-small Cell Lung Cancer: Epidemiology, Risk Factors, Treatm...\n",
      "  ‚Ä¢ [NarrativeText] Gray J, Rodriguez-Abreu D, Powell SF, et al. FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrex...\n",
      "  ‚Ä¢ [NarrativeText] American Cancer Society. Lung Cancer Survival Rates. https://www.cancer.org/cancer/lung-cancer/detec...\n",
      "  ‚Ä¢ [NarrativeText] Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-mutated or MET-amplified Non-small-cell Lun...\n",
      "  ‚Ä¢ [NarrativeText] Planchard D, Smit EF, Groen HJM, et al. Dabrafenib Plus Trametinib in Patients With Previously Untre...\n",
      "  ‚Ä¢ [Title] References (2 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Goto K, Oxnard GR, Tan DS-W, et al. Selpercatinib (LOXO-292) in Patients With RET-fusion+ Non-small ...\n",
      "  ‚Ä¢ [NarrativeText] Tan DSW, Geater S, Yu CJ, et al. Ceritinib Efficacy and Safety in Treatment-na√Øve Asian Patients Wit...\n",
      "  ‚Ä¢ [NarrativeText] Bearz A, Martini JF, Jassem J, et al. Efficacy of Lorlatinib in Treatment-na√Øve Patients (pts) With ...\n",
      "  ‚Ä¢ [NarrativeText] Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab Plus Chemotherapy in Metastatic Non-sma...\n",
      "  ‚Ä¢ [NarrativeText] Dietel M, Savelov N, Salanova R, et al. Real-world Prevalence of Programmed Death Ligand 1 Expressio...\n",
      "  ‚Ä¢ [NarrativeText] Reck M, Rodr√≠guez-Abreu D, Robinson AG, et al. Five-year Outcomes With Pembrolizumab Versus Chemothe...\n",
      "  ‚Ä¢ [NarrativeText] Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab Plus Chemotherapy for Squamous Non-small-cell Lu...\n",
      "  ‚Ä¢ [NarrativeText] Robinson AG, Vicente D, Tafreshi A, et al. 970 First-line Pembrolizumab Plus Chemotherapy for Patien...\n",
      "  ‚Ä¢ [Title] References (3 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Garon EB, Scagliotti GV, Gautschi O, et al. Exploratory Analysis of Front-Line Therapies in REVEL: A...\n",
      "  ‚Ä¢ [NarrativeText] Groh√© C, Wehler T, Dechow T, et al. Second-line Nintedanib Plus Docetaxel for Patients With Lung Ade...\n",
      "  ‚Ä¢ [NarrativeText] Brueckl WM, Reck M, Rittmeyer A, et al. Efficacy of Docetaxel Plus Ramucirumab as Palliative Second-...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer. ...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Wakelee H, Liberman M, Kato T, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lun...\n",
      "  ‚Ä¢ [Title] References (1 of 2)\n",
      "  ‚Ä¢ [NarrativeText] Zamora AE, Crawford JC, Thomas PG. Hitting the Target: How T Cells Detect and Eliminate Tumors. J Im...\n",
      "  ‚Ä¢ [NarrativeText] Antohe M, Nedelcu RI, Nichita L, et al. Tumor Infiltrating Lymphocytes: The Regulator of Melanoma Ev...\n",
      "  ‚Ä¢ [NarrativeText] Charoentong C, Finotello F, Angelova M, et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Imm...\n",
      "  ‚Ä¢ [NarrativeText] Raskov H, Orhan A, Christensen JP, G√∂genur I. Cytotoxic CD8+ T Cells in Cancer and Cancer Immunother...\n",
      "  ‚Ä¢ [NarrativeText] Ch√°vez-Gal√°n L, Arenas-Del Angel MC, Zenteno E, Ch√°vez R, Lascurain R. Cell Death Mechanisms Induced...\n",
      "  ‚Ä¢ [UncategorizedText] Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-Infiltrating Lymphocytes and Their...\n",
      "  ‚Ä¢ [UncategorizedText] Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. ...\n",
      "  ‚Ä¢ [NarrativeText] Monjazeb AM, Zamora AE, Grossenbacher SK, et al. Immunoediting and Antigen Loss: Overcoming the Achi...\n",
      "  ‚Ä¢ [NarrativeText] Fardis M, DiTrapani K, Chartier C, Finckenstein FG. Current and Future Directions for Tumor Infiltra...\n",
      "  ‚Ä¢ [Title] References (2 of 2)\n",
      "  ‚Ä¢ [NarrativeText] Rosenberg SA, Packard BS, Aebersold PM, et al. Use of Tumor-Infiltrating Lymphocytes and Interleukin...\n",
      "  ‚Ä¢ [NarrativeText] Schumacher TN, Schreiber RD. Neoantigens in Cancer Immunotherapy. Science. 2015;(6230):69-74.\n",
      "  ‚Ä¢ [NarrativeText] Han X-J, Ma X-L, Yang L, et al. Progress in Neoantigen Targeted Cancer Immunotherapies. Front Cell D...\n",
      "  ‚Ä¢ [NarrativeText] Neagu M, Constantin C, Zurac S. Immune Parameters in the Prognosis and Therapy Monitoring of Cutaneo...\n",
      "  ‚Ä¢ [NarrativeText] Litwin TR, Irvin SR, Chornock RL, Sahasrabuddhe VV, Stanley M, Wentzensen N. Infiltrating T-cell Mar...\n",
      "  ‚Ä¢ [NarrativeText] Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective Measurement and Clinical Significance of...\n",
      "  ‚Ä¢ [Title] References \n",
      "  ‚Ä¢ [Title] References (1 of 2)\n",
      "  ‚Ä¢ [NarrativeText] Mullinax JE, Egger ME, McCarter M, et al. Surgical Considerations for Tumor Tissue Procurement to Ob...\n",
      "  ‚Ä¢ [NarrativeText] Egger ME, McCarter M, Olino K, et al. Lifileucel TIL Cell Therapy in Patients With Advanced Melanoma...\n",
      "  ‚Ä¢ [NarrativeText] Chesney JA. Lifileucel (LN-144), a Cryopreserved Autologous Tumor Infiltrating Lymphocyte (TIL) Ther...\n",
      "  ‚Ä¢ [NarrativeText] Larkin J, Sarnaik A, Chesney JA, et al. Lifileucel (LN-144), a Cryopreserved Autologous Tumor Infilt...\n",
      "  ‚Ä¢ [UncategorizedText] Simpson-Abelson MR, D‚ÄôArigo K, Hilton F, Fardis M, Chartier C. Iovance Generation-2 Tumor-infiltrati...\n",
      "  ‚Ä¢ [NarrativeText] Wardell S, Lienlaf-Moreno M, Blaskovich M, et al. Iovance Gen 2 TIL Manufacturing Process Produces D...\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, Lewis KD, Kluger H, et al. Efficacy and Safety of Lifileucel, a One-time Autologous Tumor...\n",
      "  ‚Ä¢ [NarrativeText] Sethuraman J, Prewitt J, Hutchinson A, et al. Successful Expansion and Characterization of Tumor Inf...\n",
      "  ‚Ä¢ [Title] References (2 of 2)\n",
      "  ‚Ä¢ [NarrativeText] Simpson-Abelson MR, Hilton A, D‚ÄôArigo K, et al. Expanding Iovance‚Äôs Tumor Infiltrating Lymphocytes (...\n",
      "  ‚Ä¢ [NarrativeText] Ullenhag GJ, Sadeghi AM, Carlsson B, et al. Adoptive T-Cell Therapy for Malignant Melanoma Patients ...\n",
      "  ‚Ä¢ [NarrativeText] Onimus K, Wells A, Herman C, et al. Successful Manufacturing of Tumor-infiltrating Lymphocyte (TIL) ...\n",
      "  ‚Ä¢ [NarrativeText] Fardis M, D‚ÄôTrapani K, Chartier C, Finckenstein FG. Current and Future Directions for Tumor Infiltra...\n",
      "  ‚Ä¢ [NarrativeText] Rohaan MW, van den Berg JH, Kvistborg P, Haanen J. Adoptive Transfer of Tumor-infiltrating Lymphocyt...\n",
      "  ‚Ä¢ [NarrativeText] Frank A, Stramer A, Blaskovich MA, et al. Remarkably Stable Tumor-Infiltrating Lymphocytes (TIL) For...\n",
      "  ‚Ä¢ [NarrativeText] Schoenfeld AJ, Lee S, Paz-Ares L, et al. First Phase 2 Results of Autologous Tumor Infiltrating Lymp...\n",
      "  ‚Ä¢ [NarrativeText] Ritthipichai K, Frank IF, Machin M, et al. Studies of Key Quality Attributes for TIL Product, LN 144...\n",
      "  ‚Ä¢ [NarrativeText] Onimus K, Wells A, Gerges N, et al. 101 Expansion of Tumor-infiltrating Lymphocytes (TIL) Using Stat...\n",
      "  ‚Ä¢ [NarrativeText] Kn√∂rck A, Sch√§fer G, Alansary D, et al. Cytotoxic Efficiency of Human CD8+ T Cell Memory Subtypes. F...\n",
      "  ‚Ä¢ [PageBreak] \n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a Tumor-infiltrating Lymphocyte Therapy, in M...\n",
      "  ‚Ä¢ [NarrativeText] Lee S, Margolin K. Tumor-infiltrating Lymphocytes in Melanoma. Curr Oncol Rep. 2012;14:468-1474.\n",
      "  ‚Ä¢ [NarrativeText] Rohaan MW, van den Berg JH, Kvistborg P, et al. Adoptive Transfer of Tumor-infiltrating Lymphocytes ...\n",
      "  ‚Ä¢ [NarrativeText] Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of Homeostatic Cytokine Sinks by Lymphodep...\n",
      "  ‚Ä¢ [NarrativeText] Klebanoff CA, Khong HT, Antony PA, et al. Sinks, Suppressors and Antigen Presenters: How Lymphodeple...\n",
      "  ‚Ä¢ [NarrativeText] Fardis M, D‚ÄôTrapani K, Chartier C, Finckenstein FG. Current and Future Directions for Tumor Infiltra...\n",
      "  ‚Ä¢ [Title] References (1 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Sarnaik A, Lewis KD, Kluger H, et al. Lifileucel TIL Cell Monotherapy in Patients With Advanced Mela...\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, Lewis KD, Kluger H, et al. Efficacy and Safety of Lifileucel, a One-Time Autologous Tumor...\n",
      "  ‚Ä¢ [NarrativeText] Hamid O, Sarnaik A, Kluger H, et al. Lifileucel TIL Cell Monotherapy in Patients With Advanced Melan...\n",
      "  ‚Ä¢ [Title] References (2 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Medina T, Chesney J, Whitman E, et al. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltratin...\n",
      "  ‚Ä¢ [NarrativeText] Medina T, Chesney J, Whitman E, et al. Long-Term Efficacy and Patterns of Response of Lifileucel Tum...\n",
      "  ‚Ä¢ [NarrativeText] Sarnaik A, Chesney J, Medina T, et al. Response to Lifileucel Tumor‚ÄëInfiltrating Lymphocyte (TIL) Ce...\n",
      "  ‚Ä¢ [NarrativeText] Kluger HM, Tawbi HA, Ascierto ML, et al. Defining Tumor Resistance to PD-1 Pathway Blockade: Recomme...\n",
      "  ‚Ä¢ [NarrativeText] Grigoleit GU, Kluger H, Thomas S, et al. Lifileucel Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy...\n",
      "  ‚Ä¢ [Title] References (3 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Kluger H, Grigoleit GU, Thomas S, et al. Lifileucel Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy...\n",
      "  ‚Ä¢ [NarrativeText] D‚ÄôAngelo SP, Larkin J, Sosman JA, et al. Efficacy and Safety of Nivolumab Alone or in Combination Wi...\n",
      "  ‚Ä¢ [NarrativeText] Mignard C, Huvier AD, Gillibert A, et al. Efficacy of Immunotherapy in Patients With Metastatic Muco...\n",
      "  ‚Ä¢ [NarrativeText] Hamid O, Robert C, Ribas A, et al. Antitumour Activity of Pembrolizumab in Advanced Mucosal Melanoma...\n",
      "  ‚Ä¢ [NarrativeText] Teterycz P, Czarnecka AM, Indini A, et al. Multimodal Treatment of Advanced Mucosal Melanoma in the ...\n",
      "  ‚Ä¢ [NarrativeText] Nakamura Y, Namikawa K, Yoshikawa S, et al.  Anti-PD-1 Antibody Monotherapy Versus Anti-PD-1 Plus An...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Thomas S, Gogas H, Hong YK, et al. Efficacy and Safety of Lifileucel, an Autologous Tumor-Infiltrati...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Jazaeri AA, Zsiros E, Amaria RN, et al. Safety & Efficacy of Adoptive Cell Transfer Using Autologous...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] O'Malley D, Lee SM, Psyrri A, et al. Phase 2 Efficacy and Safety of Autologous Tumor-Infiltrating Ly...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Schoenfeld AJ, Lee SM, Doger de Sp√©ville, et al. Lifileucel, an Autologous Tumor-infiltrating Lympho...\n",
      "  ‚Ä¢ [NarrativeText] Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: Rev...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Schoenfeld A, He K, Chesney J, et al. Multicenter Phase II Trial of LN-145 TIL Cell Therapy Plus Pem...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a Tumor-infiltrating Lymphocyte Therapy, in M...\n",
      "  ‚Ä¢ [NarrativeText] Gettinger S, Kluger H, Schoenfeld A, et al. Trial in Progress: A Phase 2, Multicenter Study of Autol...\n",
      "  ‚Ä¢ [NarrativeText] NCT05176470. Available at https://clinicaltrials.gov/ct2/show/NCT05176470. Accessed June 13, 2022. \n",
      "  ‚Ä¢ [NarrativeText] Olson DJ, Larkin J, Hong YK, et al. TILVANCE-301, a Phase 3 Study of Lifileucel Tumor-Infiltrating L...\n",
      "  ‚Ä¢ [NarrativeText] Hong YK, Olson DJ, Larkin J, et al. TILVANCE-301, a Phase 3 Study of Lifileucel Tumor-Infiltrating L...\n",
      "  ‚Ä¢ [NarrativeText] NCT03108495. Available at: https://clinicaltrials.gov/ct2/show/NCT03108495. Accessed June 13, 2022.\n",
      "  ‚Ä¢ [NarrativeText] Chesney JA, Schoenfeld AJ, Wise-Draper T, et al. Trial In Progress: A Phase 2 Multicenter Study (IOV...\n",
      "  ‚Ä¢ [NarrativeText] NCT03449108. Available at https://clinicaltrials.gov/ct2/show/NCT03449108. Accessed June 13, 2022.\n",
      "  ‚Ä¢ [NarrativeText] NCT04111510. Available at https://clinicaltrials.gov/ct2/show/NCT04111510. Accessed June 13, 2022.\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] NCT05361174. Available at https://clinicaltrials.gov/ct2/show/NCT05361174. Accessed June 13, 2022.\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [UncategorizedText] Ritthipichai K, Machin M, Juillerat A, Poirot L, Fardis M, Chartier C. Genetic Modification of Iovan...\n",
      "  ‚Ä¢ [NarrativeText] Natarajan A, Veerapathran A, Wells A, et al. Preclinical Activity and Manufacturing Feasibility of G...\n",
      "  ‚Ä¢ [Title] References (1 of 4)\n",
      "  ‚Ä¢ [NarrativeText] National Comprehensive Cancer Network. NCCN Guidelines: Melanoma, cutaneous. Version 3.2024. 2024.\n",
      "  ‚Ä¢ [NarrativeText] Andtbacka RHI, Collichio F, Harrington KJ, et al. Final Analyses of OPTiM: A Randomized Phase III Tr...\n",
      "  ‚Ä¢ [NarrativeText] Davar D, Ding F, Saul M, et al. High-Dose Interleukin-2 (HD IL-2) for Advanced Melanoma: A Single Ce...\n",
      "  ‚Ä¢ [NarrativeText] Siegel RL, Giaquinto AN, Jemal A. Cancer Statistics, 2024. CA Cancer J Clin. 2024;74:12-49.\n",
      "  ‚Ä¢ [NarrativeText] SEER Cancer Stat Facts. Melanoma of the Skin. National Cancer Institute. Bethesda, MD. https://seer....\n",
      "  ‚Ä¢ [NarrativeText] Davis LE, Shalin SC, Tackett AJ. Current State of Melanoma Diagnosis and Treatment. Cancer Biol Ther...\n",
      "  ‚Ä¢ [NarrativeText] Arnold M, Singh D, Laversanne M, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections ...\n",
      "  ‚Ä¢ [Title] References (2 of 4)\n",
      "  ‚Ä¢ [NarrativeText] Regan¬†MM,¬†Mantia¬†CM,¬†Werner¬†L, et al. Treatment-free Survival Over Extended Follow-up of Patients Wi...\n",
      "  ‚Ä¢ [NarrativeText] Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab Versus Placebo in Resected Stage I...\n",
      "  ‚Ä¢ [NarrativeText] Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE...\n",
      "  ‚Ä¢ [NarrativeText] Long GV, Hodi S, Lipson EJ, et al. Relatlimab and Nivolumab Versus Nivolumab in Previously Untreated...\n",
      "  ‚Ä¢ [NarrativeText] Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab Versus Nivolumab in Untreated Ad...\n",
      "  ‚Ä¢ [NarrativeText] Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab ...\n",
      "  ‚Ä¢ [NarrativeText] Ascierto P,A, McArthur GA, Dreno B, et al. Cobimetinib Combined with Vemurafenib in Advanced BRAF(V6...\n",
      "  ‚Ä¢ [PageBreak] \n",
      "  ‚Ä¢ [Title] References (3 of 4)\n",
      "  ‚Ä¢ [NarrativeText] Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year Outcomes with Dabrafenib Plus Trametinibd in Me...\n",
      "  ‚Ä¢ [NarrativeText] Drummer R, Ascierto PA, Gogas HJ, et al. Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafe...\n",
      "  ‚Ä¢ [NarrativeText] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in ...\n",
      "  ‚Ä¢ [NarrativeText] Warner AB, Palmer JS, Shoushtari AN, et al. Long-term Outcomes and Responses to Retreatment in Patie...\n",
      "  ‚Ä¢ [NarrativeText] Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafen...\n",
      "  ‚Ä¢ [NarrativeText] Long GV, Menzies AM, Nagrial AM, et al. Prognostic and Clinicopathologic Associations of Oncogenic B...\n",
      "  ‚Ä¢ [NarrativeText] Krauthammer M, Kong Y, Bacchiocchi A, et al. Exome Sequencing Identifies Recurrent Mutations in NF1 ...\n",
      "  ‚Ä¢ [NarrativeText] Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year Outcomes With Dabrafenib Plus Trametinib in Met...\n",
      "  ‚Ä¢ [NarrativeText] Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant Advanced Melanoma Treated With V...\n",
      "  ‚Ä¢ [PageBreak] \n",
      "  ‚Ä¢ [Title] References (4 of 4)\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Patel S, Othus M, Prieto V, et al. Neoadjuvant versus adjuvant pembrolizumab for resected stage III-...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Khattak A,¬†Carlino, C, Meniawy T,¬†et al. Abstract CT001: A Personalized Cancer Vaccine, mRNA-4157, C...\n",
      "  ‚Ä¢ [NarrativeText] Khattak A,¬†Carlino, C, Meniawy T,¬†et al.  A Personalized Cancer Vaccine, mRNA-4157, Combined With Pe...\n",
      "  ‚Ä¢ [NarrativeText] Khattak A,¬†Weber JS,¬†Meniawy T,¬†et al. Distant Metastasis-Free Survival Results From the Randomized,...\n",
      "  ‚Ä¢ [NarrativeText] Sullivan RJ, Carlino M, Weber JS, et al. mRNA-4157 (V940), a Personalized Cancer Vaccine, in Combina...\n",
      "  ‚Ä¢ [NarrativeText] Carlino MS, Khattak A, Weber JS, et al. Minimal residual disease by circulating tumor DNA as a bioma...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Tawbi HA, Hodi FS, Lipson EJ, et al. Nivolumab (NIVO) Plus Relatlimab (RELA) vs NIVO in Previously U...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in ...\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, Lewis KD, Kluger H, et al. Efficacy and Safety of Lifileucel, a One-Time Autologous Tumor...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Ascierto PA, Lipson EJ, Dummer R, Larkin J, et al. Nivolumab and Relatlimab in Patients with Advance...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Robert C, Milhem MM, Sacco JJ, et al. Primary efficacy, safety, and survival data from the registrat...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Menzies AM, Pires da Silva I, Trojaniello C,  et al. CTLA-4 Blockade Resistance after Relatlimab and...\n",
      "  ‚Ä¢ [Title] References (1 of 3)\n",
      "  ‚Ä¢ [NarrativeText] SEER Cancer Stat Facts. Cervical Cancer. National Cancer Institute. Bethesda, MD. https://seer.cance...\n",
      "  ‚Ä¢ [NarrativeText] Siegel RL, Miller KD, Fuchs HE. Cancer Statistics, 2021. CA Cancer J Clin. 2021;7:7-33.\n",
      "  ‚Ä¢ [NarrativeText] Zhou H, Li Q, Xu C, et al. Prognosis of Stage III Cervical Cancer: A Two-way Outcome Study. Transl C...\n",
      "  ‚Ä¢ [NarrativeText] Bandyopadhyay A, Mukherjee U, Ghosh S, Ghosh S, Sarkar SK. Pattern of Failure With Locally Advanced ...\n",
      "  ‚Ä¢ [NarrativeText] Katanyoo K. Comparing Treatment Outcomes of Stage IIIB Cervical Cancer Patients Between Those With a...\n",
      "  ‚Ä¢ [NarrativeText] Espenel S, Garcia MA, Trone JC,¬†et al.¬†From IB2 to IIIB Locally Advanced Cervical Cancers: Report of...\n",
      "  ‚Ä¢ [NarrativeText] Poolkerd S, Leelahakorn S, Manusirivithaya S, et al. Survival Rate of Recurrent Cervical Cancer Pati...\n",
      "  ‚Ä¢ [NarrativeText] Liu SP, Yang JX, Cao DY, Shen K. Analysis of 30 Patients With Persistent or Recurrent Squamous Cell ...\n",
      "  ‚Ä¢ [NarrativeText] Zhou S, Peng F. Patterns of Metastases in Cervical Cancer:  A Population-based Study. Int J Clin Exp...\n",
      "  ‚Ä¢ [NarrativeText] American Cancer Society. Survival Rates for Cervical Cancer. https://www.cancer.org/cancer/cervical-...\n",
      "  ‚Ä¢ [Title] References (2 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Tewari KS, Sill MW, Penson RT, et al. Final Overall Survival of the Phase III Randomised Trial of Ch...\n",
      "  ‚Ä¢ [NarrativeText] Tewari KS, Sill MW, Long HJ, 3rd, et al. Improved Survival With Bevacizumab in Advanced Cervical Can...\n",
      "  ‚Ä¢ [NarrativeText] Skelton WP 4th, Castagno J, Cardenas-Goicoechea J, Daily K, Yeung A, Markham MJ. Bevacizumab Eligibi...\n",
      "  ‚Ä¢ [NarrativeText] Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervica...\n",
      "  ‚Ä¢ [NarrativeText] Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in Squamous Cell Carcinoma of the Cervix: A Pha...\n",
      "  ‚Ä¢ [NarrativeText] Garcia AA, Blessing JA, Vaccarello L, et al. Phase II Clinical Trial of Docetaxel in Refractory Squa...\n",
      "  ‚Ä¢ [NarrativeText] Miller DS, Blessing JA, Bodurka DC, et al. Evaluation of Pemetrexed (Alimta, LY231514) as Second Lin...\n",
      "  ‚Ä¢ [NarrativeText] Schilder RJ, Blessing J, Cohn DE. Evaluation of Gemcitabine in Previously Treated Patients With Non-...\n",
      "  ‚Ä¢ [Title] References (3 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Chung HC, Ros W, Delord J-P, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advan...\n",
      "  ‚Ä¢ [NarrativeText] Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and Safety of Tisotumab Vedotin in Previously Tr...\n",
      "  ‚Ä¢ [NarrativeText] TIVDAK (tisotumab vedotin-tftv) for injection. Prescribing instructions. Seagen Inc. and Genmab; 202...\n",
      "  ‚Ä¢ [NarrativeText] O'Malley  D, Neffa M, Monk BJ, et al. 724MO - Balstilimab (anti-PD-1) in Combination With Zalifrelim...\n",
      "  ‚Ä¢ [NarrativeText] Tewari KS, Monk BJ, Vergote I, et al. VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim Analy...\n",
      "  ‚Ä¢ [NarrativeText] O'Malley DM, Oaknin A, Monk BJ, et al. Phase II Study of the Safety and Efficacy of the Anti-PD-1 An...\n",
      "  ‚Ä¢ [NarrativeText] Naumann RW, Oaknin A, Meyer T, et al. Efficacy and Safety of Nivolumab (Nivo) 1 Ipilimumab (Ipi) in ...\n",
      "  ‚Ä¢ [NarrativeText] Randall LM, Walker AJ, Jia AY, et al. Expanding Our Impact in Cervical Cancer Treatment: Novel Immun...\n",
      "  ‚Ä¢ [PageBreak] \n",
      "  ‚Ä¢ [Title] References (1 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incid...\n",
      "  ‚Ä¢ [NarrativeText] Jemal A, Fedewa SA. Lung Cancer Screening With Low-dose Computed Tomography in the United States‚Äî201...\n",
      "  ‚Ä¢ [NarrativeText] Lewis JA, Petty WJ, Tooze JA, et al. Low-dose CT Lung Cancer Screening Practices and Attitudes Among...\n",
      "  ‚Ä¢ [NarrativeText] Planchard D, Popat S, Kerr K, et al. Metastatic Non-small Cell Lung Cancer: ESMO Clinical Practice G...\n",
      "  ‚Ä¢ [NarrativeText] Molina JR, Yang P, Cassivi SD, et al. Non-small Cell Lung Cancer: Epidemiology, Risk Factors, Treatm...\n",
      "  ‚Ä¢ [NarrativeText] Gray J, Rodriguez-Abreu D, Powell SF, et al. FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrex...\n",
      "  ‚Ä¢ [NarrativeText] American Cancer Society. Lung Cancer Survival Rates. https://www.cancer.org/cancer/lung-cancer/detec...\n",
      "  ‚Ä¢ [NarrativeText] Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-mutated or MET-amplified Non-small-cell Lun...\n",
      "  ‚Ä¢ [NarrativeText] Planchard D, Smit EF, Groen HJM, et al. Dabrafenib Plus Trametinib in Patients With Previously Untre...\n",
      "  ‚Ä¢ [Title] References (2 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Goto K, Oxnard GR, Tan DS-W, et al. Selpercatinib (LOXO-292) in Patients With RET-fusion+ Non-small ...\n",
      "  ‚Ä¢ [NarrativeText] Tan DSW, Geater S, Yu CJ, et al. Ceritinib Efficacy and Safety in Treatment-na√Øve Asian Patients Wit...\n",
      "  ‚Ä¢ [NarrativeText] Bearz A, Martini JF, Jassem J, et al. Efficacy of Lorlatinib in Treatment-na√Øve Patients (pts) With ...\n",
      "  ‚Ä¢ [NarrativeText] Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab Plus Chemotherapy in Metastatic Non-sma...\n",
      "  ‚Ä¢ [NarrativeText] Dietel M, Savelov N, Salanova R, et al. Real-world Prevalence of Programmed Death Ligand 1 Expressio...\n",
      "  ‚Ä¢ [NarrativeText] Reck M, Rodr√≠guez-Abreu D, Robinson AG, et al. Five-year Outcomes With Pembrolizumab Versus Chemothe...\n",
      "  ‚Ä¢ [NarrativeText] Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab Plus Chemotherapy for Squamous Non-small-cell Lu...\n",
      "  ‚Ä¢ [NarrativeText] Robinson AG, Vicente D, Tafreshi A, et al. 970 First-line Pembrolizumab Plus Chemotherapy for Patien...\n",
      "  ‚Ä¢ [Title] References (3 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Garon EB, Scagliotti GV, Gautschi O, et al. Exploratory Analysis of Front-Line Therapies in REVEL: A...\n",
      "  ‚Ä¢ [NarrativeText] Groh√© C, Wehler T, Dechow T, et al. Second-line Nintedanib Plus Docetaxel for Patients With Lung Ade...\n",
      "  ‚Ä¢ [NarrativeText] Brueckl WM, Reck M, Rittmeyer A, et al. Efficacy of Docetaxel Plus Ramucirumab as Palliative Second-...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer. ...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Wakelee H, Liberman M, Kato T, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lun...\n",
      "  ‚Ä¢ [Title] References (1 of 2)\n",
      "  ‚Ä¢ [NarrativeText] Zamora AE, Crawford JC, Thomas PG. Hitting the Target: How T Cells Detect and Eliminate Tumors. J Im...\n",
      "  ‚Ä¢ [NarrativeText] Antohe M, Nedelcu RI, Nichita L, et al. Tumor Infiltrating Lymphocytes: The Regulator of Melanoma Ev...\n",
      "  ‚Ä¢ [NarrativeText] Charoentong C, Finotello F, Angelova M, et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Imm...\n",
      "  ‚Ä¢ [NarrativeText] Raskov H, Orhan A, Christensen JP, G√∂genur I. Cytotoxic CD8+ T Cells in Cancer and Cancer Immunother...\n",
      "  ‚Ä¢ [NarrativeText] Ch√°vez-Gal√°n L, Arenas-Del Angel MC, Zenteno E, Ch√°vez R, Lascurain R. Cell Death Mechanisms Induced...\n",
      "  ‚Ä¢ [UncategorizedText] Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-Infiltrating Lymphocytes and Their...\n",
      "  ‚Ä¢ [UncategorizedText] Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. ...\n",
      "  ‚Ä¢ [NarrativeText] Monjazeb AM, Zamora AE, Grossenbacher SK, et al. Immunoediting and Antigen Loss: Overcoming the Achi...\n",
      "  ‚Ä¢ [NarrativeText] Fardis M, DiTrapani K, Chartier C, Finckenstein FG. Current and Future Directions for Tumor Infiltra...\n",
      "  ‚Ä¢ [Title] References (2 of 2)\n",
      "  ‚Ä¢ [NarrativeText] Rosenberg SA, Packard BS, Aebersold PM, et al. Use of Tumor-Infiltrating Lymphocytes and Interleukin...\n",
      "  ‚Ä¢ [NarrativeText] Schumacher TN, Schreiber RD. Neoantigens in Cancer Immunotherapy. Science. 2015;(6230):69-74.\n",
      "  ‚Ä¢ [NarrativeText] Han X-J, Ma X-L, Yang L, et al. Progress in Neoantigen Targeted Cancer Immunotherapies. Front Cell D...\n",
      "  ‚Ä¢ [NarrativeText] Neagu M, Constantin C, Zurac S. Immune Parameters in the Prognosis and Therapy Monitoring of Cutaneo...\n",
      "  ‚Ä¢ [NarrativeText] Litwin TR, Irvin SR, Chornock RL, Sahasrabuddhe VV, Stanley M, Wentzensen N. Infiltrating T-cell Mar...\n",
      "  ‚Ä¢ [NarrativeText] Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective Measurement and Clinical Significance of...\n",
      "  ‚Ä¢ [Title] References \n",
      "  ‚Ä¢ [Title] References (1 of 2)\n",
      "  ‚Ä¢ [NarrativeText] Mullinax JE, Egger ME, McCarter M, et al. Surgical Considerations for Tumor Tissue Procurement to Ob...\n",
      "  ‚Ä¢ [NarrativeText] Egger ME, McCarter M, Olino K, et al. Lifileucel TIL Cell Therapy in Patients With Advanced Melanoma...\n",
      "  ‚Ä¢ [NarrativeText] Chesney JA. Lifileucel (LN-144), a Cryopreserved Autologous Tumor Infiltrating Lymphocyte (TIL) Ther...\n",
      "  ‚Ä¢ [NarrativeText] Larkin J, Sarnaik A, Chesney JA, et al. Lifileucel (LN-144), a Cryopreserved Autologous Tumor Infilt...\n",
      "  ‚Ä¢ [UncategorizedText] Simpson-Abelson MR, D‚ÄôArigo K, Hilton F, Fardis M, Chartier C. Iovance Generation-2 Tumor-infiltrati...\n",
      "  ‚Ä¢ [NarrativeText] Wardell S, Lienlaf-Moreno M, Blaskovich M, et al. Iovance Gen 2 TIL Manufacturing Process Produces D...\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, Lewis KD, Kluger H, et al. Efficacy and Safety of Lifileucel, a One-time Autologous Tumor...\n",
      "  ‚Ä¢ [NarrativeText] Sethuraman J, Prewitt J, Hutchinson A, et al. Successful Expansion and Characterization of Tumor Inf...\n",
      "  ‚Ä¢ [Title] References (2 of 2)\n",
      "  ‚Ä¢ [NarrativeText] Simpson-Abelson MR, Hilton A, D‚ÄôArigo K, et al. Expanding Iovance‚Äôs Tumor Infiltrating Lymphocytes (...\n",
      "  ‚Ä¢ [NarrativeText] Ullenhag GJ, Sadeghi AM, Carlsson B, et al. Adoptive T-Cell Therapy for Malignant Melanoma Patients ...\n",
      "  ‚Ä¢ [NarrativeText] Onimus K, Wells A, Herman C, et al. Successful Manufacturing of Tumor-infiltrating Lymphocyte (TIL) ...\n",
      "  ‚Ä¢ [NarrativeText] Fardis M, D‚ÄôTrapani K, Chartier C, Finckenstein FG. Current and Future Directions for Tumor Infiltra...\n",
      "  ‚Ä¢ [NarrativeText] Rohaan MW, van den Berg JH, Kvistborg P, Haanen J. Adoptive Transfer of Tumor-infiltrating Lymphocyt...\n",
      "  ‚Ä¢ [NarrativeText] Frank A, Stramer A, Blaskovich MA, et al. Remarkably Stable Tumor-Infiltrating Lymphocytes (TIL) For...\n",
      "  ‚Ä¢ [NarrativeText] Schoenfeld AJ, Lee S, Paz-Ares L, et al. First Phase 2 Results of Autologous Tumor Infiltrating Lymp...\n",
      "  ‚Ä¢ [NarrativeText] Ritthipichai K, Frank IF, Machin M, et al. Studies of Key Quality Attributes for TIL Product, LN 144...\n",
      "  ‚Ä¢ [NarrativeText] Onimus K, Wells A, Gerges N, et al. 101 Expansion of Tumor-infiltrating Lymphocytes (TIL) Using Stat...\n",
      "  ‚Ä¢ [NarrativeText] Kn√∂rck A, Sch√§fer G, Alansary D, et al. Cytotoxic Efficiency of Human CD8+ T Cell Memory Subtypes. F...\n",
      "  ‚Ä¢ [PageBreak] \n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a Tumor-infiltrating Lymphocyte Therapy, in M...\n",
      "  ‚Ä¢ [NarrativeText] Lee S, Margolin K. Tumor-infiltrating Lymphocytes in Melanoma. Curr Oncol Rep. 2012;14:468-1474.\n",
      "  ‚Ä¢ [NarrativeText] Rohaan MW, van den Berg JH, Kvistborg P, et al. Adoptive Transfer of Tumor-infiltrating Lymphocytes ...\n",
      "  ‚Ä¢ [NarrativeText] Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of Homeostatic Cytokine Sinks by Lymphodep...\n",
      "  ‚Ä¢ [NarrativeText] Klebanoff CA, Khong HT, Antony PA, et al. Sinks, Suppressors and Antigen Presenters: How Lymphodeple...\n",
      "  ‚Ä¢ [NarrativeText] Fardis M, D‚ÄôTrapani K, Chartier C, Finckenstein FG. Current and Future Directions for Tumor Infiltra...\n",
      "  ‚Ä¢ [Title] References (1 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Sarnaik A, Lewis KD, Kluger H, et al. Lifileucel TIL Cell Monotherapy in Patients With Advanced Mela...\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, Lewis KD, Kluger H, et al. Efficacy and Safety of Lifileucel, a One-Time Autologous Tumor...\n",
      "  ‚Ä¢ [NarrativeText] Hamid O, Sarnaik A, Kluger H, et al. Lifileucel TIL Cell Monotherapy in Patients With Advanced Melan...\n",
      "  ‚Ä¢ [Title] References (2 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Medina T, Chesney J, Whitman E, et al. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltratin...\n",
      "  ‚Ä¢ [NarrativeText] Medina T, Chesney J, Whitman E, et al. Long-Term Efficacy and Patterns of Response of Lifileucel Tum...\n",
      "  ‚Ä¢ [NarrativeText] Sarnaik A, Chesney J, Medina T, et al. Response to Lifileucel Tumor‚ÄëInfiltrating Lymphocyte (TIL) Ce...\n",
      "  ‚Ä¢ [NarrativeText] Kluger HM, Tawbi HA, Ascierto ML, et al. Defining Tumor Resistance to PD-1 Pathway Blockade: Recomme...\n",
      "  ‚Ä¢ [NarrativeText] Grigoleit GU, Kluger H, Thomas S, et al. Lifileucel Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy...\n",
      "  ‚Ä¢ [Title] References (3 of 3)\n",
      "  ‚Ä¢ [NarrativeText] Kluger H, Grigoleit GU, Thomas S, et al. Lifileucel Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy...\n",
      "  ‚Ä¢ [NarrativeText] D‚ÄôAngelo SP, Larkin J, Sosman JA, et al. Efficacy and Safety of Nivolumab Alone or in Combination Wi...\n",
      "  ‚Ä¢ [NarrativeText] Mignard C, Huvier AD, Gillibert A, et al. Efficacy of Immunotherapy in Patients With Metastatic Muco...\n",
      "  ‚Ä¢ [NarrativeText] Hamid O, Robert C, Ribas A, et al. Antitumour Activity of Pembrolizumab in Advanced Mucosal Melanoma...\n",
      "  ‚Ä¢ [NarrativeText] Teterycz P, Czarnecka AM, Indini A, et al. Multimodal Treatment of Advanced Mucosal Melanoma in the ...\n",
      "  ‚Ä¢ [NarrativeText] Nakamura Y, Namikawa K, Yoshikawa S, et al.  Anti-PD-1 Antibody Monotherapy Versus Anti-PD-1 Plus An...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Thomas S, Gogas H, Hong YK, et al. Efficacy and Safety of Lifileucel, an Autologous Tumor-Infiltrati...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Jazaeri AA, Zsiros E, Amaria RN, et al. Safety & Efficacy of Adoptive Cell Transfer Using Autologous...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] O'Malley D, Lee SM, Psyrri A, et al. Phase 2 Efficacy and Safety of Autologous Tumor-Infiltrating Ly...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Schoenfeld AJ, Lee SM, Doger de Sp√©ville, et al. Lifileucel, an Autologous Tumor-infiltrating Lympho...\n",
      "  ‚Ä¢ [NarrativeText] Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: Rev...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Schoenfeld A, He K, Chesney J, et al. Multicenter Phase II Trial of LN-145 TIL Cell Therapy Plus Pem...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a Tumor-infiltrating Lymphocyte Therapy, in M...\n",
      "  ‚Ä¢ [NarrativeText] Gettinger S, Kluger H, Schoenfeld A, et al. Trial in Progress: A Phase 2, Multicenter Study of Autol...\n",
      "  ‚Ä¢ [NarrativeText] NCT05176470. Available at https://clinicaltrials.gov/ct2/show/NCT05176470. Accessed June 13, 2022. \n",
      "  ‚Ä¢ [NarrativeText] Olson DJ, Larkin J, Hong YK, et al. TILVANCE-301, a Phase 3 Study of Lifileucel Tumor-Infiltrating L...\n",
      "  ‚Ä¢ [NarrativeText] Hong YK, Olson DJ, Larkin J, et al. TILVANCE-301, a Phase 3 Study of Lifileucel Tumor-Infiltrating L...\n",
      "  ‚Ä¢ [NarrativeText] NCT03108495. Available at: https://clinicaltrials.gov/ct2/show/NCT03108495. Accessed June 13, 2022.\n",
      "  ‚Ä¢ [NarrativeText] Chesney JA, Schoenfeld AJ, Wise-Draper T, et al. Trial In Progress: A Phase 2 Multicenter Study (IOV...\n",
      "  ‚Ä¢ [NarrativeText] NCT03449108. Available at https://clinicaltrials.gov/ct2/show/NCT03449108. Accessed June 13, 2022.\n",
      "  ‚Ä¢ [NarrativeText] NCT04111510. Available at https://clinicaltrials.gov/ct2/show/NCT04111510. Accessed June 13, 2022.\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] NCT05361174. Available at https://clinicaltrials.gov/ct2/show/NCT05361174. Accessed June 13, 2022.\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [UncategorizedText] Ritthipichai K, Machin M, Juillerat A, Poirot L, Fardis M, Chartier C. Genetic Modification of Iovan...\n",
      "  ‚Ä¢ [NarrativeText] Natarajan A, Veerapathran A, Wells A, et al. Preclinical Activity and Manufacturing Feasibility of G...\n",
      "\n",
      "üìÑ prc-us-00483-ref4-NCCN Guidelines Cutaneous Melanoma V2 2025.pdf (232 removed)\n",
      "  ‚Ä¢ [Title] Footnotes on ME-6A Neoadjuvant references on ME-6B\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-6\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] REFERENCES FOR NEOADJUVANT THERAPY\n",
      "  ‚Ä¢ [Title] Neoadjuvant references on ME-6B\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] MELSYS 1 OF 7\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [Footer] Note: All dati te 2A unl therwise indicated jote: recommenaations are categor unless otherwise indic...\n",
      "  ‚Ä¢ [Title] SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE DISEASE REFERENCES\n",
      "  ‚Ä¢ [Title] SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE DISEASE REFERENCES\n",
      "  ‚Ä¢ [Title] OTHER SYSTEMIC THERAPIES ‚Äì REFERENCES\n",
      "  ‚Ä¢ [Title] OTHER SYSTEMIC THERAPIES ‚Äì REFERENCES\n",
      "  ‚Ä¢ [Title] OTHER SYSTEMIC THERAPIES ‚Äì REFERENCES\n",
      "  ‚Ä¢ [Title] RISK FACTORS FOR DEVELOPMENT OF SINGLE OR MULTIPLE PRIMARY MELANOMAS REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 Siegel RL, Miller KD, Fuchs BS, et al. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7-33.\n",
      "  ‚Ä¢ [ListItem] 2 Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi. Markers for increased risk for melanoma. Can...\n",
      "  ‚Ä¢ [NarrativeText] 3 Chen ST, Geller AC, Tsao H. Update on the epidemiology of melanoma. Curr Dermatol Rep 2013;2:24-34...\n",
      "  ‚Ä¢ [ListItem] 4 Wu S, Han J, Laden F, Qureshi AA. Long-term ultraviolet flux, other potential risk factors, and sk...\n",
      "  ‚Ä¢ [ListItem] 5 Lam CJ, Curtis RE, Dores GM, et al. Risk factors for melanoma among survivors of non-Hodgkin lymph...\n",
      "  ‚Ä¢ [ListItem] 6 Olsen CM, Lane SW, Green AC. Increased risk of melanoma in patients with chronic lymphocytic leuka...\n",
      "  ‚Ä¢ [ListItem] 7 Pappo AS, Armstrong GT, Liu W, et al. Melanoma as a subsequent neoplasm in adult survivors of chil...\n",
      "  ‚Ä¢ [ListItem] 8 Robbins HA, Clarke CA, Arron ST, et al. Melanoma risk and survival among organ transplant recipien...\n",
      "  ‚Ä¢ [ListItem] 9 Omland SH, Gniadecki R, Haedersdal M, et al. Skin cancer risk in hematopoietic stem-cell transplan...\n",
      "  ‚Ä¢ [ListItem] 10 Olsen CM, Knight LL, Green AC. Risk of melanoma in people with HIV/AIDS in the pre- and post-HAAR...\n",
      "  ‚Ä¢ [ListItem] 11 Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalit...\n",
      "  ‚Ä¢ [ListItem] 12 Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamar...\n",
      "  ‚Ä¢ [UncategorizedText] 9595.\n",
      "  ‚Ä¢ [NarrativeText] 16 Funchain P, Ni Y, Heald B, et al. Germline cancer susceptibility in individuals with melanoma. J ...\n",
      "  ‚Ä¢ [ListItem] 18 Lazovich D, Vogel RI, Berwick M, et al. Indoor tanning and risk of melanoma: a case-control study...\n",
      "  ‚Ä¢ [NarrativeText] 19 Cust AE, Armstrong BK, Goumas C, et al. Sunbed use during adolescence and early adulthood is asso...\n",
      "  ‚Ä¢ [NarrativeText] 20 Richards TB, Johnson CJ, Tatalovich Z, et al. Association between cutaneous melanoma incidence ra...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-A 2 OF 2\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] REFERENCES FOR PRINCIPLES OF PATHOLOGY FOR PRIMARY MELANOMA\n",
      "  ‚Ä¢ [NarrativeText] 1 Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneo...\n",
      "  ‚Ä¢ [NarrativeText] 3 Gershenwald JE, Scolyer RA, Hess JM, et al. Melanoma of the Skin In: Amin MB, Edge SB, Green FL, e...\n",
      "  ‚Ä¢ [ListItem] 4 Shon W, Frishberg DP, Gershenwald J, et al. Protocol for the examination of biopsy specimens from ...\n",
      "  ‚Ä¢ [ListItem] 5 Shon W, Frishberg DP, Gershenwald J, et al. Protocol for the examination of excision specimens fro...\n",
      "  ‚Ä¢ [ListItem] 6 Barnhill RL, Elder DE, Piepkorn MW, et al. Revision of the Melanocytic Pathology Assessment Tool a...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-B 3 OF 3\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF IMAGING REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 Gold JS, Jaques DP, Busam KJ, et al. Yield and predictors of radiologic studies for identifying di...\n",
      "  ‚Ä¢ [ListItem] 2 Leiter U, Buettner PG, Eigentler TK, et al. Is detection of melanoma metastasis during surveillanc...\n",
      "  ‚Ä¢ [ListItem] 3 Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomogra...\n",
      "  ‚Ä¢ [ListItem] 4 Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutan...\n",
      "  ‚Ä¢ [ListItem] 5 Moore Dalal K, Zhou Q, Panageas KS, et al. Methods of detection of first recurrence in patients wi...\n",
      "  ‚Ä¢ [ListItem] 6 Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomograph...\n",
      "  ‚Ä¢ [ListItem] 7 Podlipnik S, Carrera C, Sanchez M, et al. Performance of diagnostic tests in an intensive follow-u...\n",
      "  ‚Ä¢ [ListItem] 13 Voit CA, van Akkooi ACJ, Schafer-Hesterberg G, et al. Rotterdam Criteria for sentinel node (SN) t...\n",
      "  ‚Ä¢ [ListItem] 14 Voit CA, Oude CMC, Ulrich J, et al. Ultrasound of the sentinel node in melanoma patients: echo-fr...\n",
      "  ‚Ä¢ [ListItem] 15 Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node...\n",
      "  ‚Ä¢ [ListItem] 16 Bartlett E, Lee AY, Spanheimer PM, et al. Nodal and systemic recurrence following observation of ...\n",
      "  ‚Ä¢ [ListItem] 17 Schr√∂er-G√ºnther MA, Wolff RF, Westwood ME, et al. F-18-fluoro-2- deoxyglucose positron emission t...\n",
      "  ‚Ä¢ [ListItem] 18 Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging a...\n",
      "  ‚Ä¢ [ListItem] 19 Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol 2009;20:vi1...\n",
      "  ‚Ä¢ [ListItem] 8 Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patien...\n",
      "  ‚Ä¢ [ListItem] 20 Gao G, Gong B, Shen W. Meta-analysis of the additional value of integrated 18FDG PET-CT for tumor...\n",
      "  ‚Ä¢ [ListItem] 9 Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging an...\n",
      "  ‚Ä¢ [ListItem] 10 Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagn...\n",
      "  ‚Ä¢ [NarrativeText] 11 Dieng M, Lord SJ, Turner RM, et al. The impact of surveillance imaging\n",
      "  ‚Ä¢ [UncategorizedText] frequency on the detection of distant disease for patients with resected stage III\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF SURGICAL MARGINS FOR WIDE EXCISION OF PRIMARY MELANOMA REFERENCES\n",
      "  ‚Ä¢ [ListItem] 1 Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comp...\n",
      "  ‚Ä¢ [NarrativeText] 14 Le M, Gabrielli S, Zloty D. Mohs Micrographic Surgery Is Equivalent to Nail Unit Excision or Ampu...\n",
      "  ‚Ä¢ [ListItem] 2 Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melan...\n",
      "  ‚Ä¢ [ListItem] 3 Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the ...\n",
      "  ‚Ä¢ [ListItem] 4 Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thick...\n",
      "  ‚Ä¢ [ListItem] 5 Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 ...\n",
      "  ‚Ä¢ [ListItem] 6 Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for le...\n",
      "  ‚Ä¢ [ListItem] 7 Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N E...\n",
      "  ‚Ä¢ [ListItem] 8 Hayes AJ, Maynard L, Coombes G, et al. Wide versus narrow excision margins for high-risk, primary ...\n",
      "  ‚Ä¢ [ListItem] 15 MacKenzie Ross AD, Haydu LE, Quinn MJ, et al. The association between excision margins and local ...\n",
      "  ‚Ä¢ [ListItem] 16 Haydu LE, Stollman JT, Scolyer RA, et al. Minimum safe pathologic excision margins for primary cu...\n",
      "  ‚Ä¢ [ListItem] 17 Lamboo LG, Haydu LE, Scolyer RA, et al. The optimum excision margin and regional node management ...\n",
      "  ‚Ä¢ [ListItem] 18 Pasquali S, Haydu LE, Scolyer RA, et al. The importance of adequate primary tumor excision margin...\n",
      "  ‚Ä¢ [ListItem] 19 Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol ...\n",
      "  ‚Ä¢ [ListItem] 20 de Vries K, Greveling K, Prens LM, et al. Recurrence rate of lentigo maligna after micrographical...\n",
      "  ‚Ä¢ [ListItem] 9 Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary c...\n",
      "  ‚Ä¢ [ListItem] 21 Hanson J, Demer A, Liszewski W, et al. Improved overall survival of melanoma of the head and neck...\n",
      "  ‚Ä¢ [ListItem] 10 Utjes D, Malmstedt J, Teras J, et al. 2-cm versus 4-cm surgical excision margins for primary cuta...\n",
      "  ‚Ä¢ [NarrativeText] multicentre, randomised trial. Lancet 2019;394:471-477.\n",
      "  ‚Ä¢ [ListItem] 11 Maurichi A, Barretta F, Patuzzo R, et al. Association of excision margin size with local recurren...\n",
      "  ‚Ä¢ [ListItem] 12 Adelsteinsson JN, Stoj VJ, Algzlan H, et al. Limitations in the literature regarding Mohs surgery...\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF SURGICAL MARGINS FOR WIDE EXCISION OF PRIMARY MELANOMA REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 26 Longo C, Navarrete-Dechent C, Tschandl P, et al. Delphi Consensus Among International Experts on ...\n",
      "  ‚Ä¢ [NarrativeText] 27 Kwak R, Joyce C, Werchniak AE, et al. Clinical and histologic features associated with lentigo ma...\n",
      "  ‚Ä¢ [NarrativeText] 28 Guitera P, Waddell A, Paton E, et al. A practical guide on the use of imiquimod cream to treat le...\n",
      "  ‚Ä¢ [NarrativeText] 30 Tio D, van der Woude J, Prinsen CAC, et al. A systematic review on the role of imiquimod in lenti...\n",
      "  ‚Ä¢ [ListItem] 31 Swetter SM, Chen FW, Kim DD, Egbert BM. Imiquimod 5% cream as primary or adjuvant therapy for mel...\n",
      "  ‚Ä¢ [ListItem] 32 Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monot...\n",
      "  ‚Ä¢ [NarrativeText] 33 Hendrickx A, Cozzio A, Plasswilm L, Panje CM. Radiotherapy for lentigo maligna and lentigo malign...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-E 3 OF 3\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Footer] , ‚Äî‚Äî Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF SENTINEL LYMPH NODE BIOPSY (SLNB) REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 El Sharouni MA, Stodell MD, Ahmed T, et al. Sentinel node biopsy in patients with melanoma improve...\n",
      "  ‚Ä¢ [ListItem] 2 Multicenter Selective Lymphadenectomy Trials Study Group, Crystal JS, Thompson JF, Hyngstrom J, et...\n",
      "  ‚Ä¢ [NarrativeText] 3 Hanna AN, Sinnamon AJ, Roses RE, et al. Relationship between age and likelihood of lymph node meta...\n",
      "  ‚Ä¢ [NarrativeText] 4 Sinnamon AJ, Neuwirth MG, Yalamanchi P, et al. Association between patient age and lymph node posi...\n",
      "  ‚Ä¢ [ListItem] 7 Miller JR 3rd, Lo SN, Nosrati M, et al. Improving Selection for Sentinel Lymph Node Biopsy Among P...\n",
      "  ‚Ä¢ [NarrativeText] Expression Profiling of Primary Cutaneous Melanoma. Ann Surg Oncol. 2024 Oct 29. doi: 10.1245/s10434...\n",
      "  ‚Ä¢ [ListItem] 9 Scolyer R, Balamurgan T, Busam K, et al. Invasive Melanoma, Histopathology Reporting Guide, 2nd Ed...\n",
      "  ‚Ä¢ [ListItem] 10 Lezcano C, Pulitzer M, Moy AP, et al. Immunohistochemistry for PRAME in the distinction of nodal ...\n",
      "  ‚Ä¢ [UncategorizedText] 508.\n",
      "  ‚Ä¢ [ListItem] 11 Lezcano C, Jungbluth AA, Nehal KS, et al. PRAME Expression in melanocytic tumors. Am J Surg Patho...\n",
      "  ‚Ä¢ [NarrativeText] 12 Lezcano C, Jungbluth AA, Busum K, et al. Comparison of immunohistochemistry for PRAME with cytoge...\n",
      "  ‚Ä¢ [NarrativeText] 13 LeBlanc RE, Barton DT, Li Z, et al. Small and isolated immunohistochemistry-positive cells in mel...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-F\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [ListItem] 1 Schermers B, Franke V, Rozeman EA, et al. Surgical removal of the index node marked using magnetic...\n",
      "  ‚Ä¢ [ListItem] 2 Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo a...\n",
      "  ‚Ä¢ [ListItem] 3 Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvan...\n",
      "  ‚Ä¢ [ListItem] 4 Reijers ILM, Rawson RV, Colebatch AJ, et al. Representativeness of the Index Lymph Node for Total ...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-G\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF RADIATION THERAPY REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 Adams G, Foote M, Brown S, Burmeister B. Adjuvant external beam radiotherapy after therapeutic gro...\n",
      "  ‚Ä¢ [ListItem] 2 Mattes MD, Zhou Y, Berry SL, Barker CA. Dosimetric comparison of axilla and groin radiotherapy tec...\n",
      "  ‚Ä¢ [ListItem] 3 Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo malign...\n",
      "  ‚Ä¢ [ListItem] 4 Harwood AR. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentig...\n",
      "  ‚Ä¢ [ListItem] 5 Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma....\n",
      "  ‚Ä¢ [ListItem] 6 Christie DR, Tiver KW. Radiotherapy for melanotic freckles. Australas Radiol 1996;40:331-333.\n",
      "  ‚Ä¢ [ListItem] 7 Agrawal S, Kane JM III, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after the...\n",
      "  ‚Ä¢ [ListItem] 8 Rule WG, Allred JB, Pockaj BA, et al. Results of NCCTG N0275 (Alliance) - a phase II trial evaluat...\n",
      "  ‚Ä¢ [ListItem] 9 Guadagnolo BA, Prieto V, Weber R, et al. The role of adjuvant radiotherapy in the local management...\n",
      "  ‚Ä¢ [NarrativeText] 10 Strom T, Caudell JJ, Han D, et al. Radiotherapy influences local control in\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF RADIATION THERAPY REFERENCES\n",
      "  ‚Ä¢ [ListItem] 27 Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with who...\n",
      "  ‚Ä¢ [ListItem] 28 Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole...\n",
      "  ‚Ä¢ [ListItem] 38 Seung SK, Curti BD, Crittenden M, et al. Phase 1 study of stereotactic body radiotherapy and inte...\n",
      "  ‚Ä¢ [ListItem] 39 Singh D, Chen Y, Hare MZ, et al. Local control rates with five-fraction stereotactic body radioth...\n",
      "  ‚Ä¢ [ListItem] 40 Kroeze SG, Fritz C, Hoyer M, et al. Toxicity of concurrent stereotactic radiotherapy and targeted...\n",
      "  ‚Ä¢ [ListItem] 29 Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus mema...\n",
      "  ‚Ä¢ [ListItem] 41 Bang A, Wilhite TJ, Pike LRG, et al. Multicenter evaluation of the tolerability of combined treat...\n",
      "  ‚Ä¢ [ListItem] 30 Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotac...\n",
      "  ‚Ä¢ [ListItem] 31 Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patie...\n",
      "  ‚Ä¢ [ListItem] 42 Barker CA, Postow MA, Khan SA, et al. Concurrent radiotherapy and ipilimumab immunotherapy for pa...\n",
      "  ‚Ä¢ [ListItem] 43 Anker CJ, Ribas A, Grossmann AH, et al. Severe liver and skin toxicity after radiation and vemura...\n",
      "  ‚Ä¢ [ListItem] 44 Peuvrel L, Ruellan AL, Thillays F, et al. Severe radiotherapy-induced extracutaneous toxicity und...\n",
      "  ‚Ä¢ [ListItem] 32 Hong AM, Fogarty GB, Dolven-Jacobsen K, et al. Adjuvant whole-brain radiation therapy compared wi...\n",
      "  ‚Ä¢ [ListItem] 45 Anker CJ, Grossmann KF, Atkins MB, et al. Avoiding severe toxicity from combined BRAF inhibitor a...\n",
      "  ‚Ä¢ [ListItem] 33 Olivier KR, Schild SE, Morris CG, et al. A higher radiotherapy dose is associated with more durab...\n",
      "  ‚Ä¢ [ListItem] 46 Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated wit...\n",
      "  ‚Ä¢ [ListItem] 34 Gerszten PC, Burton SA, Quinn AE, et al. Radiosurgery for the treatment of spinal melanoma metast...\n",
      "  ‚Ä¢ [ListItem] 35 Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma an...\n",
      "  ‚Ä¢ [ListItem] 36 Sahgal A, Roberge D, Schellenberg D, et al. The Canadian Association of Radiation Oncology scope ...\n",
      "  ‚Ä¢ [ListItem] 47 Hiniker SM, Reddy SA, Maecker HT, et al. A prospective clinical trial combining radiation therapy...\n",
      "  ‚Ä¢ [ListItem] 48 Williams NL, Wuthrick EJ, Kim H, et al. Phase 1 study of ipilimumab combined with whole brain rad...\n",
      "  ‚Ä¢ [ListItem] stereotactic body radiotherapy. Clin Oncol (R Coll Radiol) 2012;24:629-639.\n",
      "  ‚Ä¢ [ListItem] 37 Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal ...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-H 7 OF 7\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Footer] - ‚Äî‚Äî Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF NEOADJUVANT THERAPY REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 Patel SP, Othus M, Chen Y, et al. Neoadjuvant -adjuvant or adjuvant only pembrolizumab in advanced...\n",
      "  ‚Ä¢ [NarrativeText] 3 Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage II...\n",
      "  ‚Ä¢ [ListItem] 5 Tetzlaff MT, Adhikari C, Lo S, et al. Histopathological features of complete pathological response...\n",
      "  ‚Ä¢ [ListItem] 6 Rawson RV, Adhikari C, Bierman C, et al. Pathological response and tumour bed histopathological fe...\n",
      "  ‚Ä¢ [ListItem] 7 Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations...\n",
      "  ‚Ä¢ [ListItem] 8 Sharon CE, Tortorello GN, Ma KL, et al. Long-term outcomes to neoadjuvant pembrolizumab based on p...\n",
      "  ‚Ä¢ [ListItem] 9 Blank CU, Reijers L, Saw RPM, et al. Survival data of PRADO: a phase 2 study of personalized respo...\n",
      "  ‚Ä¢ [ListItem] 10 Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolu...\n",
      "  ‚Ä¢ [ListItem] 11 Dummer R, Gyorki DE, Hyngstrom J, et al. Neoadjuvant talimogene laherparepvec plus surgery versus...\n",
      "  ‚Ä¢ [ListItem] 12 Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanom...\n",
      "  ‚Ä¢ [ListItem] 14 Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib ver...\n",
      "  ‚Ä¢ [ListItem] 15 Reijers ILM, Menzies AM, Versluis JM, et al. The impact of response-directed surgery and adjuvant...\n",
      "  ‚Ä¢ [ListItem] 16 Bhave P, Hong A, Lo SN, et al. Efficacy and toxicity of adjuvant radiotherapy in recurrent melano...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-I 6 OF 6\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] 1 Maloney NJ, Rana J, Yang JJ, et al. Clinical features of drug-induced hypersensitivity syndrome to...\n",
      "  ‚Ä¢ [NarrativeText] 2 Lamiaux M, Scalbert C, Lepesant P, et al. Severe skin toxicity with organ damage under the combina...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-K\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF BRAIN METASTASES MANAGEMENT REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 Tawbi HA-H, Forsyth PAJ, Hodi FS, et al. Efficacy and safety of the combination of nivolumab (NIVO...\n",
      "  ‚Ä¢ [NarrativeText] 2 Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain me...\n",
      "  ‚Ä¢ [NarrativeText] 3 Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases...\n",
      "  ‚Ä¢ [ListItem] 5 Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-posit...\n",
      "  ‚Ä¢ [ListItem] 6 Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant...\n",
      "  ‚Ä¢ [ListItem] 7 Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation...\n",
      "  ‚Ä¢ [ListItem] 8 Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus meman...\n",
      "  ‚Ä¢ [ListItem] 9 Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the ma...\n",
      "  ‚Ä¢ [ListItem] 10 Chen CC, Rennert RC, Olson JJ. Congress of Neurological Surgeons Systematic Review and Evidence-B...\n",
      "  ‚Ä¢ [ListItem] 11 Glitza IC, Guha-Thakurta N, D'Souza NM, et al. Bevacizumab as an effective treatment for radiatio...\n",
      "  ‚Ä¢ [UncategorizedText] Melanoma Res 2017;27:580-584.\n",
      "  ‚Ä¢ [ListItem] 12 Sep√∫lveda-S√°nchez JM and P√©rez-N√∫√±ez A. The ESMO-EANO clinical practice guidelines for neurologic...\n",
      "  ‚Ä¢ [NarrativeText] 13 Anker CJ, Grossmann KF, Atkins MB, et al. Avoiding severe toxicity from combined BRAF inhibitor a...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-L 5 OF 5\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] Name and References\n",
      "  ‚Ä¢ [Image] Brain Tx   78%b   41%   None   14%   HD-ipi (n = 51)   --   71%b   48%   All   HD-ipi (n = 21)   5% ...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. Available ...\n",
      "  ‚Ä¢ [Table] http://www.ncbi.nlm.nih.gov/pubmed/26742998. http://www.ncbi.nlm.nih.gov/pubmed/24629998. 11. Gordon...\n",
      "  ‚Ä¢ [NarrativeText] 9. Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. Dermatol Surg 2006;32:481-492. Avail...\n",
      "  ‚Ä¢ [NarrativeText] Version 2.2025 ¬© 2025 National Comprehensive Cancer Network¬© (NCCN¬©), All rights reserved. NCCN Guid...\n",
      "  ‚Ä¢ [UncategorizedText] MS-84\n",
      "\n",
      "üìÑ prc-us-00469-ref2-Chesney 2022.pdf (19 removed)\n",
      "  ‚Ä¢ [Title] REFERENCES\n",
      "  ‚Ä¢ [ListItem] 1 Arnold M, Singh D, Laversanne M, et a/. Global burden of cutaneous melanoma in 2020 and projection...\n",
      "  ‚Ä¢ [ListItem] 2 Long GV, Robert C, Butler MO, et al. Standard-Dose pembrolizumab plus Alternate-Dose ipilimumab in...\n",
      "  ‚Ä¢ [ListItem] 3 Postow MA, Goldman DA, Shoushtari AN, et a/. Adaptive dosing of nivolumab + ipilimumab immunothera...\n",
      "  ‚Ä¢ [ListItem] 4 Tawbi HA, Schadendorf D, Lipson Eu, et a/. Relatlimab and nivolumab versus nivolumab in untreated ...\n",
      "  ‚Ä¢ [ListItem] 5 Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy i...\n",
      "  ‚Ä¢ [ListItem] 6 Mooradian MJ, Sullivan RJ. What to do when anti-PD-1 therapy fails in patients with melanoma. Onco...\n",
      "  ‚Ä¢ [ListItem] 7 Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma ...\n",
      "  ‚Ä¢ [ListItem] 8 Wolchok JD, Chiarion-Sileni V, Gonzalez R, et a/. Overall survival with combined nivolumab and ipi...\n",
      "  ‚Ä¢ [ListItem] 9 Betof Warner A, Palmer JS, Shoushtari AN, et a/. Long-term outcomes and responses to retreatment i...\n",
      "  ‚Ä¢ [ListItem] 10 Dummer R, Ascierto PA, Gogas Hy, et a/. Encorafenib plus binimetinib versus vemurafenib or encora...\n",
      "  ‚Ä¢ [ListItem] 11 Sosman JA, Kim KB, Schuchter L, et a/. Survival in BRAF V600- mutant advanced melanoma treated wi...\n",
      "  ‚Ä¢ [ListItem] 12 Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in ...\n",
      "  ‚Ä¢ [ListItem] 13 Long GV, Menzies AM, Nagrial AM, et a/. Prognostic and clinicopathologic associations of oncogeni...\n",
      "  ‚Ä¢ [ListItem] 14 Mason R, Heng ¬ß, Atkinson V. Outcomes following progression on BRAF/MEK inhibition in metastatic ...\n",
      "  ‚Ä¢ [ListItem] 15 Keytruda. Prescribing information, 2021.\n",
      "  ‚Ä¢ [ListItem] 16 Weber JS, D'Angelo SP, Minor D, et a/. Nivolumab versus chemotherapy in patients with advanced me...\n",
      "  ‚Ä¢ [ListItem] 17 Goldinger SM, Buder-Bakhaya K, Lo SN, et a/. Chemotherapy after immune checkpoint inhibitor failu...\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, et al. J Immunother Cancer 2022;10:e005755. doi:10.1136/jitc-2022-005755\n",
      "\n",
      "üìÑ Sarnaik_C-144-01-Cohort-2-4-SITC-Poster_Nov2022-2409-publication.pdf (6 removed)\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [NarrativeText] Cybulska-Stopa B et al. l. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of...\n",
      "  ‚Ä¢ [UncategorizedText] 6.\n",
      "  ‚Ä¢ [UncategorizedText] |\n",
      "  ‚Ä¢ [NarrativeText] Rosenberg SA et al. Durable complete responses in heavily pretreated patients with metastatic melano...\n",
      "\n",
      "üìÑ PRC_AMTAGVI updated HCP website (April 2025)_041025.pdf (9 removed)\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor...\n",
      "  ‚Ä¢ [UncategorizedText] J,\n",
      "  ‚Ä¢ [ListItem] 2. Larkin Chiarion-Sileni 2019;381(16):1535-1546.\n",
      "  ‚Ä¢ [NarrativeText] V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma...\n",
      "\n",
      "üìÑ PRJ5231_AMTAGVI_Website_Updates_v6_FCv1_EK.pdf (42 removed)\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [NarrativeText] AMTAGVI. Prescribing Information. Iovance Biotherapeutics, Inc.; 2024. Referenced with permission fr...\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [UncategorizedText] 2.\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, Lewis KD, Kluger H, et al. Ecacy and safety of liÔ¨Åleucel, a one-time autologous tumor-inÔ¨Å...\n",
      "  ‚Ä¢ [UncategorizedText] 3.\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [NarrativeText] 1. Chesney J, Lewis KD, Kluger H, et al. Ecacy and safety of liÔ¨Åleucel, a one-time autologous tumor-...\n",
      "  ‚Ä¢ [UncategorizedText] J Immunother Cancer. 2022;10(12):e005755.\n",
      "  ‚Ä¢ [UncategorizedText] 2.\n",
      "  ‚Ä¢ [NarrativeText] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipili...\n",
      "  ‚Ä¢ [UncategorizedText] 2019;381(16):1535-1546.\n",
      "  ‚Ä¢ [ListItem] 3. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 4. Tawbi HA, Schadendorf D, Lipson EJ, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [UncategorizedText] 5.\n",
      "  ‚Ä¢ [NarrativeText] Patrinely JR Jr, Baker LX, Davis EJ, Song H, Ye F, Johnson DB. Outcomes after progression of disease...\n",
      "  ‚Ä¢ [UncategorizedText] melanoma. Cancer. 2020;126(15):3448-3455.\n",
      "  ‚Ä¢ [NarrativeText] 6. AMTAGVI. Prescribing Information. Iovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [UncategorizedText] IDV, ANCE PRIVACY POLICY WASHINGTON HEALTH DATA PRIVACY POLICY TERMS OF USE BIOTHERAPEUTICS SITE MAP\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [ListItem] 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline...\n",
      "  ‚Ä¢ [ListItem] 3. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [NarrativeText] YOVANCE BIOTHERAPEUTICS\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [ListItem] 2. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [ListItem] 3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five- year survival with combined nivolumab and i...\n",
      "  ‚Ä¢ [ListItem] 4. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 5. Tawbi HA, Schadendorf D, Lipson Eu, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [ListItem] 2. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five- year survival with combined nivolumab and i...\n",
      "  ‚Ä¢ [ListItem] 3. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 4. Tawbi HA, Schadendorf D, Lipson Eu, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [ListItem] 5. Patrinely JR Jr, Baker LX, Davis EJ, Song H, Ye F, Johnson DB. Outcomes after progression of dise...\n",
      "  ‚Ä¢ [ListItem] 6. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [NarrativeText] YOVANCE BIOTHERAPEUTICS\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "\n",
      "üìÑ prc-us-xxxxx-ref2-Tawbi 2022.pdf (28 removed)\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] 1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [NarrativeText] 3. Durham NM, Nirschl CJ, Jackson CM, et al. Lymphocyte Activation Gene 3 (LAG-3) modulates the abil...\n",
      "  ‚Ä¢ [NarrativeText] 4. Workman CJ, Cauley LS, Kim I-J, Blackman MA, Woodland DL, Vignali DAA. Lymphocyte activation gene...\n",
      "  ‚Ä¢ [NarrativeText] 5. Hemon P, Jean-Louis F, Ramgolam K, et al. MHC class II engagement by its li- gand LAG-3 (CD223) c...\n",
      "  ‚Ä¢ [NarrativeText] 6. Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergisticall...\n",
      "  ‚Ä¢ [NarrativeText] 9. Ascierto PA, Melero I, Bhatia S, et al. Initial efficacy of anti-lymphocyte activa- tion gene-3 (...\n",
      "  ‚Ä¢ [NarrativeText] 10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:...\n",
      "  ‚Ä¢ [NarrativeText] 11. American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. Chi- cago: American Coll...\n",
      "  ‚Ä¢ [NarrativeText] 13. Rabin R, de Charro F. EQ-5D: a mea- sure of health status from the EuroQol Group. Ann Med 2001; ...\n",
      "  ‚Ä¢ [NarrativeText] 14. Phillips T, Millett MM, Zhang X, et al. Development of a diagnostic programmed cell death 1‚Äìliga...\n",
      "  ‚Ä¢ [NarrativeText] EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007; 5: 70. 18. Wolchok JD, Chiar...\n",
      "  ‚Ä¢ [NarrativeText] 19. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone vers...\n",
      "  ‚Ä¢ [NarrativeText] 20. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, ESMO Guide- lines Committee. Cut...\n",
      "  ‚Ä¢ [NarrativeText] 21. Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Onco...\n",
      "  ‚Ä¢ [NarrativeText] noma without BRAF mutation. N Engl J\n",
      "  ‚Ä¢ [NarrativeText] 7. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with speciali...\n",
      "  ‚Ä¢ [NarrativeText] 8. Lipson E, Gopal A, Neelapu SS, et al. Initial experience administering BMS- 986016, a monoclonal ...\n",
      "  ‚Ä¢ [NarrativeText] 15. Dillon LM, Wojcik J, Desai K, et al. Distribution and prevalence of LAG-3 ex- pression in sample...\n",
      "  ‚Ä¢ [NarrativeText] 16. Askew RL, Xing Y, Palmer JL, Cella D, Moye LA, Cormier JN. Evaluating mini- mal important differ...\n",
      "  ‚Ä¢ [NarrativeText] 17. Pickard AS, Neary MP, Cella D. Estima- tion of minimally important differences in\n",
      "  ‚Ä¢ [UncategorizedText] Med 2015; 372: 320-30.\n",
      "  ‚Ä¢ [NarrativeText] 24. Long GV, Dummer R, Hamid O, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizu...\n",
      "  ‚Ä¢ [NarrativeText] 25. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in ad- vanced melanoma. N...\n",
      "  ‚Ä¢ [NarrativeText] Copyright ¬© 2022 Massachusetts Medical Society.\n",
      "  ‚Ä¢ [NarrativeText] n engl j med 386;1 nejm.org January 6, 2022\n",
      "  ‚Ä¢ [NarrativeText] The New England Journal of Medicine\n",
      "  ‚Ä¢ [NarrativeText] Downloaded from nejm.org at Copyright Clearance Center on January 6, 2022. For personal use only. No...\n",
      "\n",
      "üìÑ ANN_5231_AMTAGVI HCP Website Layouts_R3_040725.pdf (18 removed)\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [NarrativeText] 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline...\n",
      "  ‚Ä¢ [ListItem] 3. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [Image] | IV, AN C E BIOTHERAPEUTICS\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [NarrativeText] 2. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [ListItem] 3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [ListItem] 4. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 5. Tawbi HA, Schadendorf D, Lipson Eu, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [ListItem] 2. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [ListItem] 3. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 4. Tawbi HA, Schadendorf D, Lipson Ev, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [ListItem] 5. Patrinely JR Jr, Baker LX, Davis EJ, Song H, Ye F, Johnson DB. Outcomes after progression of dise...\n",
      "  ‚Ä¢ [ListItem] 6. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "\n",
      "üìÑ 5231_AMTAGVI Website Updates_Layout_R2_040225_RD.pdf (4 removed)\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "\n",
      "üìÑ CLEAN_5231_AMTAGVI HCP Website Layouts_R3_040725.pdf (18 removed)\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [NarrativeText] 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline...\n",
      "  ‚Ä¢ [ListItem] 3. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [Image] | IV, AN C E BIOTHERAPEUTICS\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [NarrativeText] 2. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [ListItem] 3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [ListItem] 4. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 5. Tawbi HA, Schadendorf D, Lipson Eu, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [ListItem] 2. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [ListItem] 3. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 4. Tawbi HA, Schadendorf D, Lipson Ev, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [ListItem] 5. Patrinely JR Jr, Baker LX, Davis EJ, Song H, Ye F, Johnson DB. Outcomes after progression of dise...\n",
      "  ‚Ä¢ [ListItem] 6. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "\n",
      "üìÑ PRJ5231_AMTAGVI_Website_Updates_v6_FCv1.pdf (42 removed)\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [NarrativeText] AMTAGVI. Prescribing Information. Iovance Biotherapeutics, Inc.; 2024. Referenced with permission fr...\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [UncategorizedText] 2.\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, Lewis KD, Kluger H, et al. Ecacy and safety of liÔ¨Åleucel, a one-time autologous tumor-inÔ¨Å...\n",
      "  ‚Ä¢ [UncategorizedText] 3.\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [NarrativeText] 1. Chesney J, Lewis KD, Kluger H, et al. Ecacy and safety of liÔ¨Åleucel, a one-time autologous tumor-...\n",
      "  ‚Ä¢ [UncategorizedText] J Immunother Cancer. 2022;10(12):e005755.\n",
      "  ‚Ä¢ [UncategorizedText] 2.\n",
      "  ‚Ä¢ [NarrativeText] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipili...\n",
      "  ‚Ä¢ [UncategorizedText] 2019;381(16):1535-1546.\n",
      "  ‚Ä¢ [ListItem] 3. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 4. Tawbi HA, Schadendorf D, Lipson EJ, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [UncategorizedText] 5.\n",
      "  ‚Ä¢ [NarrativeText] Patrinely JR Jr, Baker LX, Davis EJ, Song H, Ye F, Johnson DB. Outcomes after progression of disease...\n",
      "  ‚Ä¢ [UncategorizedText] melanoma. Cancer. 2020;126(15):3448-3455.\n",
      "  ‚Ä¢ [NarrativeText] 6. AMTAGVI. Prescribing Information. Iovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [UncategorizedText] IDV, ANCE PRIVACY POLICY WASHINGTON HEALTH DATA PRIVACY POLICY TERMS OF USE BIOTHERAPEUTICS SITE MAP\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [ListItem] 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline...\n",
      "  ‚Ä¢ [ListItem] 3. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [NarrativeText] YOVANCE BIOTHERAPEUTICS\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [ListItem] 2. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [ListItem] 3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five- year survival with combined nivolumab and i...\n",
      "  ‚Ä¢ [ListItem] 4. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 5. Tawbi HA, Schadendorf D, Lipson Eu, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [ListItem] 2. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five- year survival with combined nivolumab and i...\n",
      "  ‚Ä¢ [ListItem] 3. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 4. Tawbi HA, Schadendorf D, Lipson Eu, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [ListItem] 5. Patrinely JR Jr, Baker LX, Davis EJ, Song H, Ye F, Johnson DB. Outcomes after progression of dise...\n",
      "  ‚Ä¢ [ListItem] 6. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [NarrativeText] YOVANCE BIOTHERAPEUTICS\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "\n",
      "üìÑ prc-us-xxxxx-ref4-NCCN Guidelines Cutaneous Melanoma V2 2025.pdf (232 removed)\n",
      "  ‚Ä¢ [Title] Footnotes on ME-6A Neoadjuvant references on ME-6B\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-6\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] REFERENCES FOR NEOADJUVANT THERAPY\n",
      "  ‚Ä¢ [Title] Neoadjuvant references on ME-6B\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] MELSYS 1 OF 7\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [Footer] Note: All dati te 2A unl therwise indicated jote: recommenaations are categor unless otherwise indic...\n",
      "  ‚Ä¢ [Title] SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE DISEASE REFERENCES\n",
      "  ‚Ä¢ [Title] SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE DISEASE REFERENCES\n",
      "  ‚Ä¢ [Title] OTHER SYSTEMIC THERAPIES ‚Äì REFERENCES\n",
      "  ‚Ä¢ [Title] OTHER SYSTEMIC THERAPIES ‚Äì REFERENCES\n",
      "  ‚Ä¢ [Title] OTHER SYSTEMIC THERAPIES ‚Äì REFERENCES\n",
      "  ‚Ä¢ [Title] RISK FACTORS FOR DEVELOPMENT OF SINGLE OR MULTIPLE PRIMARY MELANOMAS REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 Siegel RL, Miller KD, Fuchs BS, et al. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7-33.\n",
      "  ‚Ä¢ [ListItem] 2 Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi. Markers for increased risk for melanoma. Can...\n",
      "  ‚Ä¢ [NarrativeText] 3 Chen ST, Geller AC, Tsao H. Update on the epidemiology of melanoma. Curr Dermatol Rep 2013;2:24-34...\n",
      "  ‚Ä¢ [ListItem] 4 Wu S, Han J, Laden F, Qureshi AA. Long-term ultraviolet flux, other potential risk factors, and sk...\n",
      "  ‚Ä¢ [ListItem] 5 Lam CJ, Curtis RE, Dores GM, et al. Risk factors for melanoma among survivors of non-Hodgkin lymph...\n",
      "  ‚Ä¢ [ListItem] 6 Olsen CM, Lane SW, Green AC. Increased risk of melanoma in patients with chronic lymphocytic leuka...\n",
      "  ‚Ä¢ [ListItem] 7 Pappo AS, Armstrong GT, Liu W, et al. Melanoma as a subsequent neoplasm in adult survivors of chil...\n",
      "  ‚Ä¢ [ListItem] 8 Robbins HA, Clarke CA, Arron ST, et al. Melanoma risk and survival among organ transplant recipien...\n",
      "  ‚Ä¢ [ListItem] 9 Omland SH, Gniadecki R, Haedersdal M, et al. Skin cancer risk in hematopoietic stem-cell transplan...\n",
      "  ‚Ä¢ [ListItem] 10 Olsen CM, Knight LL, Green AC. Risk of melanoma in people with HIV/AIDS in the pre- and post-HAAR...\n",
      "  ‚Ä¢ [ListItem] 11 Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalit...\n",
      "  ‚Ä¢ [ListItem] 12 Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamar...\n",
      "  ‚Ä¢ [UncategorizedText] 9595.\n",
      "  ‚Ä¢ [NarrativeText] 16 Funchain P, Ni Y, Heald B, et al. Germline cancer susceptibility in individuals with melanoma. J ...\n",
      "  ‚Ä¢ [ListItem] 18 Lazovich D, Vogel RI, Berwick M, et al. Indoor tanning and risk of melanoma: a case-control study...\n",
      "  ‚Ä¢ [NarrativeText] 19 Cust AE, Armstrong BK, Goumas C, et al. Sunbed use during adolescence and early adulthood is asso...\n",
      "  ‚Ä¢ [NarrativeText] 20 Richards TB, Johnson CJ, Tatalovich Z, et al. Association between cutaneous melanoma incidence ra...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-A 2 OF 2\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] REFERENCES FOR PRINCIPLES OF PATHOLOGY FOR PRIMARY MELANOMA\n",
      "  ‚Ä¢ [NarrativeText] 1 Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneo...\n",
      "  ‚Ä¢ [NarrativeText] 3 Gershenwald JE, Scolyer RA, Hess JM, et al. Melanoma of the Skin In: Amin MB, Edge SB, Green FL, e...\n",
      "  ‚Ä¢ [ListItem] 4 Shon W, Frishberg DP, Gershenwald J, et al. Protocol for the examination of biopsy specimens from ...\n",
      "  ‚Ä¢ [ListItem] 5 Shon W, Frishberg DP, Gershenwald J, et al. Protocol for the examination of excision specimens fro...\n",
      "  ‚Ä¢ [ListItem] 6 Barnhill RL, Elder DE, Piepkorn MW, et al. Revision of the Melanocytic Pathology Assessment Tool a...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-B 3 OF 3\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF IMAGING REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 Gold JS, Jaques DP, Busam KJ, et al. Yield and predictors of radiologic studies for identifying di...\n",
      "  ‚Ä¢ [ListItem] 2 Leiter U, Buettner PG, Eigentler TK, et al. Is detection of melanoma metastasis during surveillanc...\n",
      "  ‚Ä¢ [ListItem] 3 Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomogra...\n",
      "  ‚Ä¢ [ListItem] 4 Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutan...\n",
      "  ‚Ä¢ [ListItem] 5 Moore Dalal K, Zhou Q, Panageas KS, et al. Methods of detection of first recurrence in patients wi...\n",
      "  ‚Ä¢ [ListItem] 6 Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomograph...\n",
      "  ‚Ä¢ [ListItem] 7 Podlipnik S, Carrera C, Sanchez M, et al. Performance of diagnostic tests in an intensive follow-u...\n",
      "  ‚Ä¢ [ListItem] 13 Voit CA, van Akkooi ACJ, Schafer-Hesterberg G, et al. Rotterdam Criteria for sentinel node (SN) t...\n",
      "  ‚Ä¢ [ListItem] 14 Voit CA, Oude CMC, Ulrich J, et al. Ultrasound of the sentinel node in melanoma patients: echo-fr...\n",
      "  ‚Ä¢ [ListItem] 15 Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node...\n",
      "  ‚Ä¢ [ListItem] 16 Bartlett E, Lee AY, Spanheimer PM, et al. Nodal and systemic recurrence following observation of ...\n",
      "  ‚Ä¢ [ListItem] 17 Schr√∂er-G√ºnther MA, Wolff RF, Westwood ME, et al. F-18-fluoro-2- deoxyglucose positron emission t...\n",
      "  ‚Ä¢ [ListItem] 18 Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging a...\n",
      "  ‚Ä¢ [ListItem] 19 Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol 2009;20:vi1...\n",
      "  ‚Ä¢ [ListItem] 8 Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patien...\n",
      "  ‚Ä¢ [ListItem] 20 Gao G, Gong B, Shen W. Meta-analysis of the additional value of integrated 18FDG PET-CT for tumor...\n",
      "  ‚Ä¢ [ListItem] 9 Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging an...\n",
      "  ‚Ä¢ [ListItem] 10 Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagn...\n",
      "  ‚Ä¢ [NarrativeText] 11 Dieng M, Lord SJ, Turner RM, et al. The impact of surveillance imaging\n",
      "  ‚Ä¢ [UncategorizedText] frequency on the detection of distant disease for patients with resected stage III\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF SURGICAL MARGINS FOR WIDE EXCISION OF PRIMARY MELANOMA REFERENCES\n",
      "  ‚Ä¢ [ListItem] 1 Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comp...\n",
      "  ‚Ä¢ [NarrativeText] 14 Le M, Gabrielli S, Zloty D. Mohs Micrographic Surgery Is Equivalent to Nail Unit Excision or Ampu...\n",
      "  ‚Ä¢ [ListItem] 2 Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melan...\n",
      "  ‚Ä¢ [ListItem] 3 Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the ...\n",
      "  ‚Ä¢ [ListItem] 4 Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thick...\n",
      "  ‚Ä¢ [ListItem] 5 Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 ...\n",
      "  ‚Ä¢ [ListItem] 6 Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for le...\n",
      "  ‚Ä¢ [ListItem] 7 Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N E...\n",
      "  ‚Ä¢ [ListItem] 8 Hayes AJ, Maynard L, Coombes G, et al. Wide versus narrow excision margins for high-risk, primary ...\n",
      "  ‚Ä¢ [ListItem] 15 MacKenzie Ross AD, Haydu LE, Quinn MJ, et al. The association between excision margins and local ...\n",
      "  ‚Ä¢ [ListItem] 16 Haydu LE, Stollman JT, Scolyer RA, et al. Minimum safe pathologic excision margins for primary cu...\n",
      "  ‚Ä¢ [ListItem] 17 Lamboo LG, Haydu LE, Scolyer RA, et al. The optimum excision margin and regional node management ...\n",
      "  ‚Ä¢ [ListItem] 18 Pasquali S, Haydu LE, Scolyer RA, et al. The importance of adequate primary tumor excision margin...\n",
      "  ‚Ä¢ [ListItem] 19 Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol ...\n",
      "  ‚Ä¢ [ListItem] 20 de Vries K, Greveling K, Prens LM, et al. Recurrence rate of lentigo maligna after micrographical...\n",
      "  ‚Ä¢ [ListItem] 9 Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary c...\n",
      "  ‚Ä¢ [ListItem] 21 Hanson J, Demer A, Liszewski W, et al. Improved overall survival of melanoma of the head and neck...\n",
      "  ‚Ä¢ [ListItem] 10 Utjes D, Malmstedt J, Teras J, et al. 2-cm versus 4-cm surgical excision margins for primary cuta...\n",
      "  ‚Ä¢ [NarrativeText] multicentre, randomised trial. Lancet 2019;394:471-477.\n",
      "  ‚Ä¢ [ListItem] 11 Maurichi A, Barretta F, Patuzzo R, et al. Association of excision margin size with local recurren...\n",
      "  ‚Ä¢ [ListItem] 12 Adelsteinsson JN, Stoj VJ, Algzlan H, et al. Limitations in the literature regarding Mohs surgery...\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF SURGICAL MARGINS FOR WIDE EXCISION OF PRIMARY MELANOMA REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 26 Longo C, Navarrete-Dechent C, Tschandl P, et al. Delphi Consensus Among International Experts on ...\n",
      "  ‚Ä¢ [NarrativeText] 27 Kwak R, Joyce C, Werchniak AE, et al. Clinical and histologic features associated with lentigo ma...\n",
      "  ‚Ä¢ [NarrativeText] 28 Guitera P, Waddell A, Paton E, et al. A practical guide on the use of imiquimod cream to treat le...\n",
      "  ‚Ä¢ [NarrativeText] 30 Tio D, van der Woude J, Prinsen CAC, et al. A systematic review on the role of imiquimod in lenti...\n",
      "  ‚Ä¢ [ListItem] 31 Swetter SM, Chen FW, Kim DD, Egbert BM. Imiquimod 5% cream as primary or adjuvant therapy for mel...\n",
      "  ‚Ä¢ [ListItem] 32 Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monot...\n",
      "  ‚Ä¢ [NarrativeText] 33 Hendrickx A, Cozzio A, Plasswilm L, Panje CM. Radiotherapy for lentigo maligna and lentigo malign...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-E 3 OF 3\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Footer] , ‚Äî‚Äî Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF SENTINEL LYMPH NODE BIOPSY (SLNB) REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 El Sharouni MA, Stodell MD, Ahmed T, et al. Sentinel node biopsy in patients with melanoma improve...\n",
      "  ‚Ä¢ [ListItem] 2 Multicenter Selective Lymphadenectomy Trials Study Group, Crystal JS, Thompson JF, Hyngstrom J, et...\n",
      "  ‚Ä¢ [NarrativeText] 3 Hanna AN, Sinnamon AJ, Roses RE, et al. Relationship between age and likelihood of lymph node meta...\n",
      "  ‚Ä¢ [NarrativeText] 4 Sinnamon AJ, Neuwirth MG, Yalamanchi P, et al. Association between patient age and lymph node posi...\n",
      "  ‚Ä¢ [ListItem] 7 Miller JR 3rd, Lo SN, Nosrati M, et al. Improving Selection for Sentinel Lymph Node Biopsy Among P...\n",
      "  ‚Ä¢ [NarrativeText] Expression Profiling of Primary Cutaneous Melanoma. Ann Surg Oncol. 2024 Oct 29. doi: 10.1245/s10434...\n",
      "  ‚Ä¢ [ListItem] 9 Scolyer R, Balamurgan T, Busam K, et al. Invasive Melanoma, Histopathology Reporting Guide, 2nd Ed...\n",
      "  ‚Ä¢ [ListItem] 10 Lezcano C, Pulitzer M, Moy AP, et al. Immunohistochemistry for PRAME in the distinction of nodal ...\n",
      "  ‚Ä¢ [UncategorizedText] 508.\n",
      "  ‚Ä¢ [ListItem] 11 Lezcano C, Jungbluth AA, Nehal KS, et al. PRAME Expression in melanocytic tumors. Am J Surg Patho...\n",
      "  ‚Ä¢ [NarrativeText] 12 Lezcano C, Jungbluth AA, Busum K, et al. Comparison of immunohistochemistry for PRAME with cytoge...\n",
      "  ‚Ä¢ [NarrativeText] 13 LeBlanc RE, Barton DT, Li Z, et al. Small and isolated immunohistochemistry-positive cells in mel...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-F\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [ListItem] 1 Schermers B, Franke V, Rozeman EA, et al. Surgical removal of the index node marked using magnetic...\n",
      "  ‚Ä¢ [ListItem] 2 Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo a...\n",
      "  ‚Ä¢ [ListItem] 3 Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvan...\n",
      "  ‚Ä¢ [ListItem] 4 Reijers ILM, Rawson RV, Colebatch AJ, et al. Representativeness of the Index Lymph Node for Total ...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-G\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF RADIATION THERAPY REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 Adams G, Foote M, Brown S, Burmeister B. Adjuvant external beam radiotherapy after therapeutic gro...\n",
      "  ‚Ä¢ [ListItem] 2 Mattes MD, Zhou Y, Berry SL, Barker CA. Dosimetric comparison of axilla and groin radiotherapy tec...\n",
      "  ‚Ä¢ [ListItem] 3 Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo malign...\n",
      "  ‚Ä¢ [ListItem] 4 Harwood AR. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentig...\n",
      "  ‚Ä¢ [ListItem] 5 Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma....\n",
      "  ‚Ä¢ [ListItem] 6 Christie DR, Tiver KW. Radiotherapy for melanotic freckles. Australas Radiol 1996;40:331-333.\n",
      "  ‚Ä¢ [ListItem] 7 Agrawal S, Kane JM III, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after the...\n",
      "  ‚Ä¢ [ListItem] 8 Rule WG, Allred JB, Pockaj BA, et al. Results of NCCTG N0275 (Alliance) - a phase II trial evaluat...\n",
      "  ‚Ä¢ [ListItem] 9 Guadagnolo BA, Prieto V, Weber R, et al. The role of adjuvant radiotherapy in the local management...\n",
      "  ‚Ä¢ [NarrativeText] 10 Strom T, Caudell JJ, Han D, et al. Radiotherapy influences local control in\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF RADIATION THERAPY REFERENCES\n",
      "  ‚Ä¢ [ListItem] 27 Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with who...\n",
      "  ‚Ä¢ [ListItem] 28 Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole...\n",
      "  ‚Ä¢ [ListItem] 38 Seung SK, Curti BD, Crittenden M, et al. Phase 1 study of stereotactic body radiotherapy and inte...\n",
      "  ‚Ä¢ [ListItem] 39 Singh D, Chen Y, Hare MZ, et al. Local control rates with five-fraction stereotactic body radioth...\n",
      "  ‚Ä¢ [ListItem] 40 Kroeze SG, Fritz C, Hoyer M, et al. Toxicity of concurrent stereotactic radiotherapy and targeted...\n",
      "  ‚Ä¢ [ListItem] 29 Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus mema...\n",
      "  ‚Ä¢ [ListItem] 41 Bang A, Wilhite TJ, Pike LRG, et al. Multicenter evaluation of the tolerability of combined treat...\n",
      "  ‚Ä¢ [ListItem] 30 Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotac...\n",
      "  ‚Ä¢ [ListItem] 31 Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patie...\n",
      "  ‚Ä¢ [ListItem] 42 Barker CA, Postow MA, Khan SA, et al. Concurrent radiotherapy and ipilimumab immunotherapy for pa...\n",
      "  ‚Ä¢ [ListItem] 43 Anker CJ, Ribas A, Grossmann AH, et al. Severe liver and skin toxicity after radiation and vemura...\n",
      "  ‚Ä¢ [ListItem] 44 Peuvrel L, Ruellan AL, Thillays F, et al. Severe radiotherapy-induced extracutaneous toxicity und...\n",
      "  ‚Ä¢ [ListItem] 32 Hong AM, Fogarty GB, Dolven-Jacobsen K, et al. Adjuvant whole-brain radiation therapy compared wi...\n",
      "  ‚Ä¢ [ListItem] 45 Anker CJ, Grossmann KF, Atkins MB, et al. Avoiding severe toxicity from combined BRAF inhibitor a...\n",
      "  ‚Ä¢ [ListItem] 33 Olivier KR, Schild SE, Morris CG, et al. A higher radiotherapy dose is associated with more durab...\n",
      "  ‚Ä¢ [ListItem] 46 Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated wit...\n",
      "  ‚Ä¢ [ListItem] 34 Gerszten PC, Burton SA, Quinn AE, et al. Radiosurgery for the treatment of spinal melanoma metast...\n",
      "  ‚Ä¢ [ListItem] 35 Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma an...\n",
      "  ‚Ä¢ [ListItem] 36 Sahgal A, Roberge D, Schellenberg D, et al. The Canadian Association of Radiation Oncology scope ...\n",
      "  ‚Ä¢ [ListItem] 47 Hiniker SM, Reddy SA, Maecker HT, et al. A prospective clinical trial combining radiation therapy...\n",
      "  ‚Ä¢ [ListItem] 48 Williams NL, Wuthrick EJ, Kim H, et al. Phase 1 study of ipilimumab combined with whole brain rad...\n",
      "  ‚Ä¢ [ListItem] stereotactic body radiotherapy. Clin Oncol (R Coll Radiol) 2012;24:629-639.\n",
      "  ‚Ä¢ [ListItem] 37 Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal ...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-H 7 OF 7\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Footer] - ‚Äî‚Äî Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF NEOADJUVANT THERAPY REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 Patel SP, Othus M, Chen Y, et al. Neoadjuvant -adjuvant or adjuvant only pembrolizumab in advanced...\n",
      "  ‚Ä¢ [NarrativeText] 3 Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage II...\n",
      "  ‚Ä¢ [ListItem] 5 Tetzlaff MT, Adhikari C, Lo S, et al. Histopathological features of complete pathological response...\n",
      "  ‚Ä¢ [ListItem] 6 Rawson RV, Adhikari C, Bierman C, et al. Pathological response and tumour bed histopathological fe...\n",
      "  ‚Ä¢ [ListItem] 7 Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations...\n",
      "  ‚Ä¢ [ListItem] 8 Sharon CE, Tortorello GN, Ma KL, et al. Long-term outcomes to neoadjuvant pembrolizumab based on p...\n",
      "  ‚Ä¢ [ListItem] 9 Blank CU, Reijers L, Saw RPM, et al. Survival data of PRADO: a phase 2 study of personalized respo...\n",
      "  ‚Ä¢ [ListItem] 10 Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolu...\n",
      "  ‚Ä¢ [ListItem] 11 Dummer R, Gyorki DE, Hyngstrom J, et al. Neoadjuvant talimogene laherparepvec plus surgery versus...\n",
      "  ‚Ä¢ [ListItem] 12 Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanom...\n",
      "  ‚Ä¢ [ListItem] 14 Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib ver...\n",
      "  ‚Ä¢ [ListItem] 15 Reijers ILM, Menzies AM, Versluis JM, et al. The impact of response-directed surgery and adjuvant...\n",
      "  ‚Ä¢ [ListItem] 16 Bhave P, Hong A, Lo SN, et al. Efficacy and toxicity of adjuvant radiotherapy in recurrent melano...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-I 6 OF 6\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] 1 Maloney NJ, Rana J, Yang JJ, et al. Clinical features of drug-induced hypersensitivity syndrome to...\n",
      "  ‚Ä¢ [NarrativeText] 2 Lamiaux M, Scalbert C, Lepesant P, et al. Severe skin toxicity with organ damage under the combina...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-K\n",
      "  ‚Ä¢ [Title] References on\n",
      "  ‚Ä¢ [Title] PRINCIPLES OF BRAIN METASTASES MANAGEMENT REFERENCES\n",
      "  ‚Ä¢ [NarrativeText] 1 Tawbi HA-H, Forsyth PAJ, Hodi FS, et al. Efficacy and safety of the combination of nivolumab (NIVO...\n",
      "  ‚Ä¢ [NarrativeText] 2 Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain me...\n",
      "  ‚Ä¢ [NarrativeText] 3 Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases...\n",
      "  ‚Ä¢ [ListItem] 5 Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-posit...\n",
      "  ‚Ä¢ [ListItem] 6 Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant...\n",
      "  ‚Ä¢ [ListItem] 7 Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation...\n",
      "  ‚Ä¢ [ListItem] 8 Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus meman...\n",
      "  ‚Ä¢ [ListItem] 9 Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the ma...\n",
      "  ‚Ä¢ [ListItem] 10 Chen CC, Rennert RC, Olson JJ. Congress of Neurological Surgeons Systematic Review and Evidence-B...\n",
      "  ‚Ä¢ [ListItem] 11 Glitza IC, Guha-Thakurta N, D'Souza NM, et al. Bevacizumab as an effective treatment for radiatio...\n",
      "  ‚Ä¢ [UncategorizedText] Melanoma Res 2017;27:580-584.\n",
      "  ‚Ä¢ [ListItem] 12 Sep√∫lveda-S√°nchez JM and P√©rez-N√∫√±ez A. The ESMO-EANO clinical practice guidelines for neurologic...\n",
      "  ‚Ä¢ [NarrativeText] 13 Anker CJ, Grossmann KF, Atkins MB, et al. Avoiding severe toxicity from combined BRAF inhibitor a...\n",
      "  ‚Ä¢ [Footer] Note: All recommendations are category 2A unless otherwise indicated.\n",
      "  ‚Ä¢ [Footer] Version 2.2025, 01/28/25 ¬© 2025 National Comprehensive Cancer Network¬Æ (NCCN¬Æ), All rights reserved....\n",
      "  ‚Ä¢ [Footer] ME-L 5 OF 5\n",
      "  ‚Ä¢ [NarrativeText] Printed by Kaitlin Rogers on 4/21/2025 1:19:17 PM. For personal use only. Not approved for distribut...\n",
      "  ‚Ä¢ [Title] Name and References\n",
      "  ‚Ä¢ [Image] Brain Tx   78%b   41%   None   14%   HD-ipi (n = 51)   --   71%b   48%   All   HD-ipi (n = 21)   5% ...\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [NarrativeText] 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. Available ...\n",
      "  ‚Ä¢ [Table] http://www.ncbi.nlm.nih.gov/pubmed/26742998. http://www.ncbi.nlm.nih.gov/pubmed/24629998. 11. Gordon...\n",
      "  ‚Ä¢ [NarrativeText] 9. Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. Dermatol Surg 2006;32:481-492. Avail...\n",
      "  ‚Ä¢ [NarrativeText] Version 2.2025 ¬© 2025 National Comprehensive Cancer Network¬© (NCCN¬©), All rights reserved. NCCN Guid...\n",
      "  ‚Ä¢ [UncategorizedText] MS-84\n",
      "\n",
      "üìÑ prc-us-00483-ref1-Patrinely 2020.pdf (15 removed)\n",
      "  ‚Ä¢ [Title] REFERENCES\n",
      "  ‚Ä¢ [ListItem] 1. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N...\n",
      "  ‚Ä¢ [ListItem] 2. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for ...\n",
      "  ‚Ä¢ [NarrativeText] Cancer ‚Äî August 1, 2020\n",
      "  ‚Ä¢ [ListItem] 3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [ListItem] 4. Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma...\n",
      "  ‚Ä¢ [ListItem] 5. Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer ...\n",
      "  ‚Ä¢ [ListItem] 6. Wang DY, Eroglu Z, Ozgun A, et al. Clinical features of acquired resistance to anti‚ÄìPD-1 therapy ...\n",
      "  ‚Ä¢ [ListItem] 7. Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next generation sequencing identifies markers ...\n",
      "  ‚Ä¢ [ListItem] 8. Quach HT, Dewan AK, Davis EJ, et al. Association of anti‚Äì programmed cell death 1 cutaneous toxic...\n",
      "  ‚Ä¢ [ListItem] 9. Axelrod ML, Johnson DB, Balko JM. Emerging biomarkers for cancer immunotherapy in melanoma. Semin...\n",
      "  ‚Ä¢ [ListItem] 10. Joseph RW, Elassaiss-Schaap J, Kefford R, et al. Baseline tumor size is an independent prognosti...\n",
      "  ‚Ä¢ [ListItem] 11. Davis EJ, Perez MC, Ayoubi N, et al. Clinical correlates of response to anti‚ÄìPD-1‚Äìbased therapy ...\n",
      "  ‚Ä¢ [ListItem] 12. Gershenwald JE, Scolyer RA, Hess KR, et al;for members of the American Joint Committee on Cancer...\n",
      "  ‚Ä¢ [NarrativeText] Cancer August 1, 2020.\n",
      "\n",
      "üìÑ prc-us-00484-ref2-Chesney 2022.pdf (19 removed)\n",
      "  ‚Ä¢ [Title] REFERENCES\n",
      "  ‚Ä¢ [ListItem] 1 Arnold M, Singh D, Laversanne M, et a/. Global burden of cutaneous melanoma in 2020 and projection...\n",
      "  ‚Ä¢ [ListItem] 2 Long GV, Robert C, Butler MO, et al. Standard-Dose pembrolizumab plus Alternate-Dose ipilimumab in...\n",
      "  ‚Ä¢ [ListItem] 3 Postow MA, Goldman DA, Shoushtari AN, et a/. Adaptive dosing of nivolumab + ipilimumab immunothera...\n",
      "  ‚Ä¢ [ListItem] 4 Tawbi HA, Schadendorf D, Lipson Eu, et a/. Relatlimab and nivolumab versus nivolumab in untreated ...\n",
      "  ‚Ä¢ [ListItem] 5 Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy i...\n",
      "  ‚Ä¢ [ListItem] 6 Mooradian MJ, Sullivan RJ. What to do when anti-PD-1 therapy fails in patients with melanoma. Onco...\n",
      "  ‚Ä¢ [ListItem] 7 Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma ...\n",
      "  ‚Ä¢ [ListItem] 8 Wolchok JD, Chiarion-Sileni V, Gonzalez R, et a/. Overall survival with combined nivolumab and ipi...\n",
      "  ‚Ä¢ [ListItem] 9 Betof Warner A, Palmer JS, Shoushtari AN, et a/. Long-term outcomes and responses to retreatment i...\n",
      "  ‚Ä¢ [ListItem] 10 Dummer R, Ascierto PA, Gogas Hy, et a/. Encorafenib plus binimetinib versus vemurafenib or encora...\n",
      "  ‚Ä¢ [ListItem] 11 Sosman JA, Kim KB, Schuchter L, et a/. Survival in BRAF V600- mutant advanced melanoma treated wi...\n",
      "  ‚Ä¢ [ListItem] 12 Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in ...\n",
      "  ‚Ä¢ [ListItem] 13 Long GV, Menzies AM, Nagrial AM, et a/. Prognostic and clinicopathologic associations of oncogeni...\n",
      "  ‚Ä¢ [ListItem] 14 Mason R, Heng ¬ß, Atkinson V. Outcomes following progression on BRAF/MEK inhibition in metastatic ...\n",
      "  ‚Ä¢ [ListItem] 15 Keytruda. Prescribing information, 2021.\n",
      "  ‚Ä¢ [ListItem] 16 Weber JS, D'Angelo SP, Minor D, et a/. Nivolumab versus chemotherapy in patients with advanced me...\n",
      "  ‚Ä¢ [ListItem] 17 Goldinger SM, Buder-Bakhaya K, Lo SN, et a/. Chemotherapy after immune checkpoint inhibitor failu...\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, et al. J Immunother Cancer 2022;10:e005755. doi:10.1136/jitc-2022-005755\n",
      "\n",
      "üìÑ nihms-1787822.pdf (10 removed)\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [ListItem] 1. Howlader N, et al., SEER Cancer Statistics Review, 1975‚Äì2010, National Cancer Institute. Bethesda...\n",
      "  ‚Ä¢ [ListItem] 2. Howlader N, et al., SEER Cancer Statistics Review, 1975‚Äì2017, National Cancer Institute. Bethesda...\n",
      "  ‚Ä¢ [ListItem] 3. Hodi FS, et al. , Improved survival with ipilimumab in patients with metastatic melanoma. N Engl ...\n",
      "  ‚Ä¢ [NarrativeText] Clin Cancer Res. Author manuscript; available in PMC 2023 January 15.\n",
      "  ‚Ä¢ [Title] References\n",
      "  ‚Ä¢ [ListItem] 1. Howlader N, et al., SEER Cancer Statistics Review, 1975‚Äì2010, National Cancer Institute. Bethesda...\n",
      "  ‚Ä¢ [ListItem] 2. Howlader N, et al., SEER Cancer Statistics Review, 1975‚Äì2017, National Cancer Institute. Bethesda...\n",
      "  ‚Ä¢ [ListItem] 3. Hodi FS, et al. , Improved survival with ipilimumab in patients with metastatic melanoma. N Engl ...\n",
      "  ‚Ä¢ [NarrativeText] Clin Cancer Res. Author manuscript; available in PMC 2023 January 15.\n",
      "\n",
      "üìÑ prc-us-00483-ref3-Patrinely 2020.pdf (15 removed)\n",
      "  ‚Ä¢ [Title] REFERENCES\n",
      "  ‚Ä¢ [ListItem] 1. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N...\n",
      "  ‚Ä¢ [ListItem] 2. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for ...\n",
      "  ‚Ä¢ [NarrativeText] Cancer ‚Äî August 1, 2020\n",
      "  ‚Ä¢ [ListItem] 3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [ListItem] 4. Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma...\n",
      "  ‚Ä¢ [ListItem] 5. Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer ...\n",
      "  ‚Ä¢ [ListItem] 6. Wang DY, Eroglu Z, Ozgun A, et al. Clinical features of acquired resistance to anti‚ÄìPD-1 therapy ...\n",
      "  ‚Ä¢ [ListItem] 7. Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next generation sequencing identifies markers ...\n",
      "  ‚Ä¢ [ListItem] 8. Quach HT, Dewan AK, Davis EJ, et al. Association of anti‚Äì programmed cell death 1 cutaneous toxic...\n",
      "  ‚Ä¢ [ListItem] 9. Axelrod ML, Johnson DB, Balko JM. Emerging biomarkers for cancer immunotherapy in melanoma. Semin...\n",
      "  ‚Ä¢ [ListItem] 10. Joseph RW, Elassaiss-Schaap J, Kefford R, et al. Baseline tumor size is an independent prognosti...\n",
      "  ‚Ä¢ [ListItem] 11. Davis EJ, Perez MC, Ayoubi N, et al. Clinical correlates of response to anti‚ÄìPD-1‚Äìbased therapy ...\n",
      "  ‚Ä¢ [ListItem] 12. Gershenwald JE, Scolyer RA, Hess KR, et al;for members of the American Joint Committee on Cancer...\n",
      "  ‚Ä¢ [NarrativeText] Cancer August 1, 2020.\n",
      "\n",
      "üìÑ 5231_AMTAGVI HCP Website Layout_R3_040425.pdf (22 removed)\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [UncategorizedText] 1.\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, Lewis KD, Kluger H, et al. Ecacy and safety of liÔ¨Åleucel, a one-time autologous tumor-inÔ¨Å...\n",
      "  ‚Ä¢ [NarrativeText] advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled a...\n",
      "  ‚Ä¢ [UncategorizedText] J Immunother Cancer. 2022;10(12):e005755.\n",
      "  ‚Ä¢ [UncategorizedText] 2.\n",
      "  ‚Ä¢ [NarrativeText] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipili...\n",
      "  ‚Ä¢ [UncategorizedText] 2019;381(16):1535-1546.\n",
      "  ‚Ä¢ [UncategorizedText] 3.\n",
      "  ‚Ä¢ [NarrativeText] Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE...\n",
      "  ‚Ä¢ [NarrativeText] multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239-1251.\n",
      "  ‚Ä¢ [UncategorizedText] 4.\n",
      "  ‚Ä¢ [NarrativeText] Tawbi HA, Schadendorf D, Lipson EJ, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab ve...\n",
      "  ‚Ä¢ [UncategorizedText] Engl J Med. 2022;386(1):24-34.\n",
      "  ‚Ä¢ [UncategorizedText] 5.\n",
      "  ‚Ä¢ [NarrativeText] Patrinely JR Jr, Baker LX, Davis EJ, Song H, Ye F, Johnson DB. Outcomes after progression of disease...\n",
      "  ‚Ä¢ [UncategorizedText] melanoma. Cancer. 2020;126(15):3448-3455.\n",
      "  ‚Ä¢ [UncategorizedText] 6.\n",
      "\n",
      "üìÑ prc-us-00425-ref2-Chesney 2022.pdf (19 removed)\n",
      "  ‚Ä¢ [Title] REFERENCES\n",
      "  ‚Ä¢ [ListItem] 1 Arnold M, Singh D, Laversanne M, et a/. Global burden of cutaneous melanoma in 2020 and projection...\n",
      "  ‚Ä¢ [ListItem] 2 Long GV, Robert C, Butler MO, et al. Standard-Dose pembrolizumab plus Alternate-Dose ipilimumab in...\n",
      "  ‚Ä¢ [ListItem] 3 Postow MA, Goldman DA, Shoushtari AN, et a/. Adaptive dosing of nivolumab + ipilimumab immunothera...\n",
      "  ‚Ä¢ [ListItem] 4 Tawbi HA, Schadendorf D, Lipson Eu, et a/. Relatlimab and nivolumab versus nivolumab in untreated ...\n",
      "  ‚Ä¢ [ListItem] 5 Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy i...\n",
      "  ‚Ä¢ [ListItem] 6 Mooradian MJ, Sullivan RJ. What to do when anti-PD-1 therapy fails in patients with melanoma. Onco...\n",
      "  ‚Ä¢ [ListItem] 7 Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma ...\n",
      "  ‚Ä¢ [ListItem] 8 Wolchok JD, Chiarion-Sileni V, Gonzalez R, et a/. Overall survival with combined nivolumab and ipi...\n",
      "  ‚Ä¢ [ListItem] 9 Betof Warner A, Palmer JS, Shoushtari AN, et a/. Long-term outcomes and responses to retreatment i...\n",
      "  ‚Ä¢ [ListItem] 10 Dummer R, Ascierto PA, Gogas Hy, et a/. Encorafenib plus binimetinib versus vemurafenib or encora...\n",
      "  ‚Ä¢ [ListItem] 11 Sosman JA, Kim KB, Schuchter L, et a/. Survival in BRAF V600- mutant advanced melanoma treated wi...\n",
      "  ‚Ä¢ [ListItem] 12 Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in ...\n",
      "  ‚Ä¢ [ListItem] 13 Long GV, Menzies AM, Nagrial AM, et a/. Prognostic and clinicopathologic associations of oncogeni...\n",
      "  ‚Ä¢ [ListItem] 14 Mason R, Heng ¬ß, Atkinson V. Outcomes following progression on BRAF/MEK inhibition in metastatic ...\n",
      "  ‚Ä¢ [ListItem] 15 Keytruda. Prescribing information, 2021.\n",
      "  ‚Ä¢ [ListItem] 16 Weber JS, D'Angelo SP, Minor D, et a/. Nivolumab versus chemotherapy in patients with advanced me...\n",
      "  ‚Ä¢ [ListItem] 17 Goldinger SM, Buder-Bakhaya K, Lo SN, et a/. Chemotherapy after immune checkpoint inhibitor failu...\n",
      "  ‚Ä¢ [NarrativeText] Chesney J, et al. J Immunother Cancer 2022;10:e005755. doi:10.1136/jitc-2022-005755\n",
      "\n",
      "üìÑ prc-us-xxxxx-ref3-Patrinely 2020.pdf (16 removed)\n",
      "  ‚Ä¢ [Image] ¬Æ Check for updates\n",
      "  ‚Ä¢ [Title] REFERENCES\n",
      "  ‚Ä¢ [ListItem] 1. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N...\n",
      "  ‚Ä¢ [ListItem] 2. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for ...\n",
      "  ‚Ä¢ [NarrativeText] Cancer ‚Äî August 1, 2020\n",
      "  ‚Ä¢ [ListItem] 3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [ListItem] 4. Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma...\n",
      "  ‚Ä¢ [ListItem] 5. Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer ...\n",
      "  ‚Ä¢ [ListItem] 6. Wang DY, Eroglu Z, Ozgun A, et al. Clinical features of acquired resistance to anti‚ÄìPD-1 therapy ...\n",
      "  ‚Ä¢ [ListItem] 7. Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next generation sequencing identifies markers ...\n",
      "  ‚Ä¢ [ListItem] 8. Quach HT, Dewan AK, Davis EJ, et al. Association of anti‚Äì programmed cell death 1 cutaneous toxic...\n",
      "  ‚Ä¢ [ListItem] 9. Axelrod ML, Johnson DB, Balko JM. Emerging biomarkers for cancer immunotherapy in melanoma. Semin...\n",
      "  ‚Ä¢ [ListItem] 10. Joseph RW, Elassaiss-Schaap J, Kefford R, et al. Baseline tumor size is an independent prognosti...\n",
      "  ‚Ä¢ [ListItem] 11. Davis EJ, Perez MC, Ayoubi N, et al. Clinical correlates of response to anti‚ÄìPD-1‚Äìbased therapy ...\n",
      "  ‚Ä¢ [ListItem] 12. Gershenwald JE, Scolyer RA, Hess KR, et al;for members of the American Joint Committee on Cancer...\n",
      "  ‚Ä¢ [NarrativeText] Cancer August 1, 2020.\n",
      "\n",
      "üìÑ 5231_AMTAGVI HCP Website Updates_Layout_R1_040125 PC.pdf (12 removed)\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [NarrativeText] 2. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [ListItem] 3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [ListItem] 4. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 5. Tawbi HA, Schadendorf D, Lipson Eu, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n",
      "  ‚Ä¢ [Title] References:\n",
      "  ‚Ä¢ [ListItem] 1. AMTAGVI. Prescribing Information. lovance Biotherapeutics, Inc.; 2024.\n",
      "  ‚Ä¢ [NarrativeText] 2. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tu...\n",
      "  ‚Ä¢ [ListItem] 3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ip...\n",
      "  ‚Ä¢ [ListItem] 4. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYN...\n",
      "  ‚Ä¢ [ListItem] 5. Tawbi HA, Schadendorf D, Lipson Eu, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab...\n"
     ]
    }
   ],
   "source": [
    "# =============================================================================\n",
    "# STEP 3: FILTER OUT UNWANTED SECTIONS\n",
    "# =============================================================================\n",
    "print(f\"\\nüîç Filtering out unwanted sections...\")\n",
    "\n",
    "# Keywords to filter out (easily extensible)\n",
    "FILTER_KEYWORDS = [\n",
    "    'references',\n",
    "    # 'bibliography',\n",
    "    # 'acknowledgments', \n",
    "    # 'appendix',\n",
    "    # 'glossary'\n",
    "]\n",
    "\n",
    "def filter_sections(elements, keywords):\n",
    "    \"\"\"Remove sections containing any of the specified keywords\"\"\"\n",
    "    filtered = []\n",
    "    removed = []\n",
    "    skip_section = False\n",
    "    current_heading = None\n",
    "    \n",
    "    for element in elements:\n",
    "        # Check if this is a heading/title\n",
    "        is_heading = hasattr(element, 'category') and element.category in ['Title', 'Header']\n",
    "        element_text = getattr(element, 'text', '') or ''\n",
    "        \n",
    "        if is_heading:\n",
    "            # Check if heading contains any filter keywords\n",
    "            skip_section = any(keyword.lower() in element_text.lower() for keyword in keywords)\n",
    "            if skip_section:\n",
    "                current_heading = element_text\n",
    "        \n",
    "        # Remove element if we're in a filtered section\n",
    "        if skip_section:\n",
    "            removed.append({\n",
    "                'text': element_text[:100] + ('...' if len(element_text) > 100 else ''),\n",
    "                'category': getattr(element, 'category', 'Unknown'),\n",
    "                'filename': getattr(element.metadata, 'filename', 'Unknown') if hasattr(element, 'metadata') else 'Unknown',\n",
    "                'section': current_heading\n",
    "            })\n",
    "        else:\n",
    "            filtered.append(element)\n",
    "    \n",
    "    return filtered, removed\n",
    "\n",
    "# Apply filter\n",
    "filtered_elements, removed_elements = filter_sections(all_elements, FILTER_KEYWORDS)\n",
    "\n",
    "# Print results\n",
    "print(f\"üìä Filtered {len(removed_elements)} elements from {len(all_elements)} total\")\n",
    "\n",
    "if removed_elements:\n",
    "    print(f\"\\nüóëÔ∏è REMOVED ELEMENTS:\")\n",
    "    for filename in set(elem['filename'] for elem in removed_elements):\n",
    "        file_elements = [e for e in removed_elements if e['filename'] == filename]\n",
    "        print(f\"\\nüìÑ {filename} ({len(file_elements)} removed)\")\n",
    "        for elem in file_elements:\n",
    "            print(f\"  ‚Ä¢ [{elem['category']}] {elem['text']}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "‚úÖ Now using 35565 filtered elements\n"
     ]
    }
   ],
   "source": [
    "# Update elements\n",
    "all_elements = filtered_elements\n",
    "print(f\"\\n‚úÖ Now using {len(all_elements)} filtered elements\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1661"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "embedded_images = [el for el in all_elements if getattr(el, 'category', '') == 'Image' and hasattr(el.metadata, 'image_base64')] \n",
    "len(embedded_images) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# =============================================================================\n",
    "# STEP 4: PROCESS IMAGES WITH VISION MODEL\n",
    "# =============================================================================\n",
    "print(f\"\\nüñºÔ∏è Processing images with vision model...\") \n",
    "\n",
    "# Extract embedded images from PDFs/PPTs\n",
    "embedded_images = [el for el in all_elements if getattr(el, 'category', '') == 'Image' and hasattr(el.metadata, 'image_base64')] \n",
    "\n",
    "# Process embedded images \n",
    "image_documents = [] \n",
    "\n",
    "for i, img_element in enumerate(embedded_images): \n",
    "    try:\n",
    "        # Get base64 image data \n",
    "        base64_image = img_element.metadata.image_base64 \n",
    "        \n",
    "        # Process with vision model \n",
    "        vision_content = process_image_with_vision(base64_image) \n",
    "        \n",
    "        if vision_content:\n",
    "            # Create minimal metadata\n",
    "            metadata = {\n",
    "                'filename': img_element.metadata.filename, \n",
    "                'filetype': img_element.metadata.filetype, \n",
    "                'content_type': 'image_vision_extracted',  \n",
    "                'image_source': 'embedded'\n",
    "            }\n",
    "            \n",
    "            # Create document\n",
    "            doc = Document(\n",
    "                page_content=vision_content,\n",
    "                metadata=metadata\n",
    "            )\n",
    "            \n",
    "            image_documents.append(doc)\n",
    "            print(f\"  ‚úÖ Processed embedded image {i+1}\")\n",
    "        \n",
    "    except Exception as e:\n",
    "        print(f\"  ‚ùå Error processing embedded image {i+1}: {str(e)}\")\n",
    "        continue"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'standalone_images' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mNameError\u001b[39m                                 Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[7]\u001b[39m\u001b[32m, line 7\u001b[39m\n\u001b[32m      4\u001b[39m \u001b[38;5;28;01mimport\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34;01mpickle\u001b[39;00m\n\u001b[32m      6\u001b[39m \u001b[38;5;66;03m# Only save if all_elements exists and has data\u001b[39;00m\n\u001b[32m----> \u001b[39m\u001b[32m7\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[43mstandalone_images\u001b[49m:\n\u001b[32m      8\u001b[39m     \u001b[38;5;28mprint\u001b[39m(\u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33müíæ Saving \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mlen\u001b[39m(standalone_images)\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m standalone_image chunks...\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m      9\u001b[39m     \u001b[38;5;28;01mwith\u001b[39;00m \u001b[38;5;28mopen\u001b[39m(\u001b[33m\"\u001b[39m\u001b[33m./standalone_images.pkl\u001b[39m\u001b[33m\"\u001b[39m, \u001b[33m\"\u001b[39m\u001b[33mwb\u001b[39m\u001b[33m\"\u001b[39m) \u001b[38;5;28;01mas\u001b[39;00m f:\n",
      "\u001b[31mNameError\u001b[39m: name 'standalone_images' is not defined"
     ]
    }
   ],
   "source": [
    "# =============================================================================\n",
    "# SAVE PROCESSED ELEMENTS FOR FUTURE RUNS\n",
    "# =============================================================================\n",
    "import pickle\n",
    "\n",
    "# Only save if all_elements exists and has data\n",
    "if embedded_images:\n",
    "    print(f\"üíæ Saving {len(embedded_images)} embedded_images chunks...\")\n",
    "    with open(\"./embedded_images.pkl\", \"wb\") as f:\n",
    "        pickle.dump(embedded_images, f)\n",
    "    print(\"‚úÖ Saved!\")\n",
    "else:\n",
    "    print(\"‚ö†Ô∏è No embedded_images chunks to save\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Process standalone images (MockElements)\n",
    "standalone_images = [el for el in all_elements if hasattr(el, '__class__') and el.__class__.__name__ == 'MockElement']\n",
    "\n",
    "for i, img_element in enumerate(standalone_images):\n",
    "    try:\n",
    "        # Get vision content (already processed)\n",
    "        vision_content = img_element.text\n",
    "        \n",
    "        # Get minimal metadata\n",
    "        metadata = img_element.metadata.to_dict()\n",
    "        \n",
    "        # Create document\n",
    "        doc = Document(\n",
    "            page_content=vision_content,\n",
    "            metadata=metadata\n",
    "        )\n",
    "        \n",
    "        image_documents.append(doc)\n",
    "        print(f\"  ‚úÖ Processed standalone image {i+1}\")\n",
    "        \n",
    "    except Exception as e:\n",
    "        print(f\"  ‚ùå Error processing standalone image {i+1}: {str(e)}\")\n",
    "        continue\n",
    "\n",
    "print(f\"üñºÔ∏è Created {len(image_documents)} image documents\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_table_summary(table_html, table_text):\n",
    "    \"\"\"Use LLM to create query-friendly summaries\"\"\"\n",
    "    \n",
    "    enhanced_prompt = f\"\"\"\n",
    "    Analyze this table and create a comprehensive summary that answers potential questions users might ask.\n",
    "\n",
    "    Table Data:\n",
    "    {table_text}\n",
    "    \n",
    "    Table HTML:\n",
    "    {table_html}\n",
    "    \n",
    "    IMPORTANT INSTRUCTIONS:\n",
    "    1. **Data Quality Check**: If you notice corrupted text, garbled data, or major discrepancies between the Table Data and Table HTML, acknowledge this rather than guessing. Say \"extraction quality issues detected\" if the data appears unreliable.\n",
    "    \n",
    "    2. **Source Priority**: When there are differences between Table Data and Table HTML, prioritize the Table Data section as it's usually more reliable.\n",
    "    \n",
    "    3. **Summary Requirements**:\n",
    "       - What type of data this table contains\n",
    "       - The highest/lowest values and what they represent  \n",
    "       - Any patterns, trends, or notable findings\n",
    "       - Specific numbers, percentages, and key data points\n",
    "       - Answer common questions like \"what are the most/least common\", \"which has the highest/lowest\", \"what percentage\"\n",
    "    \n",
    "    4. **Response Format**: \n",
    "       - Keep summary concise (200-300 words)\n",
    "       - Write in natural language that matches how users ask questions\n",
    "       - Include specific numbers and rankings when clearly visible\n",
    "       - If data is unclear or corrupted, state this explicitly rather than reconstructing\n",
    "    \n",
    "    5. **Accuracy Over Completeness**: Only mention specific details you can clearly see in the data. When in doubt, say the information is unclear rather than guessing.\n",
    "    \"\"\"\n",
    "    \n",
    "    enhanced_summary = llm.invoke(enhanced_prompt)\n",
    "    \n",
    "    return enhanced_summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# =============================================================================\n",
    "# STEP 5: EXTRACT AND SUMMARIZE TABLES\n",
    "# =============================================================================\n",
    "print(f\"\\nüìã Processing tables...\") \n",
    "\n",
    "tables = [el for el in all_elements if getattr(el, 'category', '') == \"Table\"] \n",
    "print(f\"Found {len(tables)} tables\") \n",
    "\n",
    "llm = ChatOpenAI(temperature=0, model=\"gpt-4o\") \n",
    "\n",
    "table_documents = [] \n",
    "\n",
    "for i, table in enumerate(tables): \n",
    "    \n",
    "    try:\n",
    "        # Get table HTML if available\n",
    "        table_html = getattr(table.metadata, 'text_as_html', None) \n",
    "        \n",
    "        if table_html:\n",
    "            # Summarize the table using LLM\n",
    "            table_doc = Document(page_content=table_html) \n",
    "            \n",
    "            summary = create_table_summary(table_html, table.text) \n",
    "            \n",
    "            # Create metadata for the table\n",
    "            metadata = table.metadata.to_dict() if hasattr(table.metadata, 'to_dict') else {} \n",
    "            \n",
    "            # Clean up metadata (fix lists that ChromaDB doesn't like)\n",
    "            for key, value in metadata.items():\n",
    "                if isinstance(value, list):\n",
    "                    if len(value) > 0:\n",
    "                        metadata[key] = str(value[0])\n",
    "                    else:\n",
    "                        metadata[key] = None\n",
    "                elif value is not None:\n",
    "                    metadata[key] = str(value)\n",
    "            \n",
    "            # Add table-specific metadata\n",
    "            metadata.update({\n",
    "                'content_type': 'table_summary',\n",
    "                'original_html': table_html\n",
    "            })\n",
    "            \n",
    "            # Create document with summary\n",
    "            table_content = f\"\"\"\n",
    "                {summary}\n",
    "\n",
    "                Source Data: {table.text}\n",
    "                \"\"\"\n",
    "            \n",
    "            doc = Document(\n",
    "                page_content=table_content,\n",
    "                metadata=metadata\n",
    "            )\n",
    "            \n",
    "            table_documents.append(doc)\n",
    "            print(f\"  ‚úÖ Summarized table {i+1}\")\n",
    "        \n",
    "        else:\n",
    "            print(f\"  ‚ö†Ô∏è Table {i+1} has no HTML content, skipping\")\n",
    "            \n",
    "    except Exception as e:\n",
    "        print(f\"  ‚ùå Error processing table {i+1}: {str(e)}\")\n",
    "        continue\n",
    "\n",
    "print(f\"üìã Created {len(table_documents)} table summary documents\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# This is for SAVING \n",
    "\n",
    "import pickle\n",
    "\n",
    "if table_documents:\n",
    "    print(f\"üíæ Saving {len(table_documents)} elements...\")\n",
    "    with open(\"./summarized_documents.pkl\", \"wb\") as f:\n",
    "        pickle.dump(table_documents, f)\n",
    "    print(\"‚úÖ Saved!\")\n",
    "else:\n",
    "    print(\"‚ö†Ô∏è No table_documents to save\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1127 table documents have been loaded\n"
     ]
    }
   ],
   "source": [
    "import pickle\n",
    "\n",
    "\n",
    "with open(\"./summarized_documents.pkl\", \"rb\") as f:\n",
    "    table_documents = pickle.load(f)\n",
    "    print(f\"{len(table_documents)} table documents have been loaded\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "‚úÇÔ∏è Chunking content...\n",
      "Created 6221 chunks\n"
     ]
    }
   ],
   "source": [
    "# =============================================================================\n",
    "# STEP 6: CHUNK THE REGULAR CONTENT  \n",
    "# =============================================================================\n",
    "print(f\"\\n‚úÇÔ∏è Chunking content...\")\n",
    "\n",
    "# Get only non-image, non-table elements for text chunking\n",
    "regular_elements = [el for el in all_elements if getattr(el, 'category', '') not in ['Image', 'Table']]\n",
    "\n",
    "# Chunk all elements\n",
    "chunks = chunk_by_title(\n",
    "    regular_elements,\n",
    "    combine_text_under_n_chars=100,\n",
    "    max_characters=3000,\n",
    ")\n",
    "\n",
    "print(f\"Created {len(chunks)} chunks\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÇÔ∏è Created 6221 chunk documents\n"
     ]
    }
   ],
   "source": [
    "# =============================================================================\n",
    "# STEP 7: CONVERT CHUNKS TO LANGCHAIN DOCUMENTS\n",
    "# =============================================================================\n",
    "\n",
    "# Convert chunks to LangChain Documents\n",
    "chunk_documents = []\n",
    "\n",
    "for i, chunk in enumerate(chunks):\n",
    "    # Extract text content\n",
    "    text_content = chunk.text\n",
    "    \n",
    "    # Get metadata\n",
    "    metadata = chunk.metadata.to_dict() if hasattr(chunk.metadata, 'to_dict') else {}\n",
    "    \n",
    "    # Clean up metadata for ChromaDB\n",
    "    for key, value in metadata.items():\n",
    "        if isinstance(value, list):\n",
    "            if len(value) > 0:\n",
    "                metadata[key] = str(value[0])\n",
    "            else:\n",
    "                metadata[key] = None\n",
    "        elif value is not None:\n",
    "            metadata[key] = str(value)\n",
    "    \n",
    "    # Add chunk info\n",
    "    metadata.update({\n",
    "        'chunk_index': i,\n",
    "        'chunk_id': getattr(chunk, 'id', f'chunk_{i}'),\n",
    "        'content_type': 'text_chunk'\n",
    "    })\n",
    "    \n",
    "    # Create document\n",
    "    doc = Document(\n",
    "        page_content=text_content,\n",
    "        metadata=metadata\n",
    "    )\n",
    "    chunk_documents.append(doc)\n",
    "\n",
    "print(f\"‚úÇÔ∏è Created {len(chunk_documents)} chunk documents\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# =============================================================================\n",
    "# STEP 8: COMBINE ALL DOCUMENTS\n",
    "# =============================================================================\n",
    "print(f\"\\nüîó Combining all documents...\")\n",
    "\n",
    "# Combine regular chunks, table summaries, and image documents\n",
    "all_documents = chunk_documents + table_documents + image_documents\n",
    "\n",
    "print(f\"Total documents for vector database: {len(all_documents)}\")\n",
    "print(f\"  - Text chunks: {len(chunk_documents)}\")\n",
    "print(f\"  - Table chunks: {len(table_documents)}\")\n",
    "print(f\"  - Image chunks: {len(image_documents)}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "üîó Combining all documents...\n",
      "Total documents for vector database: 7348\n"
     ]
    }
   ],
   "source": [
    "# =============================================================================\n",
    "# STEP 8: COMBINE ALL DOCUMENTS\n",
    "# =============================================================================\n",
    "print(f\"\\nüîó Combining all documents...\")\n",
    "\n",
    "# Combine regular chunks, table summaries, and image documents\n",
    "all_documents = chunk_documents + table_documents \n",
    "\n",
    "print(f\"Total documents for vector database: {len(all_documents)}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "üîç Deduplicating documents...\n",
      "Before deduplication: 7348 documents\n",
      "Duplicate sources: {'prc-us-00484-ref1-Amtagvi PI 02 2024.pdf', 'CLEAN_5228_BRANDED AMTAGVI SEM Ads_HCP_050225.pdf', '5237_AMTAGVI 5-Year Data Email_R3_042425.pdf', 'Medical Lifileucel Scientific Communication Platform_Revision_11-15-24-dm (1).pptx', 'Iovance Data on File 2025.pdf', 'AMTAGVI banner ads for ASCO enewsletter_040225.pdf', 'prc-us-00484-ref3-Iovance DOF 2025.pdf', 'EXTS_5228_AMTAGVI SEM Ads_R3_040825.pdf', '5237_AMTAGVI Email 1_R3_040925 PC (1).pdf', 'Comments for PRC_5228_BRANDED AMTAGVI SEM Ads_HCP_050225.pdf', 'PRC Comments_AMTAGVI.com Unbranded HCP-DTC SEM (May 2025) 4.25.25.pdf', '5228_AMTAGVI SEM Ads_r1v3_032125.xlsx', 'DRAFT Copy of 5228_AMTAGVI SEM Ads_r1v3_032125.xlsx', 'PRJ5237_IOV25_5237_Amtagvi_Email_2_v9_FCv1.pdf', '5237_AMTAGVI_Referral Email_R4v2_042925.pdf', 'AMTAGVI Order Sheet.pdf', 'IOVANCE-Unbranded Mini Campaign-RFP-Submission_v1.pptx', 'AMTAGVI 2025 NPP Media Expansion Recommendations.pptx', 'prc-us-00484-ref2-Chesney 2022.pdf', 'RP1 Background Training.pptx', 'Comments for PRC_5228_BRANDED AMTAGVI SEM Ads_DTC_050225.pdf', 'prc-us-00483-annotated.pdf', 'prc-us-00483-ref3-Patrinely 2020.pdf', '5231_AMTAGVI HCP Website Layout_R3_040425.pdf', 'prc-us-00475-ref1-Iovance DOF 2025.pdf', 'prc-us-xxxxx-ref1-Amtagvi PI 02 2024.pdf', 'UNBR KEYWORDS_5228_AMTAGVI SEM Ads_R3_040825.pdf', 'prc-us-00425-ref1-Amtagvi PI 02 2024.pdf', 'prc-us-00475-ref2-Amtagvi PI 02 2024.pdf', 'prc-us-00483-ref4-NCCN Guidelines Cutaneous Melanoma V2 2025.pdf', '5237_AMTAGVI Emails_Layout_R2_040725_PC Call.pdf', 'prc-us-00476-clean-HCP.pdf', 'prc-us-00475-annotated.pdf', 'Sarnaik_C-144-01-Cohort-2-4-SITC-Poster_Nov2022-2409-publication.pdf', 'PRJ5237_IOV25_5237_Amtagvi_Email_2_v8_clean.pdf', 'RP1 Background Training_042125.pptx', '5237_AMTAGVI Emails_Layout_r2v3_040425_RD.pdf', 'prc-us-xxxxx-ref2-Tawbi 2022.pdf', 'ANN_5231_AMTAGVI HCP Website Layouts_R3_040725.pdf', 'FOR IOV_5068_AMTAGVI Digital Media Performance Report_122024.pptx', '5228_AMTAGVI SEM Ads_R3_040825.pdf', 'prc-us-00483-ref1-Amtagvi PI 02 2024.pdf', '5237_Amtagvi_Emails_r2_040225_KR_RD.pdf', '5228_AMTAGVI SEM Ads_R3_040825.xlsx', '5071_AMTAGVI Q1 2025 Digital Media Performance Report_R2_042425.pptx', 'prc-us-xxxxx-ref4-NCCN Guidelines Cutaneous Melanoma V2 2025.pdf', 'CLEAN_5228_BRANDED AMTAGVI SEM Ads_R3_040825.pdf', 'nihms-1787822.pdf', 'ANN_5228_UNBRANDED AMTAGVI SEM Ads_R3_040825.pdf', '5072_AMTAGVI 2025 NPP Media Expansion Proposal_031725.pptx', 'BR KEYWORDS_5228_AMTAGVI SEM Ads_R3_040825.pdf', 'CLEAN_5235_AMTAGVI HCP Banner Ad_R2_040825.pdf', 'Amtagvi_onboarding_deck_0430.pptx', 'BR ADS_5228_AMTAGVI SEM Ads_R3_040825.pdf', '5231_AMTAGVI HCP Website Updates_Layout_R1_040125 PC.pdf', 'UNBR ADS_5228_AMTAGVI SEM Ads_R3_040825.pdf', 'prc-us-00483-annotated_PRC.pdf', 'unbranded test_PRC Annos.pdf', 'PRJ5237_IOV25_5237_Amtagvi_Email_1_v15_FCv1.pdf', 'prc-us-00483-ref2-Tawbi 2022.pdf', 'prc-us-00475-clean.pdf', 'ANN_5235_AMTAGVI HCP Banner Ad_R2_040825.pdf', 'PRJ5231_AMTAGVI_Website_Updates_v6_FCv1_EK.pdf', '5231_AMTAGVI Website Updates_Layout_R2_040225_RD.pdf', 'prc-us-00425-ref3-Iovance DOF 2025.pdf', '5071_AMTAGVI Q1 2025 Digital Media Performance Report_041525.pdf', 'PRJ5237_IOV25_5237_Amtagvi_Email_2_v9_FCv1 (EK_FC_FINAL).pdf', 'AMTAGVI HCP Banner Ad (May 2025) (PRT Feedback).pdf', 'PRJ5231_AMTAGVI_Website_Updates_v6_FCv1.pdf', 'prc-us-00483-ref2-Amtagvi PI 02 2024.pdf', 'Less Blurry PDF of ISI only.pdf', 'BRANDED AMTAGVI SEM Ads (Metadata Attachment).pdf', 'Comments for PRC_5228_UNBRANDED AMTAGVI SEM Ads_HCP-DTC_050225.pdf', '5237_AMTAGVI Email 1_R3_040925 PC_KR_jf_RD.pdf', 'PRC_AMTAGVI updated HCP website (April 2025)_041025.pdf', 'Iovance Corp Deck February 2025 1.pdf', 'PRJ5237_IOV25_5237_Amtagvi_Email_2_v8_annotated.pdf', 'FOR IOVANCE_5071_AMTAGVI Q1 2025 Digital Media Performance Report_R2_042625_with backup.pptx', 'CLEAN_5231_AMTAGVI HCP Website Layouts_R3_040725.pdf', '5237_AMTAGVI Emails_Layout_R2_040725 PC2.pdf', '5237_AMTAGVI Emails_Layout_R2_040725.pdf', 'IOVANCE RP1_Unbranded Mini Campaign Touchbase Call_050525.pptx', '5231_AMTAGVI Banner Ads_Layout_R1_031825 PC.pdf', 'PRJ5237_IOV25_5237_Amtagvi_Email_1_v15_FCv1 (EK_FC_FINAL).pdf', '5235_AMTAGVI Banner Ad_R2_040125.pdf', 'prc-us-00469-ref3-Iovance DOF 2025.pdf', '5237_AMTAGVI Referral Email_R5_052025.pdf', 'Amtagvi PI 2024.pdf', 'Branded Campaign Core Messages.pptx', 'CLEAN_5228_UNBRANDED AMTAGVI SEM Ads_R3_040825.pdf', '5231_AMTAGVI Website Updates Proposal_031825_IOV Feedback.pdf', 'PRC COMMENTS_AMTAGVI.com Branded HCP-DTC SEM (May 2025).pdf', 'prc-us-00425-ref2-Chesney 2022.pdf', 'prc-us-xxxxx-ref3-Patrinely 2020.pdf', '5071_AMTAGVI Q1 2025 Digital Media Performance Report_041525.pptx'}\n",
      "After deduplication: 4218 documents\n"
     ]
    }
   ],
   "source": [
    "import hashlib\n",
    "\n",
    "def deduplicate_documents_by_content(documents):\n",
    "    seen_hashes = set()\n",
    "    unique_documents = []\n",
    "    duplicate_sources = []\n",
    "    \n",
    "    for doc in documents:\n",
    "        content_hash = hashlib.md5(doc.page_content.encode()).hexdigest()\n",
    "        \n",
    "        if content_hash not in seen_hashes:\n",
    "            seen_hashes.add(content_hash)\n",
    "            unique_documents.append(doc)\n",
    "        else:\n",
    "            # Log where duplicates come from\n",
    "            source = doc.metadata.get('filename', 'unknown')\n",
    "            duplicate_sources.append(source)\n",
    "    \n",
    "    print(f\"Duplicate sources: {set(duplicate_sources)}\")\n",
    "    return unique_documents\n",
    "\n",
    "print(f\"\\nüîç Deduplicating documents...\")\n",
    "print(f\"Before deduplication: {len(all_documents)} documents\")\n",
    "\n",
    "unique_documents = deduplicate_documents_by_content(all_documents)\n",
    "\n",
    "print(f\"After deduplication: {len(unique_documents)} documents\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from pinecone import Pinecone, ServerlessSpec\n",
    "from langchain_community.retrievers import PineconeHybridSearchRetriever\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "from pinecone_text.sparse import BM25Encoder\n",
    "\n",
    "index_name = \"pixacore\"\n",
    "\n",
    "# Initialize the pinecone client\n",
    "api_key = \"pcsk_6p7LX3_MP2gq5GRAkEj8WLhoU8pCHYLwLn6xtxNsPtVtVzytR5dTGnGdwb57dwL3EhodRh\"\n",
    "pc = Pinecone(api_key=api_key)\n",
    "\n",
    "# Create the index - IMPORTANT: Must use dotproduct for hybrid search\n",
    "if index_name not in pc.list_indexes().names():\n",
    "    pc.create_index(\n",
    "        name=index_name, \n",
    "        dimension=3072,  # OpenAI embedding dimension\n",
    "        metric=\"dotproduct\",  # sparse values supported only for dotproduct\n",
    "        spec=ServerlessSpec(\n",
    "            cloud=\"aws\", \n",
    "            region=\"us-east-1\"  \n",
    "        )\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Get the index\n",
    "index = pc.Index(index_name)\n",
    "\n",
    "# Create BM25 encoder\n",
    "bm25_encoder = BM25Encoder().default()\n",
    "\n",
    "# Fit BM25 encoder on your text corpus\n",
    "text_corpus = [doc.page_content for doc in unique_documents]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà| 4218/4218 [00:04<00:00, 1040.64it/s]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<pinecone_text.sparse.bm25_encoder.BM25Encoder at 0x2b79e3750>"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "bm25_encoder.fit(text_corpus)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Store the BM25 values (optional but recommended)\n",
    "bm25_encoder.dump(\"bm25_values.json\")\n",
    "\n",
    "# Create the retriever with alpha parameter for weighting\n",
    "pinecone_retriever = PineconeHybridSearchRetriever(\n",
    "    embeddings=embedding_model,\n",
    "    sparse_encoder=bm25_encoder,\n",
    "    index=index,\n",
    "    alpha=0.5,  # Adjust this to control dense vs sparse weighting\n",
    "    top_k=30\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Add texts with metadata to the retriever\n",
    "text_list = [doc.page_content for doc in unique_documents]\n",
    "metadata_list = [doc.metadata for doc in unique_documents]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4218"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(text_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà| 132/132 [19:19<00:00,  8.78s/it] \n"
     ]
    }
   ],
   "source": [
    "# Add texts with their metadata\n",
    "pinecone_retriever.add_texts(\n",
    "    texts=text_list,\n",
    "    metadatas=metadata_list  # This preserves the Document metadata\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'chunk_id': '6786c649-4c93-4f16-8bbc-baeead097e3c', 'chunk_index': 6091.0, 'content_type': 'text_chunk', 'file_directory': './AMTAGVI/5528_Unbranded Mini Campaign RFP/00_Resources from Iovance/Reference Materials', 'filename': 'Amtagvi_onboarding_deck_0430.pptx', 'filetype': 'application/vnd.openxmlformats-officedocument.presentationml.presentation', 'languages': 'eng', 'last_modified': '2025-05-22T07:18:00', 'orig_elements': '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', 'page_number': '11', 'score': 0.423912466}, page_content='Lung\\n\\nMelanoma\\n\\nMelanoma is the most aggressive and deadly skin cancer with a steadily increasing incidence rate\\n\\nMost frequent in fair-skinned Caucasians and young and middle-aged people\\n\\nUV radiation represents a major contributor to tumor development\\n\\nPD-L1 expression status is a predictor of response to immunotherapies (IO)\\n\\nApproximately half of melanoma cases have a BRAF mutation\\n\\nIn the US, an est. 84% of patients present with localized disease and only 4% with distant metastatic disease\\n\\nLung cancer is the leading cause of cancer-related deaths in the US, of which 85% of cases are non-small cell lung cancer (NSCLC).\\n\\nPrimarily caused by constant inflammation due to cigarette smoking; however, cancer risks are increased in nonsmokers who are subject to second-hand smoke.\\n\\nAdenocarcinoma is the most common subtype of NSCLC in the US and is also the most common among nonsmokers.\\n\\nClinical outcomes are directly related to stage upon diagnosis and most NSCLC is diagnosed at Stage IV which has a 5-year survival rate of less than 6%.'),\n",
       " Document(metadata={'chunk_id': '04d88b26-6f87-4c37-92ca-2dcf8840db92', 'chunk_index': 6088.0, 'content_type': 'text_chunk', 'file_directory': './AMTAGVI/5528_Unbranded Mini Campaign RFP/00_Resources from Iovance/Reference Materials', 'filename': 'Amtagvi_onboarding_deck_0430.pptx', 'filetype': 'application/vnd.openxmlformats-officedocument.presentationml.presentation', 'languages': 'eng', 'last_modified': '2025-05-22T07:18:00', 'orig_elements': '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', 'page_number': '8', 'score': 0.397797197}, page_content='Melanoma\\n\\nMelanoma develops from melanocytes in the skin most often because of ultraviolet (UV) radiation with some genetic risk factors\\n\\nMelanocytes are cells that produce melanin, the pigment responsible for giving hair, skin and eyes their coloring and protecting against UV radiation1\\n\\nUV radiation represents a major contributor to tumor development because of its ability to damage DNA in the skin and trigger the acceleration of tumorigenesis2\\n\\nIntense and intermittent sun exposure, as well as exposure to UV-A rays from artificial sources (ie, tanning beds), has also been linked to an increased risk of melanoma development\\n\\nGenetic factors also contribute to melanoma development including a family history and mutations in the melanocortin 1 receptor (MC1R) gene2\\n\\nFamily history of melanoma is present in 5-15% of patients with cutaneous melanoma\\n\\nTrue hereditary melanoma due to transmitted genetic mutations is less common\\n\\nMC1R mutations are the most relevant genetic mutation for susceptibility to melanoma\\n\\nMelanoma is the most aggressive and deadly skin cancer with a steadily increasing incidence rate, especially in Caucasian people2\\n\\nOne of the most frequent cancers in fair-skinned people, especially those with blond or red hair, who have light-colored eyes\\n\\nUnlike other solid tumors, melanoma mainly affects young and middle-aged people\\n\\nMelanoma-related mortality has increased in parallel with its incidence rate, reaching a mortality rate of one in 4 deaths2,3\\n\\nThe outcome of melanoma depends on the stage at presentation. In the US, an est. 84% of patients with melanoma initially present with localized disease, 9% with regional disease, and 4% with distant metastatic disease\\n\\n1. Cichorek M, Wachulska M, Stasiewicz A, Tyminska A. Skin Melanocytes: biology and development. Postepy Dermatol Alergol. 2013 Feb;30(1):30-41. 2. Teixido C, Castillo P, Martinez-Vila C, Arance A, Alos L. Molecular Markers and Targets in Melanoma. Cells. 2021;10(9):2320. 3. NCCN Guidelines for Melanoma: Cutaneous V2.2024. Accessed September 10, 2024.\\n\\n9'),\n",
       " Document(metadata={'chunk_id': 'f93b65b3-2b26-4f7f-aa49-9a773ed546ca', 'chunk_index': 2541.0, 'content_type': 'text_chunk', 'file_directory': './AMTAGVI/5237_2025 Amtagvi 3rd-Party Emails/Email 1_Referral/3_Content/References/Archive', 'filename': 'prc-us-xxxxx-ref4-NCCN Guidelines Cutaneous Melanoma V2 2025.pdf', 'filetype': 'application/pdf', 'languages': 'eng', 'last_modified': '2025-05-22T07:17:00', 'orig_elements': 'eJztWFtv2zgW/iuEgQK7gK2IkmVLmadsdtGdh3YG00xfisKgRMomKpGCSNnxDva/73co+ZImM9i26Fvz4vByyO/cvnOoD3/MVKNaZfxGy9ktm/G6XNf5WsZFmvCkrNarKpfluloWScWLhM/mbNYqL6TwAvv/mFXW9lIb4ZUL40Yc7eA3O6W3O48Zvo5jyEzTBy39DrNJEmY7q40nuQ8fVlmUzlmSraP045ydhsUqymiYpOto/cI4bMfEzB2dVy1p8Kt+VM27TlRq9l8sSOVV5bU1m6oRzm263pbYFkf5Ms4ybKh1ozZS99hl+yOdEN3cvXm4e/3+55sM92ySOMnYXevFdq9Z2svFr6L3R/avVujG3YQfxje/qVr1vWhu0s29NR4WvQlTylTK3dz11U7v1Wy6z4hW0U1dXy0Gt3ikv0Wv6uXi7f39W/Z60FI12ijH7gcvjLKDY29UI4xtBXufMIIUdbI+neePXThPdF2jK0Hq3kzLENoOYhu882GmzHb2Mcw6v2mt1LVWwe904iLOFknyEK9v+fo2jkm6g+TGDG2pevIlz8ikXj2SZ2e/7FW/1+pAG08IHrRvguE/D6y1LOoiK1NRFXkuRSZXMV8LUcS8LFZ5lnznwEp5GvFLYOUZj1Y05HGeRtkLE6PA14VWscyX/EdofWFohbn+C6joOhZ/NkDOV3MmDFPO6xZxI9l6NU/zmHWAjXMdO+imYaViUoutsQ47DtrvICOZKBFGjMdznn4uILVitmbtyUraML9T7Hej6Y53nkI04uzf9qCQEXNadIrVejv0MHNte2bUgVXCYdSKI+tVhwWczwRzQ+ngBq9FwwYj4dQJPDSh3eaILZ3qa13RFkKK6532wxmPY75XQd0JGBSZFGBOea/NlsGuzFhPV9seWyP2gI3aVIgGRNET9SrEmDYDwHpLW3A41JG9ACxEQNMcgc2ToS3UxZj1uJ2OSNNXQV2kfUCaYHywNKp728JBcUJn4ncVJZeo0+50DUGFEiTRWkDuRadlc4RWgk48Mgv9cL5o9NYIUxGS0SLjNf+fEFOPleo8awZcV2FG9VHK/iEoHqxhxEBnwMUImPPgVtboWsE/uES7T6SyhMsb2xHw6pxP7ZVmnNCly2CXESQhDrNZerIWoof80SoEJjZsFRl4ClKyjmNZwY5K9C5iv2AD2X2rQrBrI/VeywHB0ViKsCSOluNewtdZ4gsKHYJOMSUQBG5o/BOfw3Ae9gH3VLalLJSkN19Fq+koAkquPltRI+aX18z/VoCjPJjogVLyhQoQL6tUpnlWFHWVL5NcqlRyUa8TCXbifP2dK0BepFFyqQA8zfMoPjN+/NLMKPK1NQBF4EcN+Ib24jdKsVqQ3dyUKGcCrppBKuY+EeMB3JyBIp01CPOddmToEPu9vpKasxZRr7tGsQrKj0yGPDt29C8yoIE9sF8eXUf4dQXa3mskGZIIhAv7Ak2rIXR1x/n0bJGHzO6RPMSQ2oB0QoHYKqPotBa2JtMhh19PU5UdjCNXbOnfRlJtAv06TYVABqUv+e2mYsWc7y0knoPRZg8O3auLpYIEMQ9+qb51IhBtuHskPobKKaTUhIxy/oR2MvycKbPXuI8SGWY6+WN0AQEnMnUOVQqF9xGWQtELhvj9/aIMlIpw1lP5QrCZUVnje10OKBu4koh14lG65dqsUbHgfKpVHqQXUg1W8gcFJj1hdYMjQtelDhRGtz9FfQZGZNo0Ayx4KpjP7UtzYjqK0ImRsmuh+ynidmBn6FsOvXGMyhbccNhZtgMxwz/bUI77l2rEWS+eoNG4tAyX4ktltaoGcnwoXsrvEKs40w7d2Kg0zoZFKph0PJmvtPJ4dvJ1T3HtluiL6Hol0yKXVZzU6WrJV1lWp1m5Fpyn66Reyvi70TXnYB/MFUUx0fE0wZfFcpxJeJrR++/5zCj01W07X/+g7G+gbCTqlGSXfg4IYEkdIJzCdS/6ccKFbrbDek1BPuWzaCjXx3XREtdJkBzO9GfqpiAnHd0TtghMgeShVwRyUipXgWaQ6C+KvdCwIalu0SibRbUDewRqoYawpZbsbzR//+6ff7+9ar2hU+CEU+5dyS1ALUOFy0f5nxhk/0z0L+TQ7G9N8Aorj8F64+th6tpF/wkrzjaiZ4qcSB3jTyNTVIi+z24keUelDiVTNC1+UB1glMVAQdHQywKN3RRa1RED0AeMT48KKksnDwbkOPKgmmZswom5tlR8QHuB1oMZn5k4oGiHyjoquqote2xwY3c97BUVCaL50z3qqALEBvxO3TMiCviSmL05H3E6t7UEs0aiXRiUjtgpIQNCo6pPUNAM1CbThIV9gHsPpicdLGX80M7Zfmj2YtRqL7agtDkrybdUCYJ2EzdPGJ9pwyjaELW0uBVUrql6UQRPT7iht4h17U/aQiP+ReQssrRIS6USWVYJqJnjn2Va0hO5Xi55+p17aY72ffwQN42zfPpux+N18Sczo8xXUnOSJ+kPav4Gar6b2huD5xz1vZ+95eanLwd4/z39HCBVp4y8kIefnqfTN4yAP+JL6iOffRVBG+ypHFy+yITeKV++Cv355SsLgF1195paF4A8fSYJ640Ff+v/EC8iBdFZoti/Gpd6tdWh+T+vUJItp1WqHeiGGOWD86H3nfZFPCPYVHYQDMEEf5GFH/8HcXqxgg==', 'page_number': '115', 'score': 0.397415221}, page_content='Overview\\n\\nIn 2016, an estimated 76,380 patients will be diagnosed with and about 10,130 patients will die of melanoma in the United States.1 However, these figures for new cases may represent a substantial underestimate, as many superficial and in situ melanomas treated in the outpatient setting are not reported. The incidence of melanoma continues to increase dramatically, at an overall rate of 33% for men and 23% women from 2002 to 2006.2 Melanoma is increasing in men more rapidly than any other malignancy, and in women more rapidly than any other malignancy except lung cancer.3 Based on data from 2009 to 2011, the lifetime risk of developing cutaneous melanoma is 1 in 34 for women and 1 in 53 for men.1 The median age at diagnosis is 59 years. On average, an individual loses 20.4 years of potential life as a result of melanoma mortality compared to 16.6 years for all malignancies.4\\n\\nRisk factors for melanoma include skin type, personal history of prior melanoma, multiple clinically atypical moles or dysplastic nevi, a positive family history of melanoma,5-8 and rarely, inherited genetic mutations. Genetic counseling could be considered for individuals with a strong family history of invasive melanoma with or without pancreatic cancer. In addition to genetic factors, environmental factors including excess sun exposure and UV-based artificial tanning contribute to the development of melanoma.9-11 The interaction between genetic susceptibility and environmental exposure is illustrated in individuals with an inability to tan and fair skin that sunburns easily who have a greater risk of developing melanoma.12,13 However, melanoma can occur in any ethnic group and also in areas of the body without substantial sun exposure.\\n\\nThere is increasing appreciation of the variations in specific genetic alterations among distinct clinical subtypes of melanoma. The currently described clinical subtypes of cutaneous melanoma are: non-chronic sun damage (non-CSD): melanomas on skin without chronic sun-induced damage; CSD: melanomas on skin with chronic sun-induced damage signified by the presence of marked solar elastosis; and acral: melanomas on the soles, palms, or sub-ungual sites. Melanocytes exist outside of the skin as well, and can give rise to non-cutaneous melanomas on mucosal membranes, the uveal tract of the eye, or leptomeninges.20 Mucosal melanomas most often occur in the head and neck sinuses and oral cavity, anorectum, vulva, and vagina, but can arise in any of the mucosal membranes lining the gastrointestinal and urogenital tracts.21\\n\\nAs with nearly all malignancies, the outcome of melanoma depends on the stage at presentation.14 In the United States, it is estimated that 84% of patients with melanoma initially present with localized disease, 9% with regional disease, and 4% with distant metastatic disease.15 In general, the'),\n",
       " Document(metadata={'content_type': 'table_summary', 'file_directory': './AMTAGVI/5527_RP1 Messaging Proposal/00_Resources/From Iovance', 'filename': 'Medical Lifileucel Scientific Communication Platform_Revision_11-15-24-dm (1).pptx', 'filetype': 'application/vnd.openxmlformats-officedocument.presentationml.presentation', 'languages': 'eng', 'last_modified': '2025-05-22T07:18:00', 'original_html': '<table><tr><td>Disease Background</td><td/><td/></tr><tr><td>1.1</td><td>Melanoma was the fifth most commonly diagnosed cancer in the US in 20244; 15% of diagnoses are made at an advanced stage (regional and distant metastasis).5 Although ~4% of all skin cancers diagnosed are melanoma, it accounts for 75% of skin cancer deaths.6 An estimated 325,000 patients were diagnosed with melanoma worldwide in 2020, with an estimated 57,000 deaths.7</td><td/></tr><tr><td>1.1.1</td><td/><td>With the widespread adoption of ICI for advanced melanoma, long-term outcomes improved substantially from a 5-year survival rate of approximately 2% to 20% in the late 1990s/early 2000s9-11 to 6.5-year survival rates of 42% to 49% in 2021,12 with 39% of patients achieving treatment-free survival at 5 years13</td></tr></table>', 'page_number': '6', 'parent_id': 'f46956e2576aa662f5a77e07c1df9fd7', 'text_as_html': '<table><tr><td>Disease Background</td><td/><td/></tr><tr><td>1.1</td><td>Melanoma was the fifth most commonly diagnosed cancer in the US in 20244; 15% of diagnoses are made at an advanced stage (regional and distant metastasis).5 Although ~4% of all skin cancers diagnosed are melanoma, it accounts for 75% of skin cancer deaths.6 An estimated 325,000 patients were diagnosed with melanoma worldwide in 2020, with an estimated 57,000 deaths.7</td><td/></tr><tr><td>1.1.1</td><td/><td>With the widespread adoption of ICI for advanced melanoma, long-term outcomes improved substantially from a 5-year survival rate of approximately 2% to 20% in the late 1990s/early 2000s9-11 to 6.5-year survival rates of 42% to 49% in 2021,12 with 39% of patients achieving treatment-free survival at 5 years13</td></tr></table>', 'score': 0.395900607}, page_content=\"\\n                content='The table provides data on melanoma, a type of skin cancer, highlighting its prevalence, mortality, and treatment outcomes. In 2024, melanoma was the fifth most commonly diagnosed cancer in the United States, with 15% of cases identified at an advanced stage involving regional and distant metastasis. Although melanoma constitutes only about 4% of all skin cancer diagnoses, it is responsible for a significant 75% of skin cancer-related deaths. Globally, in 2020, approximately 325,000 individuals were diagnosed with melanoma, resulting in an estimated 57,000 deaths.\\\\n\\\\nA notable trend in the data is the improvement in long-term survival rates for advanced melanoma due to the adoption of immune checkpoint inhibitors (ICI). Historically, the 5-year survival rate for advanced melanoma was between 2% and 20% in the late 1990s and early 2000s. However, by 2021, the 6.5-year survival rates had increased to between 42% and 49%. Additionally, 39% of patients achieved treatment-free survival at the 5-year mark.\\\\n\\\\nKey data points include the high mortality rate associated with melanoma despite its relatively low incidence among skin cancers, and the significant improvement in survival rates due to advancements in treatment. The data underscores the critical impact of ICI on patient outcomes, marking a substantial shift in the prognosis for those with advanced melanoma. Overall, the table highlights both the severity of melanoma and the promising advancements in its treatment.' additional_kwargs={'refusal': None} response_metadata={'token_usage': {'completion_tokens': 300, 'prompt_tokens': 721, 'total_tokens': 1021, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-2024-08-06', 'system_fingerprint': 'fp_07871e2ad8', 'id': 'chatcmpl-Bjh86XxuM1ZSJ4dvfn6tQiazTEY3l', 'service_tier': 'default', 'finish_reason': 'stop', 'logprobs': None} id='run--8053b983-e1bb-42d4-806e-ea993ee3a0cf-0' usage_metadata={'input_tokens': 721, 'output_tokens': 300, 'total_tokens': 1021, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}}\\n\\n                Source Data: Disease Background 1.1 Melanoma was the fifth most commonly diagnosed cancer in the US in 20244; 15% of diagnoses are made at an advanced stage (regional and distant metastasis).5 Although ~4% of all skin cancers diagnosed are melanoma, it accounts for 75% of skin cancer deaths.6 An estimated 325,000 patients were diagnosed with melanoma worldwide in 2020, with an estimated 57,000 deaths.7 1.1.1 With the widespread adoption of ICI for advanced melanoma, long-term outcomes improved substantially from a 5-year survival rate of approximately 2% to 20% in the late 1990s/early 2000s9-11 to 6.5-year survival rates of 42% to 49% in 2021,12 with 39% of patients achieving treatment-free survival at 5 years13\\n                \")]"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pinecone_retriever.invoke(\"Count of people diagnosed with melanoma\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# # What happens inside add_texts() for each document:\n",
    "# for i, text in enumerate(text_list):\n",
    "#     # Step 1: Create dense vector using OpenAI\n",
    "#     dense_vector = self.embeddings.embed_query(text)  # Uses your embedding_model\n",
    "    \n",
    "#     # Step 2: Create sparse vector using fitted BM25\n",
    "#     sparse_vector = self.sparse_encoder.encode_documents([text])[0]  # Uses your bm25_encoder\n",
    "    \n",
    "#     # Step 3: Upsert BOTH vectors together to Pinecone\n",
    "#     self.index.upsert(vectors=[{\n",
    "#         'id': f'generated_id_{i}',\n",
    "#         'values': dense_vector,           # Dense vector here\n",
    "#         'sparse_values': sparse_vector,   # Sparse vector here  \n",
    "#         'metadata': {\n",
    "#             'context': text,              # Original text\n",
    "#             **metadatas[i]               # Your metadata\n",
    "#         }\n",
    "#     }])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "üóÑÔ∏è Setting up vector database...\n",
      "üìÅ Existing vector database found! Loading from disk...\n",
      "‚úÖ Vector database loaded successfully!\n",
      "  - Database location: ./full_vector\n",
      "  - Collection name: my_documents\n",
      "  - Documents in collection: 4291\n"
     ]
    }
   ],
   "source": [
    "import time\n",
    "import os\n",
    "from typing import List\n",
    "from langchain.schema import Document\n",
    "\n",
    "# =============================================================================\n",
    "# STEP 9: CREATE OR LOAD VECTOR DATABASE\n",
    "# =============================================================================\n",
    "print(f\"\\nüóÑÔ∏è Setting up vector database...\")\n",
    "\n",
    "# Define where to save/load the database\n",
    "db_path = \"./full_vector\"\n",
    "collection_name = \"my_documents\"\n",
    "\n",
    "def create_vector_store_in_batches(\n",
    "    documents: List[Document], \n",
    "    embedding_model, \n",
    "    collection_name: str,\n",
    "    db_path: str,\n",
    "    batch_size: int = 100,  # Adjust based on your chunk sizes\n",
    "    delay: float = 1.0      # Delay between batches to respect rate limits\n",
    "):\n",
    "    \"\"\"Create vector store by processing documents in batches\"\"\"\n",
    "    \n",
    "    print(f\"üóÑÔ∏è Creating vector database in batches...\")\n",
    "    print(f\"  - Total documents: {len(documents)}\")\n",
    "    print(f\"  - Batch size: {batch_size}\")\n",
    "    \n",
    "    # Initialize vector store with first batch\n",
    "    first_batch = documents[:batch_size]\n",
    "    print(f\"Creating initial vector store with {len(first_batch)} documents...\")\n",
    "    \n",
    "    vector_store = Chroma.from_documents(\n",
    "        documents=first_batch,\n",
    "        embedding=embedding_model,\n",
    "        collection_name=collection_name,\n",
    "        persist_directory=db_path\n",
    "    )\n",
    "    \n",
    "    # Process remaining documents in batches\n",
    "    for i in range(batch_size, len(documents), batch_size):\n",
    "        batch = documents[i:i + batch_size]\n",
    "        print(f\"Adding batch {i//batch_size + 1}: documents {i+1}-{min(i+len(batch), len(documents))}\")\n",
    "        \n",
    "        try:\n",
    "            vector_store.add_documents(batch)\n",
    "            \n",
    "            # Adding delay to respect rate limits\n",
    "            if delay > 0:\n",
    "                time.sleep(delay)\n",
    "                \n",
    "        except Exception as e:\n",
    "            print(f\"Error processing batch {i//batch_size + 1}: {e}\")\n",
    "            continue\n",
    "    \n",
    "    print(f\"‚úÖ Vector database created successfully!\")\n",
    "    return vector_store\n",
    "\n",
    "# Check if database already exists\n",
    "if os.path.exists(db_path) and os.listdir(db_path):\n",
    "    print(\"üìÅ Existing vector database found! Loading from disk...\")\n",
    "    \n",
    "    # Load existing vector store\n",
    "    vector_store = Chroma(\n",
    "        collection_name=collection_name,\n",
    "        embedding_function=embedding_model,\n",
    "        persist_directory=db_path\n",
    "    )\n",
    "    \n",
    "    # Get collection info\n",
    "    try:\n",
    "        doc_count = vector_store._collection.count()\n",
    "        print(f\"‚úÖ Vector database loaded successfully!\")\n",
    "        print(f\"  - Database location: {db_path}\")\n",
    "        print(f\"  - Collection name: {collection_name}\")\n",
    "        print(f\"  - Documents in collection: {doc_count}\")\n",
    "    except Exception as e:\n",
    "        print(f\"‚ö†Ô∏è  Error getting collection info: {e}\")\n",
    "        print(f\"‚úÖ Vector database loaded successfully!\")\n",
    "        print(f\"  - Database location: {db_path}\")\n",
    "        print(f\"  - Collection name: {collection_name}\")\n",
    "    \n",
    "else:\n",
    "    print(\"üÜï No existing database found. Creating new vector database...\")\n",
    "    \n",
    "    # Create new vector store using batch processing\n",
    "    vector_store = create_vector_store_in_batches(\n",
    "        documents=unique_documents,\n",
    "        embeddings=embedding_model,\n",
    "        collection_name=collection_name,\n",
    "        db_path=db_path,\n",
    "        batch_size=100,  # Start small and increase if needed\n",
    "        delay=1.0\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pickle\n",
    "import json\n",
    "import os\n",
    "from pathlib import Path\n",
    "from langchain_community.retrievers import BM25Retriever\n",
    "from langchain.schema import Document\n",
    "import nltk\n",
    "from nltk.tokenize import word_tokenize\n",
    "\n",
    "try:\n",
    "    nltk.data.find('tokenizers/punkt')\n",
    "except LookupError:\n",
    "    nltk.download('punkt', quiet=True)\n",
    "    nltk.download('punkt_tab', quiet=True)\n",
    "\n",
    "\n",
    "def save_bm25(bm25_retriever, file_path):\n",
    "    \"\"\"\n",
    "    Save BM25 retriever to disk\n",
    "    \n",
    "    Args:\n",
    "        bm25_retriever: Your BM25Retriever object\n",
    "        file_path: Where to save it\n",
    "    \"\"\"\n",
    "    print(f\"üíæ Saving BM25 to {file_path}...\")\n",
    "    \n",
    "    Path(file_path).parent.mkdir(parents=True, exist_ok=True)\n",
    "    \n",
    "    with open(file_path, 'wb') as f:\n",
    "        pickle.dump(bm25_retriever, f)\n",
    "    \n",
    "    print(f\"‚úÖ BM25 saved successfully!\")\n",
    "    nltk.download(\"punkt_tab\", quiet=True)\n",
    "\n",
    "\n",
    "def load_bm25(file_path):\n",
    "    \"\"\"\n",
    "    Load BM25 retriever from disk\n",
    "    \n",
    "    Args:\n",
    "        file_path: Where to load from\n",
    "        \n",
    "    Returns:\n",
    "        BM25Retriever object or None if file doesn't exist\n",
    "    \"\"\"\n",
    "    if not os.path.exists(file_path):\n",
    "        print(f\"‚ùå No BM25 file found at {file_path}\")\n",
    "        return None\n",
    "    \n",
    "    print(f\"üìÇ Loading BM25 from {file_path}...\")\n",
    "    \n",
    "    with open(file_path, 'rb') as f:\n",
    "        bm25_retriever = pickle.load(f)\n",
    "    \n",
    "    print(f\"‚úÖ BM25 loaded successfully! ({len(bm25_retriever.docs)} documents)\")\n",
    "    return bm25_retriever\n",
    "\n",
    "\n",
    "\n",
    "def create_or_load_bm25(documents, file_path, force_rebuild=False):\n",
    "\n",
    "    if not force_rebuild:\n",
    "        bm25_retriever = load_bm25(file_path)\n",
    "        if bm25_retriever is not None:\n",
    "            return bm25_retriever\n",
    "    \n",
    "    # Create new BM25\n",
    "    print(f\"üîß Building new BM25 index from {len(documents)} documents...\")\n",
    "    \n",
    "    bm25_retriever = BM25Retriever.from_documents(\n",
    "        documents=documents, \n",
    "        preprocess_func=word_tokenize\n",
    "    )\n",
    "    bm25_retriever.k = 25  # Return top 25 results\n",
    "    \n",
    "    # Save for next time\n",
    "    save_bm25(bm25_retriever, file_path)\n",
    "    \n",
    "    return bm25_retriever\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "üìÇ Loading BM25 from ./full_bm25_retriever.pkl...\n",
      "‚úÖ BM25 loaded successfully! (4291 documents)\n"
     ]
    }
   ],
   "source": [
    "import pickle\n",
    "\n",
    "def load_bm25(file_path):\n",
    "    \"\"\"\n",
    "    Load BM25 retriever from disk\n",
    "    \n",
    "    Args:\n",
    "        file_path: Where to load from\n",
    "        \n",
    "    Returns:\n",
    "        BM25Retriever object or None if file doesn't exist\n",
    "    \"\"\"\n",
    "    if not os.path.exists(file_path):\n",
    "        print(f\"‚ùå No BM25 file found at {file_path}\")\n",
    "        return None\n",
    "    \n",
    "    print(f\"üìÇ Loading BM25 from {file_path}...\")\n",
    "    \n",
    "    with open(file_path, 'rb') as f:\n",
    "        bm25_retriever = pickle.load(f)\n",
    "    \n",
    "    print(f\"‚úÖ BM25 loaded successfully! ({len(bm25_retriever.docs)} documents)\")\n",
    "    return bm25_retriever\n",
    "\n",
    "\n",
    "bm25_retriever = load_bm25(file_path=\"./full_bm25_retriever.pkl\")\n",
    "bm25_retriever.k = 15\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "üìÇ Loading BM25 from ./full_bm25_retriever.pkl...\n",
      "‚úÖ BM25 loaded successfully! (4291 documents)\n",
      "‚úÖ bm25_retriever created successfully!\n"
     ]
    }
   ],
   "source": [
    "# bm25_retriever = BM25Retriever.from_documents(documents=all_documents, preprocess_func=word_tokenize) \n",
    "\n",
    "bm25_retriever = create_or_load_bm25(\n",
    "    documents=unique_documents,\n",
    "    file_path=\"./full_bm25_retriever.pkl\"\n",
    ") \n",
    "\n",
    "bm25_retriever.k = 15\n",
    "\n",
    "print(f\"‚úÖ bm25_retriever created successfully!\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ vector_retriever created successfully!\n"
     ]
    }
   ],
   "source": [
    "# Create vector retriever\n",
    "vector_retriever = vector_store.as_retriever( \n",
    "    search_type=\"similarity\", \n",
    "    search_kwargs={\"k\": 15}\n",
    ") \n",
    "\n",
    "print(f\"‚úÖ vector_retriever created successfully!\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.retrievers import EnsembleRetriever\n",
    "\n",
    "ensemble_retriever = EnsembleRetriever(\n",
    "    retrievers=[vector_retriever, bm25_retriever], \n",
    "    weights=[0.5, 0.5]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_query_variations(original_query, num_variations):\n",
    "\n",
    "    from langchain_openai import ChatOpenAI\n",
    "    from langchain_core.messages import HumanMessage, SystemMessage\n",
    "    from pydantic import BaseModel, Field\n",
    "    from typing import List\n",
    "    \n",
    "    class QueryVariations(BaseModel):\n",
    "        \"\"\"Schema for query variations response\"\"\"\n",
    "        variations: List[str] = Field(\n",
    "            description=f\"Exactly {num_variations} different variations of the original query\",\n",
    "            min_length=num_variations,\n",
    "            max_length=num_variations\n",
    "        )\n",
    "    \n",
    "    system_prompt = \"\"\"You are an expert at generating search query variations. Your task is to create different ways to ask the same question that will help retrieve comprehensive information from a knowledge base.\n",
    "\n",
    "For each variation, use different:\n",
    "- Terminology (technical vs common terms, synonyms)\n",
    "- Phrasing and sentence structure  \n",
    "- Keywords while maintaining the same core intent\n",
    "\n",
    "Keep variations focused, specific, and don't change the fundamental meaning.\"\"\"\n",
    "\n",
    "    human_prompt = f\"\"\"Generate {num_variations} different variations of this query:\n",
    "\n",
    "\"{original_query}\"\n",
    "\n",
    "Each variation should capture the same intent but use different wording, terminology, or phrasing.\"\"\"\n",
    "\n",
    "    try:\n",
    "        llm = ChatOpenAI(\n",
    "            model=\"gpt-4o\",  \n",
    "            temperature=0.0\n",
    "        )\n",
    "        \n",
    "        structured_llm = llm.with_structured_output(QueryVariations)\n",
    "        \n",
    "        messages = [\n",
    "            SystemMessage(content=system_prompt),\n",
    "            HumanMessage(content=human_prompt)\n",
    "        ]\n",
    "        \n",
    "        response = structured_llm.invoke(messages) \n",
    "        \n",
    "        all_queries = [original_query] + response.variations \n",
    "        \n",
    "        print(f\"‚úÖ Generated {len(response.variations)} query variations:\")\n",
    "        for i, query in enumerate(all_queries):\n",
    "            prefix = \"Original\" if i == 0 else f\"Variation {i}\"\n",
    "            print(f\"   {prefix}: {query}\")\n",
    "        \n",
    "        return all_queries\n",
    "        \n",
    "    except Exception as e:\n",
    "        print(f\"‚ö†Ô∏è Error generating query variations: {e}\")\n",
    "        print(\"üìù Falling back to original query only\")\n",
    "        return [original_query]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "from simhash import Simhash\n",
    "import time\n",
    "\n",
    "def simhash_deduplication(docs, similarity_threshold):\n",
    "    \"\"\"\n",
    "    Deduplicate documents using Simhash\n",
    "    \n",
    "    Args:\n",
    "        docs: List of LangChain Document objects\n",
    "        similarity_threshold: Hamming distance threshold (lower = more similar)\n",
    "                             Typical values: 0-3 for very similar, 3-6 for similar\n",
    "    \"\"\"\n",
    "    if len(docs) <= 10:\n",
    "        return docs\n",
    "    \n",
    "    print(f\"üîç Simhash deduplicating {len(docs)} documents...\")\n",
    "    start = time.time()\n",
    "    \n",
    "    # Create simhashes for all documents\n",
    "    doc_hashes = []\n",
    "    for doc in docs:\n",
    "        # Create simhash from document content\n",
    "        sim_hash = Simhash(doc.page_content)\n",
    "        doc_hashes.append(sim_hash)\n",
    "    \n",
    "    print(f\"   Hash generation: {time.time() - start:.2f}s\")\n",
    "    start = time.time()\n",
    "    \n",
    "    # Find duplicates\n",
    "    to_remove = set()\n",
    "    for i in range(len(docs)):\n",
    "        if i in to_remove:\n",
    "            continue\n",
    "        for j in range(i + 1, len(docs)):\n",
    "            if j in to_remove:\n",
    "                continue\n",
    "            \n",
    "            # Calculate Hamming distance between hashes\n",
    "            distance = doc_hashes[i].distance(doc_hashes[j])\n",
    "            if distance <= similarity_threshold:\n",
    "                to_remove.add(j)  # Remove the later document\n",
    "    \n",
    "    # Filter documents\n",
    "    final_docs = [doc for i, doc in enumerate(docs) if i not in to_remove]\n",
    "    \n",
    "    print(f\"   Comparison: {time.time() - start:.2f}s\")\n",
    "    print(f\"   Simhash filtering: {len(docs)} ‚Üí {len(final_docs)} docs\")\n",
    "    \n",
    "    return final_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "üéØ Setting up Cohere reranking with contextual compression...\n",
      "‚úÖ RAG Fusion pipeline setup complete!\n"
     ]
    }
   ],
   "source": [
    "from langchain_cohere import CohereRerank\n",
    "\n",
    "print(f\"\\nüéØ Setting up Cohere reranking with contextual compression...\")\n",
    "\n",
    "cohere_reranker = CohereRerank(\n",
    "    model=\"rerank-english-v3.0\",  \n",
    "    top_n=10,  \n",
    "    cohere_api_key=os.getenv(\"COHERE_API_KEY\")  \n",
    ")\n",
    "\n",
    "def retrieve_chunks(query):\n",
    "\n",
    "    total_start = time.time()\n",
    "\n",
    "    start = time.time()\n",
    "\n",
    "    # all_results = ensemble_retriever.invoke(query)\n",
    "    all_results = retriever.invoke(query)\n",
    "    print(f\"Ensemble Retriever Results {len(all_results)}\")\n",
    "\n",
    "    print(f\"Step 1: {time.time() - start:.2f}s\")\n",
    "\n",
    "    start = time.time()\n",
    "\n",
    "    deduplicated_docs = simhash_deduplication(\n",
    "        all_results, \n",
    "        similarity_threshold=2, \n",
    "    )\n",
    "    print(f\"Step 2: {time.time() - start:.2f}s\")\n",
    "    print(f\"deduplicated_docs: {len(deduplicated_docs)}\")\n",
    "\n",
    "    \n",
    "    start = time.time()\n",
    "\n",
    "    if len(deduplicated_docs) <= 10:\n",
    "        print(f\"Step 3: 0.00s (skipped - only {len(deduplicated_docs)} docs)\")\n",
    "        final_docs = deduplicated_docs\n",
    "    else:\n",
    "        start = time.time()\n",
    "        final_docs = cohere_reranker.compress_documents(\n",
    "            documents=deduplicated_docs[:20],  \n",
    "            query=query\n",
    "        )\n",
    "       \n",
    "\n",
    "    print(f\"final_docs: {len(final_docs)}\")\n",
    "\n",
    "    print(f\"Step 3: {time.time() - start:.2f}s\") \n",
    "    \n",
    "    print(f\"TOTAL: {time.time() - total_start:.2f}s\")\n",
    "    \n",
    "    return final_docs\n",
    "\n",
    "print(f\"‚úÖ RAG Fusion pipeline setup complete!\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai import ChatOpenAI\n",
    "from langchain_core.messages import HumanMessage, SystemMessage\n",
    "from pydantic import BaseModel, Field\n",
    "from typing import List, Optional\n",
    "\n",
    "class Citation(BaseModel):\n",
    "    filename: str = Field(description=\"The filename of the source document\")\n",
    "    page_number: Optional[str] = Field(default=None, description=\"The page number of the source document (if available)\")\n",
    "\n",
    "\n",
    "class StructuredAnswer(BaseModel):\n",
    "    answer: str = Field(description=\"The comprehensive answer to the question\")\n",
    "    citations: List[Citation] = Field(description=\"List of source filenames that support the answer\")\n",
    "\n",
    "\n",
    "llm = ChatOpenAI(\n",
    "    model=\"gpt-4o\",  \n",
    "    temperature=0.0\n",
    ")\n",
    "\n",
    "structured_llm = llm.with_structured_output(StructuredAnswer)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.prompts import ChatPromptTemplate\n",
    "from langchain.schema.runnable import RunnablePassthrough, RunnableLambda\n",
    "from langchain.schema.output_parser import StrOutputParser \n",
    "\n",
    "retriever = RunnableLambda(retrieve_chunks)\n",
    "\n",
    "def format_docs(docs):\n",
    "    formatted_chunks = []\n",
    "    \n",
    "    for i, doc in enumerate(docs):\n",
    "        filename = doc.metadata.get('filename', 'unknown')\n",
    "        page_number = doc.metadata.get('page_number', 'unknown')\n",
    "        \n",
    "        chunk_text = f\"[Source: {filename}, Page: {page_number}]\\n{doc.page_content}\\n\"\n",
    "        formatted_chunks.append(chunk_text)\n",
    "    \n",
    "    return \"\\n\".join(formatted_chunks)\n",
    "\n",
    "prompt = ChatPromptTemplate.from_template(\"\"\"\n",
    "                                          \n",
    "Please carefully review the conversation history and the provided documents below to answer the current question. Consider any context from previous exchanges when formulating your response.\n",
    "                                          \n",
    "Question: {input}\n",
    "\n",
    "If you can find a complete answer, provide it with supporting evidence. If you can only find partial information or related context, explain what you found and acknowledge what's missing. If the documents don't contain relevant information, let me know what topics or areas the documents do cover instead.\n",
    "\n",
    "Context: {context} \n",
    "\n",
    "Guidelines for your response:\n",
    "- Be helpful and informative even when information is incomplete\n",
    "- If you can't find a direct answer, mention what related information is available\n",
    "- Always cite specific evidence from the documents when possible\n",
    "- If no relevant information exists, briefly describe what the documents do contain\n",
    "\n",
    "Format your response as:\n",
    "ANSWER: [your response - can be direct answer, partial information, or explanation of available content]\n",
    "EVIDENCE: [specific quotes or references from the documents, or note if no relevant content found]\"\"\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "ename": "RecursionError",
     "evalue": "maximum recursion depth exceeded",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mRecursionError\u001b[39m                            Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[52]\u001b[39m\u001b[32m, line 6\u001b[39m\n\u001b[32m      1\u001b[39m rag_chain = (\n\u001b[32m      2\u001b[39m     {\u001b[33m\"\u001b[39m\u001b[33minput\u001b[39m\u001b[33m\"\u001b[39m: RunnablePassthrough(),  \n\u001b[32m      3\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mcontext\u001b[39m\u001b[33m\"\u001b[39m: retriever | format_docs,  \n\u001b[32m      4\u001b[39m     } | prompt | structured_llm ) \n\u001b[32m----> \u001b[39m\u001b[32m6\u001b[39m \u001b[43mrag_chain\u001b[49m\u001b[43m.\u001b[49m\u001b[43minvoke\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mwhat is amtagvi?\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/base.py:3025\u001b[39m, in \u001b[36mRunnableSequence.invoke\u001b[39m\u001b[34m(self, input, config, **kwargs)\u001b[39m\n\u001b[32m   3022\u001b[39m \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34;01mlangchain_core\u001b[39;00m\u001b[34;01m.\u001b[39;00m\u001b[34;01mbeta\u001b[39;00m\u001b[34;01m.\u001b[39;00m\u001b[34;01mrunnables\u001b[39;00m\u001b[34;01m.\u001b[39;00m\u001b[34;01mcontext\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mimport\u001b[39;00m config_with_context\n\u001b[32m   3024\u001b[39m \u001b[38;5;66;03m# setup callbacks and context\u001b[39;00m\n\u001b[32m-> \u001b[39m\u001b[32m3025\u001b[39m config = \u001b[43mconfig_with_context\u001b[49m\u001b[43m(\u001b[49m\u001b[43mensure_config\u001b[49m\u001b[43m(\u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43msteps\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   3026\u001b[39m callback_manager = get_callback_manager_for_config(config)\n\u001b[32m   3027\u001b[39m \u001b[38;5;66;03m# start the root run\u001b[39;00m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/beta/runnables/context.py:155\u001b[39m, in \u001b[36mconfig_with_context\u001b[39m\u001b[34m(config, steps)\u001b[39m\n\u001b[32m    142\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mconfig_with_context\u001b[39m(\n\u001b[32m    143\u001b[39m     config: RunnableConfig,\n\u001b[32m    144\u001b[39m     steps: \u001b[38;5;28mlist\u001b[39m[Runnable],\n\u001b[32m    145\u001b[39m ) -> RunnableConfig:\n\u001b[32m    146\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"Patch a runnable config with context getters and setters.\u001b[39;00m\n\u001b[32m    147\u001b[39m \n\u001b[32m    148\u001b[39m \u001b[33;03m    Args:\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m    153\u001b[39m \u001b[33;03m        The patched runnable config.\u001b[39;00m\n\u001b[32m    154\u001b[39m \u001b[33;03m    \"\"\"\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m155\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43m_config_with_context\u001b[49m\u001b[43m(\u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43msteps\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m_setter\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m_getter\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mthreading\u001b[49m\u001b[43m.\u001b[49m\u001b[43mEvent\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/beta/runnables/context.py:81\u001b[39m, in \u001b[36m_config_with_context\u001b[39m\u001b[34m(config, steps, setter, getter, event_cls)\u001b[39m\n\u001b[32m     75\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28many\u001b[39m(k.startswith(CONTEXT_CONFIG_PREFIX) \u001b[38;5;28;01mfor\u001b[39;00m k \u001b[38;5;129;01min\u001b[39;00m config.get(\u001b[33m\"\u001b[39m\u001b[33mconfigurable\u001b[39m\u001b[33m\"\u001b[39m, {})):\n\u001b[32m     76\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m config\n\u001b[32m     78\u001b[39m context_specs = [\n\u001b[32m     79\u001b[39m     (spec, i)\n\u001b[32m     80\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m i, step \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28menumerate\u001b[39m(steps)\n\u001b[32m---> \u001b[39m\u001b[32m81\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m spec \u001b[38;5;129;01min\u001b[39;00m \u001b[43mstep\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconfig_specs\u001b[49m\n\u001b[32m     82\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m spec.id.startswith(CONTEXT_CONFIG_PREFIX)\n\u001b[32m     83\u001b[39m ]\n\u001b[32m     84\u001b[39m grouped_by_key = {\n\u001b[32m     85\u001b[39m     key: \u001b[38;5;28mlist\u001b[39m(group)\n\u001b[32m     86\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m key, group \u001b[38;5;129;01min\u001b[39;00m groupby(\n\u001b[32m   (...)\u001b[39m\u001b[32m     89\u001b[39m     )\n\u001b[32m     90\u001b[39m }\n\u001b[32m     91\u001b[39m deps_by_key = {\n\u001b[32m     92\u001b[39m     key: {\n\u001b[32m     93\u001b[39m         _key_from_id(dep) \u001b[38;5;28;01mfor\u001b[39;00m spec \u001b[38;5;129;01min\u001b[39;00m group \u001b[38;5;28;01mfor\u001b[39;00m dep \u001b[38;5;129;01min\u001b[39;00m (spec[\u001b[32m0\u001b[39m].dependencies \u001b[38;5;129;01mor\u001b[39;00m [])\n\u001b[32m     94\u001b[39m     }\n\u001b[32m     95\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m key, group \u001b[38;5;129;01min\u001b[39;00m grouped_by_key.items()\n\u001b[32m     96\u001b[39m }\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/base.py:3675\u001b[39m, in \u001b[36mRunnableParallel.config_specs\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m   3667\u001b[39m \u001b[38;5;129m@property\u001b[39m\n\u001b[32m   3668\u001b[39m \u001b[38;5;129m@override\u001b[39m\n\u001b[32m   3669\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mconfig_specs\u001b[39m(\u001b[38;5;28mself\u001b[39m) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m   3670\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"Get the config specs of the Runnable.\u001b[39;00m\n\u001b[32m   3671\u001b[39m \n\u001b[32m   3672\u001b[39m \u001b[33;03m    Returns:\u001b[39;00m\n\u001b[32m   3673\u001b[39m \u001b[33;03m        The config specs of the Runnable.\u001b[39;00m\n\u001b[32m   3674\u001b[39m \u001b[33;03m    \"\"\"\u001b[39;00m\n\u001b[32m-> \u001b[39m\u001b[32m3675\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mget_unique_config_specs\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   3676\u001b[39m \u001b[43m        \u001b[49m\u001b[43mspec\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mstep\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43msteps__\u001b[49m\u001b[43m.\u001b[49m\u001b[43mvalues\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mspec\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mstep\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconfig_specs\u001b[49m\n\u001b[32m   3677\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/utils.py:691\u001b[39m, in \u001b[36mget_unique_config_specs\u001b[39m\u001b[34m(specs)\u001b[39m\n\u001b[32m    676\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mget_unique_config_specs\u001b[39m(\n\u001b[32m    677\u001b[39m     specs: Iterable[ConfigurableFieldSpec],\n\u001b[32m    678\u001b[39m ) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m    679\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"Get the unique config specs from a sequence of config specs.\u001b[39;00m\n\u001b[32m    680\u001b[39m \n\u001b[32m    681\u001b[39m \u001b[33;03m    Args:\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m    688\u001b[39m \u001b[33;03m        ValueError: If the runnable sequence contains conflicting config specs.\u001b[39;00m\n\u001b[32m    689\u001b[39m \u001b[33;03m    \"\"\"\u001b[39;00m\n\u001b[32m    690\u001b[39m     grouped = groupby(\n\u001b[32m--> \u001b[39m\u001b[32m691\u001b[39m         \u001b[38;5;28;43msorted\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mspecs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mkey\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43;01mlambda\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43ms\u001b[49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m(\u001b[49m\u001b[43ms\u001b[49m\u001b[43m.\u001b[49m\u001b[43mid\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m(\u001b[49m\u001b[43ms\u001b[49m\u001b[43m.\u001b[49m\u001b[43mdependencies\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[43m]\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m, \u001b[38;5;28;01mlambda\u001b[39;00m s: s.id\n\u001b[32m    692\u001b[39m     )\n\u001b[32m    693\u001b[39m     unique: \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec] = []\n\u001b[32m    694\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m spec_id, dupes \u001b[38;5;129;01min\u001b[39;00m grouped:\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/base.py:3676\u001b[39m, in \u001b[36m<genexpr>\u001b[39m\u001b[34m(.0)\u001b[39m\n\u001b[32m   3667\u001b[39m \u001b[38;5;129m@property\u001b[39m\n\u001b[32m   3668\u001b[39m \u001b[38;5;129m@override\u001b[39m\n\u001b[32m   3669\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mconfig_specs\u001b[39m(\u001b[38;5;28mself\u001b[39m) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m   3670\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"Get the config specs of the Runnable.\u001b[39;00m\n\u001b[32m   3671\u001b[39m \n\u001b[32m   3672\u001b[39m \u001b[33;03m    Returns:\u001b[39;00m\n\u001b[32m   3673\u001b[39m \u001b[33;03m        The config specs of the Runnable.\u001b[39;00m\n\u001b[32m   3674\u001b[39m \u001b[33;03m    \"\"\"\u001b[39;00m\n\u001b[32m   3675\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m get_unique_config_specs(\n\u001b[32m-> \u001b[39m\u001b[32m3676\u001b[39m         spec \u001b[38;5;28;01mfor\u001b[39;00m step \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m.steps__.values() \u001b[38;5;28;01mfor\u001b[39;00m spec \u001b[38;5;129;01min\u001b[39;00m \u001b[43mstep\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconfig_specs\u001b[49m\n\u001b[32m   3677\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/base.py:2886\u001b[39m, in \u001b[36mRunnableSequence.config_specs\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m   2877\u001b[39m \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34;01mlangchain_core\u001b[39;00m\u001b[34;01m.\u001b[39;00m\u001b[34;01mbeta\u001b[39;00m\u001b[34;01m.\u001b[39;00m\u001b[34;01mrunnables\u001b[39;00m\u001b[34;01m.\u001b[39;00m\u001b[34;01mcontext\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mimport\u001b[39;00m (\n\u001b[32m   2878\u001b[39m     CONTEXT_CONFIG_PREFIX,\n\u001b[32m   2879\u001b[39m     _key_from_id,\n\u001b[32m   2880\u001b[39m )\n\u001b[32m   2882\u001b[39m \u001b[38;5;66;03m# get all specs\u001b[39;00m\n\u001b[32m   2883\u001b[39m all_specs = [\n\u001b[32m   2884\u001b[39m     (spec, idx)\n\u001b[32m   2885\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m idx, step \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28menumerate\u001b[39m(\u001b[38;5;28mself\u001b[39m.steps)\n\u001b[32m-> \u001b[39m\u001b[32m2886\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m spec \u001b[38;5;129;01min\u001b[39;00m \u001b[43mstep\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconfig_specs\u001b[49m\n\u001b[32m   2887\u001b[39m ]\n\u001b[32m   2888\u001b[39m \u001b[38;5;66;03m# calculate context dependencies\u001b[39;00m\n\u001b[32m   2889\u001b[39m specs_by_pos = groupby(\n\u001b[32m   2890\u001b[39m     [tup \u001b[38;5;28;01mfor\u001b[39;00m tup \u001b[38;5;129;01min\u001b[39;00m all_specs \u001b[38;5;28;01mif\u001b[39;00m tup[\u001b[32m0\u001b[39m].id.startswith(CONTEXT_CONFIG_PREFIX)],\n\u001b[32m   2891\u001b[39m     itemgetter(\u001b[32m1\u001b[39m),\n\u001b[32m   2892\u001b[39m )\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/base.py:4549\u001b[39m, in \u001b[36mRunnableLambda.config_specs\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m   4546\u001b[39m \u001b[38;5;129m@property\u001b[39m\n\u001b[32m   4547\u001b[39m \u001b[38;5;129m@override\u001b[39m\n\u001b[32m   4548\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mconfig_specs\u001b[39m(\u001b[38;5;28mself\u001b[39m) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m-> \u001b[39m\u001b[32m4549\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mget_unique_config_specs\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   4550\u001b[39m \u001b[43m        \u001b[49m\u001b[43mspec\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mdep\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mdeps\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mspec\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mdep\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconfig_specs\u001b[49m\n\u001b[32m   4551\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/utils.py:691\u001b[39m, in \u001b[36mget_unique_config_specs\u001b[39m\u001b[34m(specs)\u001b[39m\n\u001b[32m    676\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mget_unique_config_specs\u001b[39m(\n\u001b[32m    677\u001b[39m     specs: Iterable[ConfigurableFieldSpec],\n\u001b[32m    678\u001b[39m ) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m    679\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"Get the unique config specs from a sequence of config specs.\u001b[39;00m\n\u001b[32m    680\u001b[39m \n\u001b[32m    681\u001b[39m \u001b[33;03m    Args:\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m    688\u001b[39m \u001b[33;03m        ValueError: If the runnable sequence contains conflicting config specs.\u001b[39;00m\n\u001b[32m    689\u001b[39m \u001b[33;03m    \"\"\"\u001b[39;00m\n\u001b[32m    690\u001b[39m     grouped = groupby(\n\u001b[32m--> \u001b[39m\u001b[32m691\u001b[39m         \u001b[38;5;28;43msorted\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mspecs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mkey\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43;01mlambda\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43ms\u001b[49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m(\u001b[49m\u001b[43ms\u001b[49m\u001b[43m.\u001b[49m\u001b[43mid\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m(\u001b[49m\u001b[43ms\u001b[49m\u001b[43m.\u001b[49m\u001b[43mdependencies\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[43m]\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m, \u001b[38;5;28;01mlambda\u001b[39;00m s: s.id\n\u001b[32m    692\u001b[39m     )\n\u001b[32m    693\u001b[39m     unique: \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec] = []\n\u001b[32m    694\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m spec_id, dupes \u001b[38;5;129;01min\u001b[39;00m grouped:\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/base.py:4550\u001b[39m, in \u001b[36m<genexpr>\u001b[39m\u001b[34m(.0)\u001b[39m\n\u001b[32m   4546\u001b[39m \u001b[38;5;129m@property\u001b[39m\n\u001b[32m   4547\u001b[39m \u001b[38;5;129m@override\u001b[39m\n\u001b[32m   4548\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mconfig_specs\u001b[39m(\u001b[38;5;28mself\u001b[39m) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m   4549\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m get_unique_config_specs(\n\u001b[32m-> \u001b[39m\u001b[32m4550\u001b[39m         spec \u001b[38;5;28;01mfor\u001b[39;00m dep \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m.deps \u001b[38;5;28;01mfor\u001b[39;00m spec \u001b[38;5;129;01min\u001b[39;00m \u001b[43mdep\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconfig_specs\u001b[49m\n\u001b[32m   4551\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/base.py:4549\u001b[39m, in \u001b[36mRunnableLambda.config_specs\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m   4546\u001b[39m \u001b[38;5;129m@property\u001b[39m\n\u001b[32m   4547\u001b[39m \u001b[38;5;129m@override\u001b[39m\n\u001b[32m   4548\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mconfig_specs\u001b[39m(\u001b[38;5;28mself\u001b[39m) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m-> \u001b[39m\u001b[32m4549\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mget_unique_config_specs\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   4550\u001b[39m \u001b[43m        \u001b[49m\u001b[43mspec\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mdep\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mdeps\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mspec\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mdep\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconfig_specs\u001b[49m\n\u001b[32m   4551\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/utils.py:691\u001b[39m, in \u001b[36mget_unique_config_specs\u001b[39m\u001b[34m(specs)\u001b[39m\n\u001b[32m    676\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mget_unique_config_specs\u001b[39m(\n\u001b[32m    677\u001b[39m     specs: Iterable[ConfigurableFieldSpec],\n\u001b[32m    678\u001b[39m ) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m    679\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"Get the unique config specs from a sequence of config specs.\u001b[39;00m\n\u001b[32m    680\u001b[39m \n\u001b[32m    681\u001b[39m \u001b[33;03m    Args:\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m    688\u001b[39m \u001b[33;03m        ValueError: If the runnable sequence contains conflicting config specs.\u001b[39;00m\n\u001b[32m    689\u001b[39m \u001b[33;03m    \"\"\"\u001b[39;00m\n\u001b[32m    690\u001b[39m     grouped = groupby(\n\u001b[32m--> \u001b[39m\u001b[32m691\u001b[39m         \u001b[38;5;28;43msorted\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mspecs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mkey\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43;01mlambda\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43ms\u001b[49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m(\u001b[49m\u001b[43ms\u001b[49m\u001b[43m.\u001b[49m\u001b[43mid\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m(\u001b[49m\u001b[43ms\u001b[49m\u001b[43m.\u001b[49m\u001b[43mdependencies\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[43m]\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m, \u001b[38;5;28;01mlambda\u001b[39;00m s: s.id\n\u001b[32m    692\u001b[39m     )\n\u001b[32m    693\u001b[39m     unique: \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec] = []\n\u001b[32m    694\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m spec_id, dupes \u001b[38;5;129;01min\u001b[39;00m grouped:\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/base.py:4550\u001b[39m, in \u001b[36m<genexpr>\u001b[39m\u001b[34m(.0)\u001b[39m\n\u001b[32m   4546\u001b[39m \u001b[38;5;129m@property\u001b[39m\n\u001b[32m   4547\u001b[39m \u001b[38;5;129m@override\u001b[39m\n\u001b[32m   4548\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mconfig_specs\u001b[39m(\u001b[38;5;28mself\u001b[39m) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m   4549\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m get_unique_config_specs(\n\u001b[32m-> \u001b[39m\u001b[32m4550\u001b[39m         spec \u001b[38;5;28;01mfor\u001b[39;00m dep \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m.deps \u001b[38;5;28;01mfor\u001b[39;00m spec \u001b[38;5;129;01min\u001b[39;00m \u001b[43mdep\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconfig_specs\u001b[49m\n\u001b[32m   4551\u001b[39m     )\n",
      "    \u001b[31m[... skipping similar frames: <genexpr> at line 4550 (987 times), RunnableLambda.config_specs at line 4549 (987 times), get_unique_config_specs at line 691 (987 times)]\u001b[39m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/base.py:4549\u001b[39m, in \u001b[36mRunnableLambda.config_specs\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m   4546\u001b[39m \u001b[38;5;129m@property\u001b[39m\n\u001b[32m   4547\u001b[39m \u001b[38;5;129m@override\u001b[39m\n\u001b[32m   4548\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mconfig_specs\u001b[39m(\u001b[38;5;28mself\u001b[39m) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m-> \u001b[39m\u001b[32m4549\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mget_unique_config_specs\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   4550\u001b[39m \u001b[43m        \u001b[49m\u001b[43mspec\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mdep\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mdeps\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mspec\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mdep\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconfig_specs\u001b[49m\n\u001b[32m   4551\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/utils.py:691\u001b[39m, in \u001b[36mget_unique_config_specs\u001b[39m\u001b[34m(specs)\u001b[39m\n\u001b[32m    676\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mget_unique_config_specs\u001b[39m(\n\u001b[32m    677\u001b[39m     specs: Iterable[ConfigurableFieldSpec],\n\u001b[32m    678\u001b[39m ) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m    679\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"Get the unique config specs from a sequence of config specs.\u001b[39;00m\n\u001b[32m    680\u001b[39m \n\u001b[32m    681\u001b[39m \u001b[33;03m    Args:\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m    688\u001b[39m \u001b[33;03m        ValueError: If the runnable sequence contains conflicting config specs.\u001b[39;00m\n\u001b[32m    689\u001b[39m \u001b[33;03m    \"\"\"\u001b[39;00m\n\u001b[32m    690\u001b[39m     grouped = groupby(\n\u001b[32m--> \u001b[39m\u001b[32m691\u001b[39m         \u001b[38;5;28;43msorted\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mspecs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mkey\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43;01mlambda\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43ms\u001b[49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m(\u001b[49m\u001b[43ms\u001b[49m\u001b[43m.\u001b[49m\u001b[43mid\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m(\u001b[49m\u001b[43ms\u001b[49m\u001b[43m.\u001b[49m\u001b[43mdependencies\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[43m]\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m, \u001b[38;5;28;01mlambda\u001b[39;00m s: s.id\n\u001b[32m    692\u001b[39m     )\n\u001b[32m    693\u001b[39m     unique: \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec] = []\n\u001b[32m    694\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m spec_id, dupes \u001b[38;5;129;01min\u001b[39;00m grouped:\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Documents/pixacore/venv/lib/python3.13/site-packages/langchain_core/runnables/base.py:4550\u001b[39m, in \u001b[36m<genexpr>\u001b[39m\u001b[34m(.0)\u001b[39m\n\u001b[32m   4546\u001b[39m \u001b[38;5;129m@property\u001b[39m\n\u001b[32m   4547\u001b[39m \u001b[38;5;129m@override\u001b[39m\n\u001b[32m   4548\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mconfig_specs\u001b[39m(\u001b[38;5;28mself\u001b[39m) -> \u001b[38;5;28mlist\u001b[39m[ConfigurableFieldSpec]:\n\u001b[32m   4549\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m get_unique_config_specs(\n\u001b[32m-> \u001b[39m\u001b[32m4550\u001b[39m         spec \u001b[38;5;28;01mfor\u001b[39;00m dep \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m.deps \u001b[38;5;28;01mfor\u001b[39;00m spec \u001b[38;5;129;01min\u001b[39;00m \u001b[43mdep\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconfig_specs\u001b[49m\n\u001b[32m   4551\u001b[39m     )\n",
      "\u001b[31mRecursionError\u001b[39m: maximum recursion depth exceeded"
     ]
    }
   ],
   "source": [
    "rag_chain = (\n",
    "    {\"input\": RunnablePassthrough(),  \n",
    "    \"context\": retriever | format_docs,  \n",
    "    } | prompt | structured_llm ) \n",
    "\n",
    "rag_chain.invoke(\"what is amtagvi?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langgraph.graph import StateGraph, END\n",
    "from typing import TypedDict, List\n",
    "from langchain_core.messages import BaseMessage, SystemMessage, HumanMessage\n",
    "import json\n",
    "\n",
    "class State(TypedDict):\n",
    "    original_question: str\n",
    "    history: List[BaseMessage]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import TypedDict, List\n",
    "from langchain_core.messages import BaseMessage, HumanMessage, AIMessage, SystemMessage\n",
    "from langchain.schema import Document\n",
    "from pydantic import BaseModel, Field\n",
    "from langchain_openai import ChatOpenAI\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from langgraph.graph import StateGraph, END\n",
    "from langgraph.checkpoint.memory import MemorySaver\n",
    "\n",
    "\n",
    "class AgentState(TypedDict):\n",
    "    messages: List[BaseMessage]\n",
    "    documents: List[Document]\n",
    "    on_topic: str\n",
    "    rephrased_question: str\n",
    "    proceed_to_generate: bool\n",
    "    rephrase_count: int\n",
    "    question: HumanMessage\n",
    "\n",
    "\n",
    "class GradeQuestion(BaseModel):\n",
    "    score: str = Field(\n",
    "        description=\"Question is about medical topics? If yes -> 'Yes' if not -> 'No'\"\n",
    "    )\n",
    "\n",
    "\n",
    "class GradeDocuments(BaseModel):\n",
    "    \"\"\"Grade multiple documents at once for relevance to the question.\"\"\"\n",
    "    relevant_document_indices: List[int] = Field(\n",
    "        description=\"List of indices (0-based) of documents that are relevant to the question\"\n",
    "    )\n",
    "    reasoning: str = Field(\n",
    "        description=\"Brief explanation of why these documents were selected as relevant\"\n",
    "    )\n",
    "\n",
    "\n",
    "def question_rewriter(state: AgentState):\n",
    "    print(f\"Entering question_rewriter with following state: {state}\")\n",
    "\n",
    "    state[\"documents\"] = []\n",
    "    state[\"on_topic\"] = \"\"\n",
    "    state[\"rephrased_question\"] = \"\"\n",
    "    state[\"proceed_to_generate\"] = False\n",
    "    state[\"rephrase_count\"] = 0\n",
    "\n",
    "    if \"messages\" not in state or state[\"messages\"] is None:\n",
    "        state[\"messages\"] = []\n",
    "\n",
    "    if state[\"question\"] not in state[\"messages\"]:\n",
    "        state[\"messages\"].append(state[\"question\"])\n",
    "\n",
    "    if len(state[\"messages\"]) > 1:\n",
    "        conversation = state[\"messages\"][:-1]\n",
    "        current_question = state[\"question\"].content\n",
    "        messages = [\n",
    "            SystemMessage(\n",
    "                content=\"You are a helpful assistant that rephrases the user's question to be a standalone question optimized for retrieval.\"\n",
    "            )\n",
    "        ]\n",
    "        messages.extend(conversation)\n",
    "        messages.append(HumanMessage(content=current_question))\n",
    "        rephrase_prompt = ChatPromptTemplate.from_messages(messages)\n",
    "        llm = ChatOpenAI(model=\"gpt-4o-mini\")\n",
    "        prompt = rephrase_prompt.format()\n",
    "        response = llm.invoke(prompt)\n",
    "        better_question = response.content.strip()\n",
    "        print(f\"question_rewriter: Rephrased question: {better_question}\")\n",
    "        state[\"rephrased_question\"] = better_question\n",
    "    else:\n",
    "        state[\"rephrased_question\"] = state[\"question\"].content\n",
    "    return state\n",
    "\n",
    "\n",
    "def question_classifier(state: AgentState):\n",
    "    print(\"Entering question_classifier\")\n",
    "    system_message = SystemMessage(\n",
    "        content=\"\"\" You are a classifier that determines whether a user's question is about medical topics including:\n",
    "    \n",
    "    1. Diseases, conditions, and symptoms\n",
    "    2. Medical treatments and procedures\n",
    "    3. Medications and pharmaceuticals\n",
    "    4. Human anatomy and physiology\n",
    "    5. Medical diagnostics and testing\n",
    "    6. Healthcare and medical advice\n",
    "    7. Mental health and psychology\n",
    "    8. Nutrition and dietary health\n",
    "    9. Medical research and studies\n",
    "    10. Any other healthcare or medical-related topics\n",
    "    \n",
    "    If the question IS about any medical topics, respond with 'Yes'. Otherwise, respond with 'No'.\n",
    "    \"\"\"\n",
    "    )\n",
    "\n",
    "    human_message = HumanMessage(\n",
    "        content=f\"User question: {state['rephrased_question']}\"\n",
    "    )\n",
    "    grade_prompt = ChatPromptTemplate.from_messages([system_message, human_message])\n",
    "    llm = ChatOpenAI(model=\"gpt-4o\")\n",
    "    structured_llm = llm.with_structured_output(GradeQuestion)\n",
    "    grader_llm = grade_prompt | structured_llm\n",
    "    result = grader_llm.invoke({})\n",
    "    state[\"on_topic\"] = result.score.strip()\n",
    "    print(f\"question_classifier: on_topic = {state['on_topic']}\")\n",
    "    return state\n",
    "\n",
    "\n",
    "def on_topic_router(state: AgentState):\n",
    "    print(\"Entering on_topic_router\")\n",
    "    on_topic = state.get(\"on_topic\", \"\").strip().lower()\n",
    "    if on_topic == \"yes\":\n",
    "        print(\"Routing to retrieve\")\n",
    "        return \"retrieve\"\n",
    "    else:\n",
    "        print(\"Routing to off_topic_response\")\n",
    "        return \"off_topic_response\"\n",
    "\n",
    "\n",
    "def retrieve(state: AgentState):\n",
    "    print(\"Entering retrieve\")\n",
    "    documents = retriever.invoke(state[\"rephrased_question\"])\n",
    "    print(f\"retrieve: Retrieved {len(documents)} documents\")\n",
    "    state[\"documents\"] = documents\n",
    "    return state\n",
    "\n",
    "\n",
    "def retrieval_grader(state: AgentState):\n",
    "    print(\"Entering retrieval_grader\")\n",
    "    \n",
    "    if not state[\"documents\"]:\n",
    "        print(\"No documents to grade\")\n",
    "        state[\"proceed_to_generate\"] = False\n",
    "        return state\n",
    "    \n",
    "    # Prepare all documents for single LLM call\n",
    "    documents_text = \"\"\n",
    "    for i, doc in enumerate(state[\"documents\"]):\n",
    "        documents_text += f\"Document {i}:\\n{doc.page_content}\\n\\n\"\n",
    "    \n",
    "    system_message = SystemMessage(\n",
    "        content=\"\"\"You are a grader assessing the relevance of retrieved documents to a user question.\n",
    "        \n",
    "You will be given multiple documents numbered from 0 onwards. Your task is to:\n",
    "1. Identify which documents contain information relevant to the user's question\n",
    "2. Return the indices (numbers) of the relevant documents\n",
    "3. Provide brief reasoning for your selection\n",
    "\n",
    "A document is relevant if it contains information that could help answer the user's question, even if partially.\"\"\"\n",
    "    )\n",
    "    \n",
    "    human_message = HumanMessage(\n",
    "        content=f\"User question: {state['rephrased_question']}\\n\\nDocuments to evaluate:\\n{documents_text}\"\n",
    "    )\n",
    "    \n",
    "    grade_prompt = ChatPromptTemplate.from_messages([system_message, human_message])\n",
    "    llm = ChatOpenAI(model=\"gpt-4o\")\n",
    "    structured_llm = llm.with_structured_output(GradeDocuments)\n",
    "    grader_llm = grade_prompt | structured_llm\n",
    "    result = grader_llm.invoke({})\n",
    "    \n",
    "    relevant_docs = []\n",
    "    for idx in result.relevant_document_indices:\n",
    "        if 0 <= idx < len(state[\"documents\"]):\n",
    "            relevant_docs.append(state[\"documents\"][idx])\n",
    "            print(f\"Document {idx} marked as relevant\")\n",
    "    \n",
    "    print(f\"Grading reasoning: {result.reasoning}\")\n",
    "    print(f\"Selected {len(relevant_docs)} relevant documents out of {len(state['documents'])}\")\n",
    "    \n",
    "    state[\"documents\"] = relevant_docs\n",
    "    state[\"proceed_to_generate\"] = len(relevant_docs) > 0\n",
    "    print(f\"retrieval_grader: proceed_to_generate = {state['proceed_to_generate']}\")\n",
    "    return state\n",
    "\n",
    "\n",
    "def proceed_router(state: AgentState):\n",
    "    print(\"Entering proceed_router\")\n",
    "    rephrase_count = state.get(\"rephrase_count\", 0)\n",
    "    if state.get(\"proceed_to_generate\", False):\n",
    "        print(\"Routing to generate_answer\")\n",
    "        return \"generate_answer\"\n",
    "    elif rephrase_count >= 2:\n",
    "        print(\"Maximum rephrase attempts reached. Cannot find relevant documents.\")\n",
    "        return \"generate_answer\"\n",
    "    else:\n",
    "        print(\"Routing to refine_question\")\n",
    "        return \"refine_question\"\n",
    "    \n",
    "\n",
    "def refine_question(state: AgentState):\n",
    "    print(\"Entering refine_question\")\n",
    "    rephrase_count = state.get(\"rephrase_count\", 0)\n",
    "    if rephrase_count >= 2:\n",
    "        print(\"Maximum rephrase attempts reached\")\n",
    "        return state\n",
    "    question_to_refine = state[\"rephrased_question\"]\n",
    "    system_message = SystemMessage(\n",
    "        content=\"\"\"You are a helpful assistant that slightly refines the user's question to improve retrieval results for medical information.\n",
    "Provide a slightly adjusted version of the question that might yield better results from a medical knowledge base.\"\"\"\n",
    "    )\n",
    "    human_message = HumanMessage(\n",
    "        content=f\"Original question: {question_to_refine}\\n\\nProvide a slightly refined question for medical information retrieval.\"\n",
    "    )\n",
    "    refine_prompt = ChatPromptTemplate.from_messages([system_message, human_message])\n",
    "    llm = ChatOpenAI(model=\"gpt-4o\")\n",
    "    prompt = refine_prompt.format()\n",
    "    response = llm.invoke(prompt)\n",
    "    refined_question = response.content.strip()\n",
    "    print(f\"refine_question: Refined question: {refined_question}\")\n",
    "    state[\"rephrased_question\"] = refined_question\n",
    "    state[\"rephrase_count\"] = rephrase_count + 1\n",
    "    return state\n",
    "\n",
    "\n",
    "def generate_answer(state: AgentState):\n",
    "    print(\"Entering generate_answer\")\n",
    "    if \"messages\" not in state or state[\"messages\"] is None:\n",
    "        raise ValueError(\"State must include 'messages' before generating an answer.\")\n",
    "\n",
    "    history = state[\"messages\"]\n",
    "    documents = state[\"documents\"]\n",
    "    rephrased_question = state[\"rephrased_question\"]\n",
    "\n",
    "    rag_chain = prompt | llm\n",
    "\n",
    "    response = rag_chain.invoke(\n",
    "        {\"chat_history\": history, \"context\": documents, \"input\": rephrased_question}\n",
    "    )\n",
    "\n",
    "    generation = response.content.strip()\n",
    "\n",
    "    state[\"messages\"].append(AIMessage(content=generation))\n",
    "    print(f\"generate_answer: Generated response: {generation}\")\n",
    "    return state\n",
    "\n",
    "def off_topic_response(state: AgentState):\n",
    "    print(\"Entering off_topic_response\")\n",
    "    if \"messages\" not in state or state[\"messages\"] is None:\n",
    "        state[\"messages\"] = []\n",
    "    state[\"messages\"].append(\n",
    "        AIMessage(\n",
    "            content=\"I'm sorry! I can only answer questions related to medical and healthcare topics.\"\n",
    "        )\n",
    "    )\n",
    "    return state\n",
    "\n",
    "\n",
    "prompt = ChatPromptTemplate.from_template(\"\"\"\n",
    "You are a document-based assistant. Answer questions using ONLY the provided context documents. Never use external knowledge or training data beyond what's in the documents.\n",
    "\n",
    "Conversation History: {chat_history}\n",
    "Question: {input}\n",
    "Context Documents: {context}\n",
    "\n",
    "INSTRUCTIONS:\n",
    "1. First, check if context documents are provided\n",
    "2. If documents exist: search for direct answers to the question\n",
    "3. If no direct answer exists: look for related, partially relevant, or tangentially connected information\n",
    "4. If documents exist but contain no relevant info: describe what topics the documents DO cover\n",
    "5. If no context documents provided: inform user that no relevant documents were found\n",
    "6. NEVER supplement with knowledge from outside the provided documents\n",
    "\n",
    "Response Format:\n",
    "ANSWER: \n",
    "- If no context provided: \"No relevant documents were found in the knowledge base for your question about [topic]\"\n",
    "- If direct answer found: [Provide complete answer]\n",
    "- If partial/related info found: [Explain what related information exists and how it connects to the question]\n",
    "- If documents exist but no relevant info: \"The provided documents do not contain information about [specific topic]. However, the documents do cover: [list main topics from the actual documents]\"\n",
    "\n",
    "EVIDENCE: \n",
    "- If no context: \"No documents retrieved from knowledge base\"\n",
    "- Otherwise: [Cite specific passages or \"No information about [topic] found in documents\"]\n",
    "\n",
    "Guidelines:\n",
    "- Be genuinely helpful by exploring connections the user might not have considered\n",
    "- Acknowledge limitations clearly when information is missing or incomplete\n",
    "- Focus on what IS available rather than what isn't\n",
    "- Never invent or assume information not explicitly in the documents\n",
    "\n",
    "Response:\"\"\")\n",
    "\n",
    "workflow = StateGraph(AgentState)\n",
    "workflow.add_node(\"question_rewriter\", question_rewriter)\n",
    "workflow.add_node(\"question_classifier\", question_classifier)\n",
    "workflow.add_node(\"off_topic_response\", off_topic_response)\n",
    "workflow.add_node(\"retrieve\", retrieve)\n",
    "workflow.add_node(\"retrieval_grader\", retrieval_grader)\n",
    "workflow.add_node(\"generate_answer\", generate_answer)\n",
    "workflow.add_node(\"refine_question\", refine_question)\n",
    "\n",
    "workflow.add_edge(\"question_rewriter\", \"question_classifier\") \n",
    "workflow.add_conditional_edges(\n",
    "    \"question_classifier\",\n",
    "    on_topic_router,\n",
    "    {\n",
    "        \"retrieve\": \"retrieve\",\n",
    "        \"off_topic_response\": \"off_topic_response\",\n",
    "    },\n",
    ")\n",
    "workflow.add_edge(\"retrieve\", \"retrieval_grader\")\n",
    "workflow.add_conditional_edges(\n",
    "    \"retrieval_grader\",\n",
    "    proceed_router,\n",
    "    {\n",
    "        \"generate_answer\": \"generate_answer\",\n",
    "        \"refine_question\": \"refine_question\"\n",
    "    },\n",
    ")\n",
    "workflow.add_edge(\"refine_question\", \"retrieve\")\n",
    "workflow.add_edge(\"generate_answer\", END)\n",
    "workflow.add_edge(\"off_topic_response\", END)\n",
    "workflow.set_entry_point(\"question_rewriter\")\n",
    "\n",
    "checkpointer = MemorySaver()\n",
    "\n",
    "graph = workflow.compile(checkpointer=checkpointer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entering question_rewriter with following state: {'question': HumanMessage(content='How is AMTAGVI provided and what is the dose?', additional_kwargs={}, response_metadata={})}\n",
      "Entering question_classifier\n",
      "question_classifier: on_topic = Yes\n",
      "Entering on_topic_router\n",
      "Routing to retrieve\n",
      "Entering retrieve\n",
      "Ensemble Retriever Results 43\n",
      "Step 1: 1.43s\n",
      "üîç Simhash deduplicating 43 documents...\n",
      "   Hash generation: 0.05s\n",
      "   Comparison: 0.00s\n",
      "   Simhash filtering: 43 ‚Üí 40 docs\n",
      "Step 2: 0.06s\n",
      "deduplicated_docs: 40\n",
      "final_docs: 10\n",
      "Step 3: 0.66s\n",
      "TOTAL: 2.15s\n",
      "retrieve: Retrieved 10 documents\n",
      "Entering retrieval_grader\n",
      "Document 0 marked as relevant\n",
      "Document 1 marked as relevant\n",
      "Document 2 marked as relevant\n",
      "Document 4 marked as relevant\n",
      "Document 6 marked as relevant\n",
      "Grading reasoning: Documents 0 and 1 clearly provide specific information on how AMTAGVI is provided and what the dose is, stating that it is a single dose of viable tumor-derived T cells in infusion bags. Document 2 describes the preparation and administration process, which is relevant to how the dose is given. Documents 4 and 6 provide dosage forms and strengths, confirming the amount of viable cells in each dose and their packaging, further complementing the exact nature of the dosing and provision of AMTAGVI.\n",
      "Selected 5 relevant documents out of 10\n",
      "retrieval_grader: proceed_to_generate = True\n",
      "Entering proceed_router\n",
      "Routing to generate_answer\n",
      "Entering generate_answer\n",
      "generate_answer: Generated response: ANSWER: AMTAGVI is provided as a single dose for infusion containing a suspension of tumor-derived T cells. The dose is supplied in 1 to 4 patient-specific IV infusion bags in individual protective metal cassettes. Each dose contains 7.5 x 10^9 to 72 x 10^9 viable cells.\n",
      "\n",
      "EVIDENCE: \n",
      "- \"AMTAGVI¬Æ is provided as a single dose for infusion containing a suspension of tumor-derived T cells. The dose is supplied in 1 to 4 patient-speciÔ¨Åc IV infusion bag(s) in individual protective metal cassettes. Each dose contains 7.5 x 10^9 to 72 x 10^9 viable cells.\" (Document metadata: 'chunk_id': '2debb310-87fc-4941-bfbd-ac5abb043f8b', 'page_number': '3')\n"
     ]
    }
   ],
   "source": [
    "input_data = {\n",
    "    \"question\": HumanMessage(\n",
    "        content=\"How is AMTAGVI provided and what is the dose?\"\n",
    "    )\n",
    "}\n",
    "\n",
    "result = graph.invoke(input=input_data, config={\"configurable\": {\"thread_id\": 15}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "AI Response:\n",
      "ANSWER: AMTAGVI is provided as a single dose for infusion containing a suspension of tumor-derived T cells. The dose is supplied in 1 to 4 patient-specific IV infusion bags in individual protective metal cassettes. Each dose contains 7.5 x 10^9 to 72 x 10^9 viable cells.\n",
      "\n",
      "EVIDENCE: \n",
      "- \"AMTAGVI¬Æ is provided as a single dose for infusion containing a suspension of tumor-derived T cells. The dose is supplied in 1 to 4 patient-speciÔ¨Åc IV infusion bag(s) in individual protective metal cassettes. Each dose contains 7.5 x 10^9 to 72 x 10^9 viable cells.\" (Document metadata: 'chunk_id': '2debb310-87fc-4941-bfbd-ac5abb043f8b', 'page_number': '3')\n",
      "\n",
      "Citations:\n",
      "Citation 1: AMTAGVI Commercial FAQ Document.pdf (page 3)\n",
      "Citation 2: Amtagvi PI 2024.pdf (page 2)\n",
      "Citation 3: prc-us-00469-ref1-Amtagvi PI 02 2024.pdf (page 3)\n",
      "Citation 4: prc-us-00483-ref2-Amtagvi PI 02 2024.pdf (page 5)\n",
      "Citation 5: prc-us-00469-ref1-Amtagvi PI 02 2024.pdf (page 5)\n"
     ]
    }
   ],
   "source": [
    "ai_message = result['messages'][-1].content\n",
    "\n",
    "print(\"AI Response:\")\n",
    "print(ai_message)\n",
    "print(\"\\nCitations:\")\n",
    "\n",
    "seen_citations = set()\n",
    "citation_count = 0\n",
    "\n",
    "for doc in result['documents']:\n",
    "    filename = doc.metadata['filename']\n",
    "    page_number = doc.metadata['page_number']\n",
    "    citation_key = (filename, page_number)\n",
    "    \n",
    "    if citation_key not in seen_citations:\n",
    "        seen_citations.add(citation_key)\n",
    "        citation_count += 1\n",
    "        print(f\"Citation {citation_count}: {filename} (page {page_number})\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
